CANCER INCIDENCE AND MORTALITY IN GREATER MUMBAI 2011

MUMBAI CANCER REGISTRY

National Cancer Registry Project Indian Council of Medical Research

Dr.Vinay Deshmane

Principal Investigator Mumbai Cancer Registry Indian Cancer Society

Mrs.S.S.Koyande

Executive In-Charge Co-Principal Investigator Mumbai Cancer Registry Indian Cancer Society

Miss.Shweta Jadhav

Computer Programmer Mumbai Cancer Registry Indian Cancer Society

PAREL, MUMBAI – 400 012 INDIA

This project is supported in part by the

Indian Council of Medical Research, New Delhi

&

Tata Memorial Centre, Mumbai

INDIAN CANCER SOCIETY

PAREL, MUMBAI – 400 012 INDIA

INDIAN CANCER SOCIETY

MANAGING COMMITTEE TRUSTEES & OFFICE BEARERS

Name Designation & Responsibility

Mr. Kewal Nohria Chairman

Mr. Ranjan Kapur Vice - Chairman

Mr. Naveen Kshatriya Hon. Secretary and Managing Trustee
Mr. Uday Khanna Hon. Treasurer & Jt. Managing Trustee

Ms. Usha Thorat Trustee
Dr. Anil Naik Jt. Secretary

Dr. Vikram Sanghvi Jt. Secretary

Other Members

Mr. Hari L. Mundra Member

Dr. Purvish Parikh Member

Dr. Brijesh Arora Member

Dr. Anil D'Cruz Member

Dr. Vinay H. Deshmane Member

Dr.R.K.Deshpande Member

Dr. (Mrs). Purna A. Kurkure Member

Mrs. Smita Aggarwal Member

Mr. Kiran Talcherkar Member

Mrs. Jyotsna Govil Member (Hon. Secretary ICS Delhi Branch)

Mr.Suresh Talwar Member

Mrs.Sheroo Kheswalla Member

Preface

In this publication the data collected by the Mumbai population based Cancer Registry for the year 2011 has been analyzed. In the first part we have given basic information about Mumbai City, the functional structure of the Registry and the methods adapted by the Registry for information on collection and data analysis. Subsequently incidence and mortality data has been analyzed and presented by site, age, method of diagnosis, extent of disease, religion, marital status, education, residence and histology.

The cumulative incidence rates and life time risk for each site by sex are also presented in this publication. Cumulative rates (for incidence and mortality) are coefficient calculated for ages in order to determine the cumulative risk which a person has of developing a cancer, or dying of a cancer, in a certain age span during his life. Thus cumulative rates describe the severity of the particular site in the general population.

Acknowledgements

The Registry staff is grateful to the various hospitals administrators, their Staff members and the

medical specialists in private practice, who have cooperated with us by permitting our social investigators

to collect the data on cancer patients in their care.

The Executive Health Officer of the Mumbai Municipal Corporation deserves special mention

and thanks, for making death records of the city available to us for abstracting information on cancer

cases. We are also grateful to the Director of Census Operations, Maharashtra, for making available to us

the population figures from the 2011 Census, for Greater Mumbai.

We are thankful to the Indian Council of Medical Research at New Delhi, for their technical guidance

and partial financial support. Our thanks are due to Dr.R. Badwe, Director of the Tata Memorial Centre for

partial financial support as well as for permitting us to utilize their records. We are also grateful to Ambani,

Nanavati, Hinduja, Prince Ali Kkan, Bombay, Sion, Jaslok, Lilavati hospitals and all other cooperating hospitals

for making data base available for the cancer registry.

Finally, the Registry Staff, consultants and volunteers are to be praised for their diligence and enthusiasm

in the performance of their duties in collecting and processing the data on which this volume is based.

Dr. Vinay Deshmane

Mrs.S.S.Koyande

5

MUMBAI CANCER REGISTRY

DIVISION OF INDIAN CANCER SOCIETY

Staff Members As on 1st January 2015

Dr. Vinay Deshmane, : Principal Investigator

Mrs.S.S.Koyande, : Executive In-charge

Mr. N.G.Shastri, : Medical Social Worker

Ms.P.M.Hate, : Medical Social Worker

Ms.K.S.Rane, : Medical Social Worker

Mr. R.M.Sagavekar, : Medical Social Worker

Mrs.P.P.Bandekar, : Medical Social Worker

Mrs.M.P.Pagare : Medical Social Worker

Mr. K.Malhari, : Medical Social Worker

Mrs. J. Malusare, : Medical Social Worker

Mr. .M.Kirtane, : Medical Social Worker

Mrs. R.P.Vagal, : Statistical Assistant

Ms. S.S.Shinde, : Statistical Assistant

Ms. S.D.Shirwadkar, : Computer Assistant

Ms. K.B.Rane, : Office Assistant

Ms. S.N.Jadhav, : Computer Programmer

Ms. P.M.Manchekar, : Computer Assistant

Ms. M.R.Prabhale, : Reasearch Assistant

Ms.P.Y.Mahabale, : Computer Assistant

Mrs.S.D.Chibade, : Computer Assistant

Mr.R.B.Mhatre : Attendant

Mr. R. Sawardekar : Attendant

CONTENTS

No.	Description	<u>Page</u>
1	Introduction	9
2	Demographic Characteristics of Greater Mumbai	9
3	Population Estimates	10
4	Sources of Information	11
5	Cancer Registration System in Greater Mumbai	11
6	Cancer Incidence Reporting System in Greater Mumbai	12
7	Incident Cases and Incidence Rates	13
8	Major Sources of Registration	15
9	Site	16
10	Common Cancers by Broad Age Group	20
11	Method of Diagnosis	21
12	Clinical Extent of Disease	22
13	Religion	23
14	Mother Tongue	24
15	Marital Status	25
16	Education	26
17	Residence	27
18	Histology	28
19	Cumulative Incidence Rate	28
20	Childhood Cancers	30
21	Tobacco Related Cancers	30
22	Cancer of Breast	31
23	Cancer of Cervix	32
24	Cancer of Ovary	33
25	Cancer of Prostate	34
26	Cancer of Lung	35
27	Cancer of Tongue	36
28	Cancer of Mouth	37
29	Mortality	38
30	Tables	41
31	Appendix	65

LIST OF TABLES

No.	<u>Description</u>	Page
1	Estimated resident population by age and sex, as on 1 st July 2011, Greater Mumbai, Total Population (All religious communities).	41
2	Estimated resident population by religion and sex, Greater Mumbai, (As on 1st July 2011)	41
3	Number of Incidence cases of cancer by age and site (ICD-10), with percentages Greater Mumbai, 2011, Male	42
4	Number of Incidence cases of cancer by age and site (ICD-10), with percentages Greater Mumbai, 2011, Female	43
5	Average Annual Age-specific, World Age-Adjusted and Truncated (35-64 years) Incidence rates of cancer cases per 100,000 persons Greater Mumbai, 2011, Male.	44
6	Average Annual Age-specific, World Age-Adjusted and Truncated (35-64 years) Incidence rates of cancer cases per 100,000 persons Greater Mumbai, 2011, Female.	45
7	Incidence cases of cancer by most valid basis of diagnosis and site (ICD-10) with percentages, Greater Mumbai, 2011, Male	46
8	Incidence cases of cancer by most valid basis of diagnosis and site (ICD-10) with percentages, Greater Mumbai, 2011, Female	47
9	Number of Incidence cases of cancer cases by clinical extent of disease and site (ICD-10) with percentages, Greater Mumbai, 2011, Male	48
10	Number of Incidence cases of cancer cases by clinical extent of disease and site (ICD-10) with percentages, Greater Mumbai, 2011, Female	49
11	Number of Incidence cases of cancer by religion and site with crude rates (CR) per 100.000 population, 2011, Male.	50
12	Number of Incidence cases of cancer by religion and site with crude rates (CR) per 100.000 population, 2011, Female.	51
13	Number of Incidence cases of cancer by language and site (ICD-10) with percentages, Greater Mumbai, 2011, Male	52
14	Number of Incidence cases of cancer by language and site (ICD-10) with percentages, Greater Mumbai, 2011, Female	53
15	Number of Incidence cases of cancer by marital status and site (ICD-10) with percentages, Greater Mumbai, 2011, Male	54
16	Number of Incidence cases of cancer by marital status and site (ICD-10) with percentages, Greater Mumbai, 2011, Female	55
17	Number of Incidence cases of cancer by education and site (ICD-10) with percentages, Greater Mumbai, 2011, Male	56
18	Number of Incidence cases of cancer by education and site (ICD-10) with percentages, Greater Mumbai, 2011, Female	57
19	Number of Incidence cases of cancer by ward and site (ICD-10) with percentages, Greater Mumbai, 2011, Male	58
20	Number of Incidence cases of cancer by ward and site (ICD-10) with percentages, Greater Mumbai, 2011, Female	59
21	Number of Incidence cases of cancer by primary histology and sex, with percentages, Greater Mumbai, 2011.	60
22	Number of cancer deaths by age and site (ICD-10), with percentages, Greater Mumbai, 2011, Male.	61
23	Number of cancer deaths by age and site (ICD-10), with percentages, Greater Mumbai, 2011, Female.	62
24	Age-specific, world age-adjusted and truncated (35-64 years) cancer death rates per 100,000 persons, Greater Mumbai, 2011, Male.	63
25	Age-specific, world age-adjusted and truncated (35-64 years) cancer death rates per 100,000 persons, Greater Mumbai, 2011, Female.	64

INTRODUCTION

The Mumbai Cancer Registry was established in June 1963 as a unit of the Indian Cancer Society, at Mumbai, with the aim of obtaining reliable morbidity data on cancer, from a precisely defined urban population (Greater Mumbai). The actual compilation of data could however only begin in 1964. Until then, no continuing surveys had ever been undertaken anywhere in India. Initially, up to 1975, the project was initiated in collaboration with financial support from Biometry branch of the National Cancer Institute of the Department of Health in Bethesda, U.S.A. From 1975-80, the project received grants from the Department of Science and Technology of the Government of India at New Delhi and from the Indian Cancer Society. Since September 1981, the project has been partially supported by the Indian Council of Medical Research, at New Delhi.

In this publication we have analyzed the cancer cases registered at the Mumbai Cancer Registry during the year 2011.

DEMOGRAPHIC CHARACTERISTICS OF GREATER MUMBAI

Greater Mumbai, a densely populated urban metropolis on the west coast of India, occupies an area of 603.0 sq.kms. and is the smallest administrative district in Maharashtra state. It is situated between latitudes $18^{0}54$ ' and $19^{0}18$ ' North and longitudes $70^{0}47$ ' and $73^{0}00$ ' East.

Greater Mumbai is in fact as island, joined to the mainland by a number of bridges. It has a warm and humid climate, the period from November to February being comparatively cooler when the temperature ranges between 20°C and 28°C. From the month of March onwards, the weather starts getting warmer. April to June is hot, the temperature often touching 35°C during day time. The rain starts by mid-June and continue through July, August and September. The average annual rainfall in 2500 mms.

For the convenience of civic administration and census operation, Greater Mumbai is divided into 15 wards, which are further subdivided into 88 sections. Currently, the city functions as the administrative Capital of Maharashtra State. For revenue collection, the Greater Mumbai area is divided into two units, the Mumbai City Area and the Mumbai Suburban District.

Mumbai residents receive their water supply from five lakes. Chlorinated water comes from Tansa, Vaitarna and Vihar and filtered water from Ulhas and Tulsi lakes, all being within 50 kms. of the city limits. All these lakes are dependent on the monsoon rains between June and October, for their water contents.

A population census is undertaken every ten years in India. The population of Greater Mumbai as per the 2011 Census was 18,414,288, (53.7% males, 46.3% females) with a sex ratio of 861 females per 1000 males the density was 19,652 inhabitants per sq.kms. confirming the fact that it was the most heavily populated district in Maharashtra State.

The literacy rate was found to be 90.78%, higher as compared to the national literacy rate of.... And For the rest of Maharashtra

The majority of hospitals in the city are maintained by the Municipal Corporation and the State Government, which are basically responsible for conducting Public Health and Medical Services in the City. Mumbai city has five medical colleges viz. The G.S.Medical College, the T.N. Medical College, the Grant Medical College (established 125 years ago), the L.T.M.G. Medical College and the Somaiya Medical College. The Tata Memorial Cancer Center is Mumbai's major Cancer Center, consists of the Tata Memorial Hospital and Cancer Research Institute. The Hospital currently has 550 beds. The centre is an autonomous unit, funded by the Department of Atomic Energy of the Government of India.

The diagnosis and treatment of cancer is undertaken by certain most hospitals in Mumbai. Major cancer surgery, is undertaken at all the major hospitals in town, as well as in some of the well-equipped nursing homes in the city. Facilities for Cobalt 60-Therapy are available in eight hospitals; a Linear accelerator unit is functioning in four hospitals, whilst Orthovoltage X-ray therapy is available in ten hospitals in the city.

POPULATION ESTIMATES


Population data was estimated from the 1991 and 2001 Census reports (As on 1st March). The estimates for the year 2011 as on 1st July were obtained by "Distribution Method" for each sex. Population distribution by age and sex for Greater Mumbai for the year 2011 is given in Table 1 and shown in age-pyramid.

Population by religion of each sex, for year 2011, is presented in Table 2. These figures have been estimated by assuming the 2001 census religious distribution for each sex.

SOURCES

- 1. Census of India 1991, Series 12, Maharashtra, Social and Cultural Tables, Part IV-A, Director of Census Operations.
- 2. Census of India 1991, Series 12, Maharashtra, Migration Tables Part V-A & B, Director of Census Operations, 1991.
- 3. Census of India 2001, Series 14, Maharashtra, Provisional Population Totals, Paper 2, Director of Census Operations, 2001.
- 4. Census of India 2011, Director of Census Operations, 2011.

PERCENTAGE DISTRIBUTION OF RESIDENT POPULATION BY AGE AND SEX, GREATER MUMBAI AS ON JULY 1, 2011



SOURCES OF INFORMATION

Two major sources have utilized for cancer data collection.

- All hospitals, nursing homes and consultants in private practice in the Registry area.
- The Vital Statistics Division of the Department of Public Health of the Mumbai Municipal Corporation.

The Mumbai Cancer Registry today covers more than 100 hospitals and private nursing homes in the metropolitan area. The majority of hospitals in Mumbai are maintained by Municipal Corporation and the State Government, which are responsible for organization of medical and public health services in the city. Our main source of cancer data collection is the Tata Memorial Cancer Hospital and Research Institute, a post-graduate teaching centre of the University and an autonomous unit supported by the Department of Atomic Energy, Government of India.

The pattern of diagnosis and treatment of cancer in Mumbai has undergone a major change over the last decade. With a mushrooming private sector, there is now an increasing number of private hospitals, both large and mid sized, which are involved in cancer care. Many have the latest facilities for treatment, including IMRT and IGRT. Major cancer surgery is undertaken at all major hospitals, as well as in a number of well equipped private nursing homes in the city.

CANCER REGISTRATION SYSTEM IN GREATER MUMBAI

Staff members personally visit the wards of the co-operating hospitals regularly; to interview all confirmed cancer patients and also those who are under cancer investigation. The record files maintained by the various departments of these hospitals viz. Pathology, Hematology, Radiology and the various registers in the specialized surgical and medical wards, are also examined. The requisite details obtained for each patient, are cross-checked with the information collected from the various departments of the collaborating hospitals, to ensure completeness of records. Full information about every cancer patient registered at each and every hospital is thus obtained, irrespective of whether or not the patient is subsequently treated at the particular hospital. Additional information is obtained every time of cancer patient is re-admitted or re-examined at the institution.

As a result of such data collected from different hospitals, the same patient is sometimes found to be registered at two or more hospitals. Care is taken to see that multiple entries of the same patient are not made in our records. On the other hand, in some instances, complete medical information is obtained by combining the data obtained from two or more hospitals, of one and the same patient.

Supplementary information can often be gleaned from the death records maintained by the Vital Statistics Division of the Mumbai Municipal Corporation. Copies are made of all death certificates, which mention cancer or tumor as the cause of death. These death certificates are then matched against the registered cases in our files. Every cancer death not traceable to an entry in our files, is labeled as an "unmatched death" and the date of death is then taken as the date of first diagnosis, and is so registered in the corresponding year's data file. Furthermore copies of all death certificates where the term 'Cancer' or 'Tumor' is mentioned as the cause of death are individually scrutinized to confirm the statement.

After collecting the necessary information from the various collaborating institutes, the Performa sheets are classified into three groups, resident, non-resident and residence not known. Non-resident cases are filed site wise and sex wise. The resident cases are cross checked with the cards of the alphabetic index. Previously reported cases were edited, registered and filed according to the site of cancer, the sex of the patient and the registration number. Copies of the death certificates, from the Vital Statistics Department of the Municipal Corporation are classified according to residential criteria. Non-resident cases are filed alphabetically, as per cause of death and sex. Resident cases are checked with the alphabetic index. Unmatched cases are registered in the morbidity files. All cancer deaths are filed numerically, by sex and cause of death.

CANCER INCIDENCE REPORTING SYSTEM IN GREATER MUMBAI

Cancer incidence is defined as the occurrence of new cancer cases in a defined population during a specified time period. For the purpose of this report, 2011 incidence is based on those cancers registered and first diagnosed between 1st January 2011 and 31st December 2011 in residents of Greater Mumbai.

Incidence reflects the number of primary tumors rather than the number of individuals with cancer. The Mumbai Cancer Registry Database records multiple primary cancer in the same person, of which only some are counted for incidence purposes according to the rules of the International Agency for Research on Cancer and International Association of Cancer Registries.

All malignant tumors including those where the pathologist may have merely suspected a malignant change are registered. Cases under code '0' (benign) or '1' (uncertain whether benign or malignant borderline malignancy) or '2' (carcinoma in situ) are not included in our files. Cancer cases where the death certificate is the only source of information, are however included. Patients, in whom cancer has been ruled out or has not yet been diagnosed, are also omitted from our register.

We utilize the coding system devised by the World Health Organization using code numbers C00.1-C98.9 as published in the Manual of the International Classification of Diseases, Injuries and Causes of Death (10th revision) for coding the primary site. We also utilize the International Classification of Diseases for Oncology, (ICDO-3) simultaneously, for coding the morphology.

For histology coding, the World Health Organization's International Classification of Diseases for Oncology (ICDO-3) giving histogenic and malignancy codes is followed, in conjunction with the primary site codes suggested by the World Health Organization.

REFERENCE:

- 1. World Health Organization Manual of the International Classification of Diseases, Injuries, causes of death (ICD-10) Vol.1, Geneva: WHO, 1992
- 2. World Health Organization International Classification of Diseases for Oncology, Third Edition, Geneva: WHO, 2000

RESULTS

During the year under report (2011), a total number of 12231 incident cases have been registered including DCO's with 5885 males and 6346 females. The Male/Female ratio of incident cases being 0.94:1. The annual Crude incidence rate (CIR) and Age adjusted incidence rate (AAR) were 87.6 and 103 among males and 110.4 and 113.0 among females respectively per 100,000 persons. The truncated rate among males and females were 145.9 and 209.4 per 100,000 persons respectively.

Pediatric cancers accounted for 2.2% of all cancers in boys and 1.2% in girls. Tobacco related cancers accounted for 40% of all cancers in males and 14.4% of all cancers in females. The mortality to incidence ratio was 51% and the proportion of cases registered with death certificate only sources accounted for 6.7%.

Cancer of Lung is predominant site of cancer among males followed by cancer of Prostate, Mouth, Tongue and Lymphoma. Among Females cancer of Breast is the commonest site of cancer followed by Cervix, Ovary, Uterus and Lung.

The number of incident cases, percent increase in number of cases (compared to base year 1982) and age-adjusted incidence rates by sex are shown in Table-A for the year 1982-2011.

Table A: Incident cases and Age-adjusted rates by sex: 1982-2011.

Year	I	ncident case	es	Percent increased	AAR/100000	
	Male	Female	Total		Male	Female
1982	3128	2526	5654	-	116.0	107.5
1983	3090	2476	5566	-1.6	109.0	100.9
1984	3244	2715	5959	5.4	115.4	107.6
1985	3470	2954	6424	13.6	119.0	114.9
1986	3484	2972	6456	14.2	116.1	111.7
1987	3569	2992	6561	16.0	116.0	108.8
1988	3579	3098	6677	18.1	114.0	111.0
1989	3697	3123	6820	20.6	113.0	108.2
1990	3931	3316	7247	28.2	118.5	111.0
1991	3890	3686	7576	34.0	113.7	119.0
1992	4035	3887	7922	40.1	114.0	121.0
1993	4094	3908	8002	41.5	113.6	117.5
1994	4094	3857	7951	40.6	111.0	112.7
1995	4147	3980	8127	43.7	109.0	111.5
1996	4408	4085	8493	50.2	112.1	111.3
1997	4177	4262	8439	49.3	103.0	111.1
1998	4441	4247	8688	53.7	106.0	107.1
1999	4428	4313	8741	54.6	103.0	104.6
2000	4453	4393	8846	56.5	101.2	103.7
2001	4517	4522	9039	59.9	99.9	103.1
2002	4631	4570	9201	62.7	99.0	100.7
2003	4575	4688	9263	63.8	95.4	100.6
2004	4749	5008	9757	72.6	96.5	104.8
2005	4981	5051	10032	77.4	98.5	102.4
2006	5383	5788	11171	97.6	103.5	111.4
2007	5151	5737	10888	92.6	97.0	107.3
2008	5204	6096	11300	99.9	95.8	112.5
2009	5571	5869	11440	102.3	99.8	106.6
2010	5854	6236	12090	113.8	103.6	110.4
2011	5885	6346	12231	116.3	103.0	113.0
Total	129860	126701	256561			




Fig. 1

A total number of 256561 cases of cancers were reported to the NCRP by the PBCR of Mumbai since the year 1982-2011. Compared to the cases registered during the year of commencement of the registry in 1982 the percentage increase in number of cases during the year under report was 116.3.

MAJOR SOURCES OF REGISTRATION

During the year 2011, 26% of the incident cases were registered from the base TMH and 74% of the cases were registered from other major hospitals and sources.

Table B: Incidence Cases of Cancer by Sources of Registration and Sex, with Percentages, Greater Mumbai, 2011

TT '/ 1	Male		Fen	nale	Total		
Hospital	#	%	#	%	#	%	
TMH	1492	25.4	1656	26.1	3148	25.7	
KDA	277	4.7	311	4.9	588	4.8	
Nanavati	263	4.5	298	4.7	561	4.6	
Hinduja	257	4.4	262	4.1	519	4.2	
PAK	232	3.9	260	4.1	492	4.0	
Bombay	202	3.4	178	2.8	380	3.1	
Sion	144	2.4	220	3.5	364	3.0	
Jaslok	164	2.8	164	2.6	328	2.7	
KEM	198	3.4	127	2.0	325	2.7	
RAHEJA	160	2.7	163	2.6	323	2.6	
Nair	132	2.2	134	2.1	266	2.2	
Shanti Avedna	137	2.3	119	1.9	256	2.1	
LILAVATI	127	2.2	120	1.9	247	2.0	
Holy Spirit	101	1.7	125	2.0	226	1.8	
BreachCandy	83	1.4	139	2.2	222	1.8	
Saifee	95	1.6	120	1.9	215	1.8	
HOLY FAMILY	67	1.1	103	1.6	170	1.4	
JJ	51	0.9	90	1.4	141	1.2	
Bhatia	53	0.9	62	1.0	115	0.9	
Cama	3	0.1	109	1.7	112	0.9	
BSES	32	0.5	45	0.7	77	0.6	
HINDU SABHA	18	0.3	57	0.9	75	0.6	
HN	33	0.6	19	0.3	52	0.4	
SEVEN HILLS	33	0.6	18	0.3	51	0.4	
SOMAIYA	25	0.4	21	0.3	46	0.4	
Shushrusha	21	0.4	19	0.3	40	0.3	
ICS	16	0.3	17	0.3	33	0.3	
B.A.R.C.	11	0.2	18	0.3	29	0.2	
Rajawadi	10	0.2	19	0.3	29	0.2	
Parsee	12	0.2	9	0.1	21	0.2	
Ramkrishna	9	0.2	12	0.2	21	0.2	
Jain	8	0.1	12	0.2	20	0.2	
BPT	11	0.2	8	0.1	19	0.2	
Cooper	12	0.2	7	0.1	19	0.2	
Inlakh	4	0.1	9	0.1	13	0.1	
Wadia-C	6	0.1	2	0.0	8	0.1	
OTHER PVT HOSPITALS	414	7.0	357	5.6	771	6.3	
SPECIALISTS	571	9.7	521	8.2	1092	8.9	
BMC	401	6.8	416	6.6	817	6.7	
Total	5885	100.0	6346	100.0	12231	100.0	




Fig. 2

In 2011, in Greater Mumbai, 12231(5885 Males, 6346 Females) new cancer cases were found to have been registered. Of these cases, 11414 were registered through collaborating hospitals during 2011, and the remaining 817 were registered from the Municipal Corporation files. A total of 3148 new cancer cases were registered from Tata Memorial Hospital. The Bombay Hospital, the King Edward Memorial Hospital, the LTMG Sion Hospital, the Nanavati Hospital, the Nair Hospital, the Hinduja Hospital, the Cama Hospital and the Jaslok Hospital are the main sources of data, from where more than 3000 new cancer cases were registered. (Table B)

SITE

The percentage distribution of new cancer cases diagnosed by sex and site group in 2011, is presented in Table C. In 2011, the proportion of male and female cancer cases was 48.1% for males and 51.8% for females. The corresponding estimated resident population of males and females was 53.9% and 46.1% respectively (Table F).

At all site groups, except the breast and genital organs, higher occurrence was noted in male. The digestive system as a whole in males was the commonest cancer site, followed by the buccal cavity and pharynx. In women, cancer involved the breast most frequently, followed by the genital organs and the digestive system (Table C).


Table C: Number of New Cancer Cases by Site and Sex with Percentage Distribution, Greater Mumbai, 2011								
SITE GROUP	MA	LE	FE	MALE	TO	TAL		
	CASES	%	CASES	%	CASES	%		
Buccal cavity & Pharynx	1133	19.3	436	6.9	1569	12.8		
Digestive Organs	1444	24.5	1085	17.1	2529	20.7		
Respiratory Organs	867	14.7	289	4.6	1156	9.5		
Bone, C.tissue, Skin & Breast	267	4.5	2088	32.9	2355	19.3		
Genital Organs	586	10.0	1334	21.0	2120	17.3		
Urinary Organs	358	6.1	118	1.9	476	3.9		
Eye, Brain, Thyroid & Secondaries	535	9.1	547	8.6	1082	8.8		
Lymphomas & Leukemia	695	11.8	449	7.1	1144	9.3		
Total	5885	100.0	6346	100.0	12231	100.0		

LEADING SITES OF CANCERS

The first ten leading sites of cancers among males and females are shown in Table D. Ranking of these sites are based on Age-adjusted rates. Among males, cancer of lung is the most predominant site of cancer constituting 10.3% of total cancers followed by cancers of the prostate(9.5%), mouth(7.7%), urinary bladder6.5%) and lymphoma(5.5%). Among females, cancer of breast is the predominant site of cancer and has accounted for 33.4% of the total cancers in females followed by cancer of cervix(9.4%), ovary(7.8%), uterus(5.7%) and lung(4.2%).

Table D: Annual Age-Adjusted Incidence Rates by Sex per 100,000 Population at Ten Leading Sites and at all Sites, Greater Mumbai 2011							
Deading t	MALE	acci ividii	FEMALE				
RANK	SITE	AAR	RANK	SITE	AAR		
1	Lung	10.3	1	Breast	33.4		
2	Prostate	9.5	2	Cervix	9.4		
3	Mouth	7.7	3	Ovary	7.8		
4	Urinary Bladder	6.5	4	Uterus	5.7		
5	Lymphoma	5.5	5	Lung	4.2		
6	Tongue	5.3	6	Lymphoma	4.0		
7	Liver	5.1	7	Mouth	3.7		
8	Larynx	4.9	8	Oesophagus	3.4		
9	Leukemia	4.4	9	Gall Bladder	3.2		
10	Oesophagus	4.2	10	Leukemia	3.1		
AAR At all Sites		103.0		AAR At all Sites	113.0		

AGE ADJUSTED INCIDENCE RATES PER 100,000 POPULATION AT TEN LEADING SITES, 2011






Fig. 3

AGE SPECIFIC INCIDENCE RATES

The age specific incidence rates ranged between 9.2 per 100,000 persons (0-4 years age group) to 942.0 (75+ years age group) per 100,000 persons among males and 5.3 per 100,000 persons (0-4 years age group) to 714.3 per 100,000 persons (75+ years age group) among females. The age specific incidence rates have crossed over 100 a decade earlier among female (40-44 years age group) than among males (50-54 years age group).

Table E: Age Specific Incidence Rates Per 100,000 For All Cancer Sites By Sex, 2011							
Age-Group	Male	Female					
00-04	9.2	5.3					
05-09	9.8	7.0					
10-14	8.3	5.3					
15-19	11.8	8.8					
20-24	8.4	9.8					
25-29	12.5	17.4					
30-34	24.4	37.9					
35-39	40.9	72.8					
40-44	59.2	122.6					
45-49	97.3	193.7					
50-54	164.5	239.8					
55-59	257.9	315.7					
60-64	370.8	423.6					
65-69	570.8	508.3					
70-74	738.5	577.0					
75+	942.0	714.3					
CR	87.6	110.6					
AAR	103.0	113.0					
TR	145.9	209.4					

AGE SPECIFIC INCIDENCE RATES PER 100,000 POPULATION, FOR ALL CANCER SITES, 2011




Fig. 4


PROPORTION OF CANCERS BY BROAD-AGE GROUPS

The current distribution of the resident population and the new cancer cases by broad age groups and sex for the year 2011 is presented in Table F.

Table F: Percentage Distribution of the Resident Population and New Cancer Cases By Age and Sex, 2011								
AGE GROUP	PO	POPULATION NEW CANCER CA				ASES		
	MALE	FEMALE	TOTAL	MALE	FEMALE	TOTAL		
00-14	11.6	10.4	22.0	1.1	0.6	1.7		
15-34	21.8	17.2	39.0	3.1	3.2	6.3		
35-64	17.8	15.5	33.3	23.5	30.1	53.6		
65+	2.7	2.8	5.5	20.4	17.4	37.8		
TOTAL	53.9	45.9	100.0	48.1	51.9	100.0		

Table F clearly indicates that cancer occurs mostly at older ages, as only 1.7% of the total number of cancer cases registered, were under 15 years of age, although this age group accounts for 22.0% of the total population in the metropolis. The association of cancer with the ageing process is clearly shown by the fact that 37.8% of the cases were diagnosed in those aged 65 and above, an age group, which comprises only 5.5% of the population (Fig 5).

PERCENTAGE DISTRIBUTION OF RESIDENT POPULATION AND CANCER CASES, 2011



COMMON CANCERS IN 0-14 YEARS AGE GROUP:

Cancer of Leukemia, brain and lymphoma tumors were the commonest sites of cancer observed in the paediatric age group in both boys and girls. These three sites together accounted for about 71.8% of the cancers in boys and 63.1% in girls. The first five leading sites by sex are shown in Table G(1).

Table G(1):

Site	Male		Site	I	Female
	#	%		#	%
Leukemia	45	34.4	Leukemia	27	35.5
Lymphoma	30	22.9	Brain & NS	15	17.1
Brain & NS	19	14.5	Bone	8	10.5
Bone	10	7.6	Ovary	7	9.2
Conn. & Soft Tis	7	5.3	Lymphoma	5	6.5
All Sites	131	2.2	All Sites	76	1.2

COMMON CANCERS IN 15-34 YEARS AGE GROUP:

About 6% of the total cancers in males and in females occurred in this age group. Cancers of leukemia, brain & nervous system, lymphoma, Tongue and Bone tumors were the commonest sites of cancers in males, whereas cancer of the breast, thyroid, leukemia, lymphoma and Brain were the commonest sites in females. The details are shown in Table G(2).

Table G(2):

Site	Male		Site	Fe	male
	#	%		#	%
Leukemia	51	13.6	Breast	77	19.6
Brain & NS	42	11.2	Thyroid	45	11.5
Lymphoma	37	9.8	Leukemia	34	8.7
Tongue	30	8.0	Lymphoma	30	7.7
Bone	30	8.0	Brain	27	6.9
All Sites	376	6.3	All Sites	392	6.2

COMMON CANCERS IN 35-64 YEARS AGE GROUP:

Among males, cancer of the mouth (12.4%), lung (8.4%), tongue (7.5%), lymphoma (5.2%) and stomach (4.3%) were the commonest sites of cancers in this truncated age group of 35-64 years. Among females, cancer of the breast was the predominant site and accounted for 34.2% of the total female cancers followed by cervix (9.8%), ovary (6.7%), corpus uteri (5.1%) and lung (3.2%). Cancers in this age group accounted for about 48.9% and 59.1% of the total cancers in males and females respectively. The five leading sites by sex are shown in table G(3).

Table G(3):

Site	Male		Site	Fem	ale
	#	%		#	%
Mouth	356	12.4	Breast	1281	34.2
Lung	243	8.4	Cervix	369	9.8
Tongue	216	7.5	Ovary	252	6.7
Lymphoma	151	5.2	Uterus	191	5.1
Stomach	123	4.3	Lung	121	3.2
All Sites	2877	48.9	All Sites	3749	59.1

COMMON CANCERS IN 65+ YEARS AGE GROUP:

The predominant sites of cancers among males in this age group were cancers of prostate (15.4%), lung (12.1%), liver (5.7%), larynx (5.4%) and oesophagus (4.4%). These five sites together constituted 41.7% of the total cancers in males. Among females, cancer of the breast is the leading site and accounted for 25.5% of the total female cancers in this age group followed by cervix(6.6%), ovary(6.4%), corpus uteri(4.9%), lung(4.9%). The leading sites in this age group are shown in Table G(4).

Table G(4):

Site	Male		Site	Fem	ale
	#	%		#	%
Prostate	385	15.4	Breast	542	25.5
Lung	302	12.1	Cervix	141	6.6
Liver	143	5.7	Ovary	136	6.4
Larynx	134	5.4	Uterus	104	4.9
Oesophagus	110	4.4	Lung	104	4.9
All Sites	2501	42.5	All Sites	2129	33.5

METHOD OF DIAGNOSIS

Although the primary site is the single most important item in the classification of cancer data, medical investigations which lead to a correct diagnosis of each case can give additional information useful in epidemiological studies. The various criteria utilized to diagnose cancer in Greater Mumbai are expressed as a percentage of all the methods used to diagnose cancer cases. The percentage of new patients diagnosed before death, is presented in Table H.

Table H: The Percentage Of New Cancer Diagnosed in Hospital and by Specialists, By Method of Diagnosis, 2011							
METHOD OF DIAGNOSIS	MALE		FEM	IALE	TOTAL		
	CASES	%	CASES	%	CASES	%	
MICROSCOPIC	5141	87.4	5522	87.0	10663	87.2	
CLINICAL ONLY	265	4.5	285	4.5	550	4.5	
CLINICAL INVEST	78	1.3	122	1.9	200	1.6	
DCO	401	6.8	417	6.6	818	6.7	
TOTAL	5885	100.0	6346	100.0	12231	100.0	


The number of cases and the percentage distribution of cancer by method of diagnosis for each site is presented for males in Table 7 and for females in Table 8 respectively. About 6.7% of cancer cases were registered through death certificates alone. Most probably these were patients with advanced disease who attended out-patient departments of various collaborating hospitals to seek medical advice at a late stage, when no active treatment was possible.

An evaluation of the reliability of cancer data is usually measured by the percentage of patients having microscopic proof of diagnosis, as compared with other methods which are considered less accurate. In our Registry about 87.2% of all new cancer cases were registered through hospitals and from specialists where microscopic confirmation is available. The percentage of microscopic proof of diagnosis for females was found to be slightly higher than that for males (Fig 6).

The percentage of patients having microscopic confirmation of cancer, depends primarily on the accessibility of the part affected. Histological confirmation of cancers arising in the buccal cavity, pharynx and the female genital tract is thus usually available with greater frequency than for tumors at inaccessible sites, such as the digestive and respiratory systems.

A few cancer patients were found to have been diagnosed on the basis of gross examination by the operating surgeon or on endoscopic appearance without biopsy e.g. after cystoscopy. The number of patients diagnosed in this manner was the highest for cancers involving the stomach, pancreas, retroperitoneal region and urinary bladder and was the least for lesions involving the oesophagus, breast and cervix uteri.

PERCENTAGE DISTRIBUTION OF CASES OF CANCER DIAGNOSED IN HOSPITAL AND SPECIALISTS, IN GREATER MUMBAI 2011






Fig.6

About 5.8% in males and 6.4% in females, cases reported by hospitals and specialists, were found to have been diagnosed on clinical grounds alone. A higher percentage of patients diagnosed in this manner, was found to have had cancer at sites inaccessible for immediate biopsy or because the patient refused to undergo further detailed investigations. However, most of these patients were not offered active treatment because of the extensive nature of the disease.

CLINICAL EXTENT OF DISEASE

The stage of disease at diagnosis is generally the most important factor in determining the prognosis and survival of cancer patients. This is because certain treatments may be available only for early stage tumors and any treatment is more likely to be successful if initiated before metastasis has occurred. The detailed information regarding stage of disease is available in hospital registries. As population based registry collects the data from too many sources, the information on exact stage of disease is not available for great number of cases. Hence the information on extent of disease serves the purpose of stage of the disease.

At our registry for determining the extent of the disease is based on the clinical assessment only i.e., before first treatment of a cancer patient. The number of new cases with percentage distribution for each category of extent of disease by site is presented in Tables 9 and 10 for males and females respectively.

Cancers arising in the buccal cavity, pharynx, larynx and female genital tract have higher percentage of localized stage as they are easily accessible for biopsy. Cancers having poor prognosis like, oesophagus, stomach, pancreas, lung and urinary bladder are either metastasized or of an advanced stage at the time of diagnosis because most of these patients have been diagnosed on the basis of gross examination by the operating surgeon or on endoscopic appearance without biopsy, e.g., after cystoscopy.

RELIGION

Considerable variation was noted in the incidence of cancer at various sites in both the sexes, in patients having their domicile in other countries and in those professing different religious faiths within a particular population, due to a variety of causes mainly endocrine, dietary or environmental. Such variations call for adequate investigations, to elucidate the complex etiology of the disease.

To study the differences in cancer incidence by religion, the crude rates by religion and sex are presented in Table I. From this table, it is evident that different religious groups in Greater Mumbai exhibit considerable variation in the total incidence of cancer in each sex.

Table I: Crude Incidence Rates By Religion and Sex, Greater Mumbai, 2011							
RELIGION	MALE	FEMALE					
Hindu	93.4	122.2					
Muslim	84.4	99.3					
Christian	140.9	137.1					
Parsi	121.8	191.1					
Buddhist	36.9	43.2					
Jain	20.6	34.6					
Sikhs	63.8	115.2					
Total	87.6	110.6					

The Parsi population appears to be at a much higher risk than those professing other religions viz. The Hindu, Muslims, Christians, Jains and Buddhists.

CRUDE INCIDENCE RATES BY RELIGION, 2011




Fig. 7

The different religious groups are distinguished from each other by their habits, customs and socio-economic status. Thus, even though living in the same environment, they present striking differences from each other, in the relative frequency with which cancer occurs at various sites. An appraisal of this situation was thus considered promising, in order to study the differences in site patterns of incidence. In order to define the magnitude and nature of the differences observed, the number of cancer cases along with the crude incidence rate of each cancer site in various religious group, is presented in Table 11 for males and Table 12 for females.

The site incidence patterns exhibit considerable differences in the various religious groups. The most common cancer sites by crude rate in each religious groups by sex are presented in Table J.

Among males, cancer of Prostate is leading site in Hindus, cancer of lung is leading site in Muslims, cancer of Lung is leading in Christians and cancer of lymphoma is leading site in Parsis. Among females, the breast is the leading site in all the religious groups. In Hindus and Muslims cervix ranked second, while in Christians and Parsis ovary ranked second.

		MALE			FEMALE			
RELIGION	RANK	SITE	Cases	CR	RANK	SITE	Cases	CR
HINDU	1	Prostate	387	8.5	1	Breast	1354	35.4
	2	Lung	358	7.8	2	Cervix	411	10.8
	3	Mouth	354	7.7	3	Ovary	326	8.5
	4	Lymphoma	249	5.5	4	Uterus	231	6.1
	5	Tongue	221	4.8	5	Lung	180	4.7
	•							
MUSLIM	1	Lung	143	11.2	1	Breast	302	29.2
	2	Mouth	96	7.5	2	Cervix	75	7.3
	3	Tongue	74	5.8	3	Ovary	63	6.1
	4	Larynx	56	4.4	4	Gall Bladder	44	4.3
	5	Leukemia	54	4.2	5	Mouth	40	3.9
	•					•		
CHRISTIAN	1	Lung	38	16.8	1	Breast	122	51.0
	2	Prostate	37	16.4	2	Ovary	31	13.0
	3	Leukemia	19	8.4	3	Cervix	21	8.8
	4	Lymphoma	17	7.5	4	Uterus	18	7.5
	5	Tongue	16	7.1	5	Lung	13	5.4
	•						· · · · · · · · · · · · · · · · · · ·	
PARSI	1	Lymphoma	5	17.9	1	Breast	23	74.5
	2	Larynx	3	10.7	2	Ovary	4	13.0
	3	Lung	3	10.7	3	Lymphoma	3	9.7
	4	Liver	3	10.7	4	Mouth	3	9.7
	5	Mouth	2	7.2	5	Colon	3	9.7

MOTHER TONGUE

In India vast differences have been known to exist in the habits and customs of different sections of the large and complex Hindu community. One of the ways of identifying the different groups is on the basis of the written and spoken language. Indian states have been organized primarily on linguistic basis and the mother tongue provides an important source of information, to study the variations found in the relative frequency of cancer.

Greater Mumbai has a cosmopolitan population drawn in sizable numbers from every state in the Indian Union. This urban centre thus represents a true cross section of the heterogeneous nature of the Indian population. Hindus constitute 67.4% of the total population. Among the Hindus, 60% are Marathi speaking, who hail from the districts to the south and east of Mumbai, whilst the Gujaratis come from the western seaboard, to the north of the city. The four linguistic groups in the Metropolis, have adequate numbers of

people available for undertaking a comparative analysis. The Marathi and Gujarati speaking people form the most common linguistic groups followed by the Hindi and Urdu speaking population. The number of cases and the percentage distribution of cancer sites in these groups are presented in Tables 13 and 14, for males and females respectively.

The site incidence patterns exhibit considerable differences in the various linguistic sections. The five most common sites in each linguistic group by sex, is presented in Table K.

Table K: Five I	Most Comm	non Sites Of Cancer	r In Diffe	erent Ling	guistic Gro	ups by Sex, Grea	ter Mumba	i, 2011
-	N	IALE				FEMALE		
LANGUAGE	RANK	SITE	N	%	RANK	SITE	N	%
GUJARATI	1	Prostate	116	14.1	1	Breast	330	35.9
	2	Lung	69	8.4	2	Uterus	59	6.4
	3	Mouth	59	7.2	3	Ovary	49	5.3
	4	Lymphoma	48	5.8	4	Cervix	47	5.1
	5	Tongue	41	5.0	5	Lymphoma	40	4.3
HINDI	1	Mouth	143	9.7	1	Breast	354	26.5
	2	Lung	133	8.8	2	Cervix	139	10.4
	3	Prostate	128	8.5	3	Ovary	93	7.0
	4	Tongue	95	6.3	4	Gall Bladder	78	5.8
	5	Lymphoma	91	6.0	5	Uterus	56	4.2
								,
MARATHI	1	Mouth	164	8.7	1	Breast	672	27.7
	2	Lung	149	7.9	2	Cervix	229	9.4
	3	Prostate	125	6.6	3	Ovary	176	7.2
	4	Liver	104	5.5	4	Uterus	112	4.6
	5	Tongue	103	5.4	5	Mouth	95	3.9
URDU	1	Lung	126	13.8	1	Breast	259	29.7
	2	Mouth	73	8.0	2	Ovary	58	6.7
	3	Tongue	56	6.1	3	Cervix	56	6.4
	4	Larynx	47	5.1	4	Gall Bladder	41	4.7
	5	Leukemia	46	5.0	5	Uterus	34	3.9

From Table K, it is seen that in males, the lung and mouth cancer are most predominant in all linguistic groups, while in females, in all the linguistic groups, the breast is the leading site, followed by the cervix and ovary in all linguistic groups.

MARITAL STATUS

An increasing incidence and mortality of cancer relevant to the marital status, have been reported in several articles during the past 50 years. In particular, attention has been focused on the relation of marital status to the morbidity and mortality of cancers of the female breast and reproductive organs. Marital status is one of the major variables included in many epidemiological studies relating to such cancers.

The number and the percentage distribution of cancer cases by marital status and site, is presented in Tables 15 and 16 for males and females respectively. For comparison, the group of divorced and separated women has not been considered, as they are very small in number.

The percentage of cancers involving the bones, connective tissue, brain, the lymphatic and hematopoietic systems, was found to be significantly higher in the unmarried group in both sexes, as the victims of these cancers are mainly children.

In unmarried males, the highest incidence was noted in leukaemias, followed by brain, lymphomas, and bones. Among married men, the highest incidence was noted for cancers involving the mouth, followed by lung, prostate, lymphoma and stomach. Among widowed men, the highest cancer incidence was noted in the prostate followed by lung, larynx and colon.

Among unmarried females, the highest incidence was noted in the breast, followed by the leukemia, lymphoma, brain and ovary. Among married women the highest incidence was noted for cancers of the breast, followed by cancers involving the cervix and ovary. Among widowed women, cancer of the breast and cervix were found to be more predominant cancers.

Cancer of the breast appeared to be predominantly a disease of married women. This is clearly seen when we compare the age-specific rates in single and married women. The differences noted between single and married women, may be interpreted to indicate that single women enter the non susceptible state 5 years later than married women. Since it has also been suggested that non susceptible state coincides with the onset of menopause, this implies that the onset of menopause in single women occurs on an average many years later than in married women.

EDUCATION

In the preceding pages, consideration has been given to examine the variation in cancer incidence that can be attributed to religion, the mother tongue and the marital status. These demographic variables are not very useful in determining the variations attributable to socio-economic status. In the Indian situation, evaluation of the socio-economic status is a very complex matter and there is no simple way of classifying the different groups that exist in the region under study. Innumerable castes and tribes make it a futile exercise to provide any meaningful grouping. Family income is a useful criteria, but in a hospital setting where the fees chargeable are often assessed on this information, it is not possible to obtain reliable data. Under these circumstances, the level of formal education provides a more appropriate measure of the socio-economic status.

We have tried to obtain information on the education level of each cancer patient. Unfortunately, for a large number of patients we could not obtain this information from the hospital records. Only when we were able to interview the patient individually, was it possible to obtain this data. In order to make the comparison reasonably meaningful, some of the different groups have been pooled together. Illiterates, who constitute a large proportion of females, are treated separately. Those who had received primary education and others who are merely literate are grouped together. Then again, those who have received secondary or technical education are also pooled together. The college educated are a small but important class who deserve separate assessment. The new cancer cases and the percentage distribution for each group by cancer site, are presented in (Tables 17 and 18) for males and females respectively.

Cancer involving the oral cavity, pharynx and the respiratory tract constitute the bulk of male cases. These are mainly tobacco related cancers and it was considered interesting to see if any variations were noted in the predominant sites in this category, associated with the educational level of the patients. The major risk factors for these cancers are well known viz. tobacco chewing, for mouth cancer, bidi smoking for cancers involving the larynx and pharynx, and cigarette or bidi smoking for lung cancer. Educational levels were also analyzed, of the patients who had a cancer at these sites and were compared with the educational levels of the patients for 'all cancers' taken together.

Table L: Percentage Distribution Of Cancer Cases For Selected Sites by Educational Level. Greater Mumbai, Males, 2011.								
SITE	ILLITERATE	LITERATE	PRIM+ MID	SEC+TEC	COLLEGE &ABOVE			
Tongue	5.0	3.5	6.7	5.8	5.4			
Mouth	7.8	5.8	9.5	8.8	5.8			
Oropharynx	1.9	0.7	1.7	1.1	0.6			
Hypopharynx	4.3	0.7	2.1	2.3	1.1			
Larynx	5.0	4.4	5.3	4.0	3.2			
Lung	8.6	11.6	10.5	7.6	6.9			
Oesophagus	3.2	4.3	3.9	3.9	3.7			
Stomach	3.0	4.0	4.0	4.0	4.7			

In general, we can conclude from the above (Table L), that lung, pharyngeal, tongue and laryngeal cancers, which are known to be associated with tobacco-chewing and cigarette and bidi-smoking habits, are more prevalent in the lower socio-economic classes.

In females, besides the breast and uterine cervix, cancer of the buccal cavity and pharynx are the most commonly affected sites. These three groups are examined in detail in relation to educational levels (Table M & Figure 8).

Table M: Percentage Distribution Of Cancer Cases For Selected Sites By Education Level, Greater Mumbai, Female,2011						
SITE	ILLITERATE	LITERATE	PRIM+ MID	SEC+TEC	COLL. & ABOVE	
Mouth	5.3	3.2	3.4	2.1	1.1	
Breast	20.2	28.2	31.2	31.3	44.8	
Cervix	14.3	8.0	8.2	6.4	3.1	

The percentage distribution for each educational level, shows a very interesting gradient with respect to occurrence of cancer at the three common sites, in women with only basic education, in whom the breast, buccal cavity and pharyngeal regions are involved. This trend is somewhat reversed in the case of those who had received secondary, technical or college education. In these categories, cancer was found to occur maximally in the breast, followed by the uterine cervix and the least involved was the oral cavity. When percentage distributions by educational level at each site is compared, cancer of the buccal cavity and pharyngeal and cervical cancers were found to be more prevalent at the lower educational level and the incidence starts to decrease as the educational level increases. The exact reverse situation is observed for cancer of the breast.

PERCENTAGE DISTRIBUTION OF CANCER CASES FOR MOUTH, BREAST, CERVIX BY EDUCATION LEVEL, GREATER MUMBAI 2011




Fig. 8

RESIDENCE

Variations in incidence rates between different population groups, as defined by personal (demographic) variables by place of residence, may suggest the importance of environmental factors in the causation of a particular cancer. Therefore, descriptive epidemiological data are often described as hypothesis generating.

Greater Mumbai is made of the city suburbs and extended suburbs. For administrative purposes the whole of Greater Mumbai area is divided into fifteen wards. Wards A,B,C,D,E,F and G constitute the city; wards H,K,L,M and N constitute the suburbs and wards P,R

and T constitute the extended suburbs. The new cancer cases with percentage distribution for city, suburb and extended suburb by cancer site are presented in Tables 19 and 20 for males and females respectively.

Among males, cancer of the mouth is the most predominant cancer followed by lung in all the three areas. Among females, incidence of cancer of the breast top the list followed by cervix and ovary in all the three areas.

HISTOLOGY

During the year 2011, 10663 cancer cases were confirmed microscopically. The proportion of histopathologically proved cases was found to be 87.2%. The various histological varieties observed for all sites together during 2011 by sex with percentage distribution is presented in Table 21.

Squamous cell neoplasms are found to be the commonest histological type constituting about 21.0% of the total number of cases. This is the most common variety affecting in males. The next common variety affecting in males is adenocarcinomas (21.2%), while in females ductal, lobular and medullary neoplasms (25.0%) is the leading histology followed by squamous cell carcinomas (16.8%) and adenocarcinoma (18.5%).

CUMULATIVE INCIDENCE RATE

The Cumulative incidence rate is simply a summary measure of the experience of a population over a longer time span or age interval. It is obtained by summing up the age specific incidences for each year in the defined age interval.

The cumulative incidence rate between birth to age 74 years is 5 times the sum of the age specific incidence rates calculated over five year age-groups, since age-specific incidence rates are usually computed for five year age intervals. The cumulative incidence is a directly standardized incidence rate and a good approximation to the actuarial or cumulative risk. The reason for interest in the cumulative incidence rate is that it has a useful probabilistic interpretation. Another advantage is that as a form of direct age standardization, the arbitrariness in choosing a standard population is removed and the computations of cumulative incidence rates are easier. The age cumulative incidence rates (00-74 years) are calculated for all sites in both the sexes (Table N). On an average 1 out of 8 males and 1 out of 8 in females gets cancer in his/her life time (0-74). In males, one in 77 and one in 112 will get lung and mouth cancer respectively while in females, one in 27 and one in 91 will get cancer of breast and cervix respectively (Table N).

Table N: Cumulative Rate (%) and Life Time Risk of developing cancer to Age 74 years by Site and Sex, Greater Mumbai, 2011 (* 1 in: Risk of developing cancer for each person)

		MALE		FEMALE	
ICD-10	SITE	Cum Rate%	*1 In	Cum Rate%	*1 In
C00	Lip	0.1	1835	0.0	10365
C01-02	Tongue	0.6	167	0.2	436
C03-06	Mouth	0.9	112	0.5	220
C07-08	Salivary Gland	0.1	1956	0.0	3895
C09-10	Oropharynx	0.2	586	0.1	1377
C11	Nasopharynx	0.0	2336	0.0	6431
C12-13	Hypopharynx	0.3	345	0.1	1094
C14	Other Oral	0.1	891	0.0	2187
C15	Oesophagus	0.5	193	0.4	272
C16	Stomach	0.5	199	0.2	437
C17	Samll Intestine	0.0	2446	0.0	2024
C18	Colon	0.4	238	0.4	280
C19-21	Rectum	0.4	271	0.3	320
C22	Liver	0.6	165	0.3	369
C23-24	Gall Bladder	0.2	405	0.4	277
C25	Pancreas	0.3	299	0.2	468
C26	Oth Dig Org	0.0	6829	0.0	11533
C30-31	Nose, Sinuse	0.1	1564	0.0	2099
C32	Larynx	0.6	173	0.1	1623
C33-34	Lung	1.3	77	0.5	199
C37-38	Mediastinum, Plura	0.0	5541	0.0	11174
C40-41	Bone	0.1	1203	0.1	1623
C43	Skin Melanoma	0.0	21638	0.0	4479
C44	Skin Others	0.2	660	0.1	770
C47	Nervous System	0.0	8237	0.0	48693
C48	Retroperitonium	0.0	26771	0.0	71244
C49	Conn & Soft Tissue	0.1	826	0.1	836
C50	Breast	0.1	1291	3.7	27
C51-52	Oth Fem Gen Org	-	-	0.1	1011
C53	Cervix	-	-	1.1	91
C54	Corpus Uteri	-	-	0.6	168
C55	Uterus	-	-	0.1	734
C56	Ovary	-	-	0.9	113
C57-58	Oth Unsp Fem Gen Or	-	-	0.0	5637
C60	Penis	0.1	725	-	-
C61	Prostate	1.2	87	-	-
C62	Testis	0.0	2198	-	-
C63	Oth Male Gen Org	0.0	23424	-	-
C64-65	Kidney	0.3	325	0.1	674
C66-68	Urinary Bladder	0.4	237	0.1	1029
C69	Eye	0.0	12024	0.0	19999
C70-72	Brain	0.3	304	0.3	382
C73	Thyroid	0.1	994	0.2	470
C74-75	Other Endocrine Gla	0.0	7685	0.0	5871
C76	Other Ill Def Sites	0.0	3390	0.0	2273
C77	Lymph Nodes	0.2	600	0.1	914
C78	Sec Resp & Dig	0.1	684	0.2	496
C79	Sec Others	0.0	2552	0.0	2827
C80	Unknown Primary	0.1	800	0.1	744
C81	Hodgkin Lymphoma	0.1	1064	0.1	1213
C82-85	N.H.Lymphoma	0.5	199	0.4	274
C90	Multiple Myloma	0.2	407	0.1	1083
C91	Lymphoid Leukemia	0.1	780	0.1	1132
C92	Myeloid Leukemia	0.2	563	0.1	775
C93-95	Other Leukemia	0.1	1402	0.1	1857
Total	All Sites	11.9	8	12.7	8

CHILDHOOD CANCERS (00-14 YRS)

Cancer in childhood constitute one of the most important groups of tumors, not only because of the age occurrence, connoting a difference set of etiological factors from those, commonly seen in adult cancers but also because in the past two decades, with advances particularly in chemotherapy, many of the childhood cancers have gain markably high potency for cure. The proportion of childhood cancers relative to all sites of cancers varies from in male and in females in Mumbai population

Table O gives the number and relative proportion of broad types of childhood cancers in Mumbai registry according to the classification scheme of IARC (Parkin et al 1988). Leukemia's and lymphomas followed closely by tumors of the central nervous systems constitutes the vast majority of childhood cancers.

Table O: Number of Childhood cancers and proportion by sex in Greater Mumbai, 2011							
Site	ICD10	Ma	ale	Female		To	tal
		#	%	#	%	#	%
Leukemias	C91, C92, C93-C95	45	34.3	27	36.0	72	34.9
Lymphomas	C81, C82-C85	30	22.9	5	6.7	35	17.0
CNS Tumor	C70-C72	19	14.5	15	20.0	34	16.5
Retinoblastoma	C69	4	3.0	4	5.3	8	3.9
Renal Tumor	C64-C65	3	2.3	2	2.7	5	2.4
Hepatic Tumor	C22	2	1.5	-	-	2	1.0
Bone Tumor	C40-C41	10	7.6	8	10.7	18	8.7
Soft Tissue	C49	6	4.6	2	2.7	8	3.9
Germ Cell Tumor	C62	0	-	0	-	0	1
Other Carcinomas		12	9.2	12	16.0	24	11.7
All Types		131	100.0	75	100.0	206	100.0

TOBACCO RELATED CANCERS

Sites of cancers that has been associated with use of tobacco (tobacco related cancers- TRC's) includes lip, tongue, oral cavity, pharynx, (including oropharynx and hypopharynx, oesophagus, larynx, lung and urinary bladder).

The total proportions of these sites of cancers to all sites in males and females are given in Table P.

Table P: Number of Tobacco related cancer cases by sex in Greater Mumbai, 2011							
Site	ICD10	N	Male		Female		tal
		#	%	#	%	#	%
Lip	C00	24	0.4	6	0.1	30	0.2
Tongue	C01-C02	330	5.6	110	1.7	440	3.6
Oral Cavity	C03-C06	482	8.2	202	3.2	684	5.6
Oropharynx	C09-C10	75	1.3	29	0.5	104	0.9
Hypopharynx	C12-C13	119	2.0	41	0.6	160	1.3
Pharynx	C14	49	0.8	24	0.4	73	0.6
Oesophagus	C15	229	3.9	187	2.9	416	3.4
Larynx	C32	270	4.6	36	0.6	306	2.5
Lung	C33-C34	554	9.4	229	3.6	783	6.4
Urinary Bladder	C66-C68	217	3.7	50	0.8	267	2.2
T.R.C.'s		2349	39.9	914	14.4	3263	26.7
Other Carcinomas		3536	60.1	5432	85.6	8968	73.3
All Types		5885	100.0	6346	100.0	12231	100.0

CANCER OF BREAST (ICD-10: C50)

CANCER OF BREAST: 2011

No. of cases	1900
% to total cases	29.9
$CIR/10^5$	33.1
$AAR/10^5$	33.4
$TR/10^5$	70.9
Ratio at risk	1:27

Number, Percent and AAR/10⁵ by Broad Age Groups

Age Group	#	%	AAR
0-14	-	-	-
15-34	77	4.1	3.1
35-64	1281	67.4	70.9
65+	542	28.5	149.9
Total	1900	100.0	33.4




Fig.9 (a)




Fig.9 (b)

CANCER OF CERVIX (ICD-10: C53)

CANCER OF CERVIX: 2011

 $AAR/10^5$

TR/10⁵
Ratio at risk

No. of cases	527
% to total cases	8.3
$CIR/10^5$	0.2

9.4 20.5

1:91

Age Group	#	%	AAR
0-14	-	-	-
15-34	17	3.2	0.3
35-64	369	70.0	25.4
65+	141	26.7	36.4
Total	527	100.0	10.5




Fig.10 (a)




Fig.10 (b)

CANCER OF OVARY (ICD-10: C56)

CANCER OF OVARY: 2011

No. of cases	440
% to total cases	6.9
CIR/10 ⁵	7.7
$AAR/10^5$	7.8

15.0

1:113

TR/10⁵

Ratio at risk

Number, Percent and AAR/ 10^5 by Broad Age Groups

Age Group	#	%	AAR
0-14	7	1.7	0.5
15-34	25	6.0	1.1
35-64	270	64.6	15.0
65+	138	33.0	37.9
Total	440	100.0	7.8




Fig.11 (a)




Fig.11 (b)

CANCER OF PROSTATE (ICD-10: C61)

CANCER OF PROSTATE: 2011

No. of cases	486
% to total cases	8.3
CIR/10 ⁵	7.2

9.5

5.8

1:87

 $AAR/10^5$

Ratio at risk

 $TR/10^{5}$

Number, Percent and AAR/10 ⁵	by Broad Age Groups
---	---------------------

Age Group	#	%	AAR
0-14	-	-	ı
15-34	-	-	-
35-64	101	20.8	5.8
65+	385	79.2	110.2
Total	486	100.0	396.6




Fig.12 (a)




Fig.12(b)

CANCER OF LUNG (ICD-10: C34)

CANCER OF LUNG: 2011

Number, Percent and AAR/10⁵ by Broad Age Groups

	MALE	FEMALE
No. of cases	554	229
% to total cases	9.4	3.6
CIR/105	8.2	4.0
AAR/105	10.3	4.2
TR/105	13.0	7.0
Ratio at risk	1:77	1:199

Age Group		MALE			FEMALI	E
	#	%	AAR	#	%	AAR
0-14	2	0.4	0.2	0	-	-
15-34	7	1.3	0.2	4	1.7	0.2
35-64	243	43.9	13.0	121	52.8	7.0
65+	302	54.5	88.4	104	45.4	28.1
Total	554	100.0	10.3	229	100.0	4.2




Fig.13 (a)




Fig.13 (b)


CANCER OF TONGUE (ICD-10: C01-C02)

CANCER OF TONGUE: 2011

Number, Percent and AAR/10⁵ by Broad Age Groups

	MALE	FEMALE
No. of cases	330	110
% to total cases	5.6	1.7
CIR/105	4.9	1.9
AAR/105	5.3	2.0
TR/105	10.5	3.4
Ratio at risk	1:167	1:436

Age Group		MALE			FEMALI	E
	#	%	AAR	#	%	AAR
0-14	-	-	-	-	-	-
15-34	30	9.1	1.0	6	5.5	0.2
35-64	216	65.5	10.5	60	54.5	3.4
65+	84	25.5	24.6	44	40	12.3
Total	330	100.0	5.3	110	100.0	2.0



CANCER OF MOUTH (ICD-10: C03-06)

CANCER OF MOUTH: 2011

Number, Percent and AAR/10⁵ by Broad Age Groups

		FEMAL
	MALE	E
No. of cases	482	202
% to total cases	8.2	3.2
CIR/105	7.2	3.5
AAR/105	7.7	3.7
TR/105	17.1	7.0
Ratio at risk	1:112	1:220

Age Group		MALE			FEMALI	E
	#	%	AAR	#	%	AAR
0-14	-	-	-	-	-	-
15-34	25	5.2	0.8	4	1.8	0.2
35-64	356	73.9	17.1	122	56.0	7.0
65+	101	21.0	30.3	76	34.9	21.4
Total	482	100.0	7.7	218	100.0	3.7




Fig.18(a)




Fig.18(b)

MORTALITY

Mortality statistics have an impressive history as a useful tool for undertaking epidemiological studies of cancer. The mortality analysis of various occupational groups has provided the evidence, which leads to the discovery of several chemical carcinogens. Examination of time trends of the deaths rates has in turn lead to the developments of new etiologic hypotheses. Furthermore, international comparison of mortality data has been productive in outlining new directions for undertaking epidemiological field studies.

The significant role played by mortality data in epidemiological studies, in the past was largely due to the unavailability of morbidity data, which is considered more valuable for undertaking epidemiological investigations. Gradually, the role of mortality studies has diminished with the establishment of population based cancer registries in various countries throughout the world and the availability of adequate morbidity data. The value of mortality data has also decreased with the increasing use of epidemiological field studies undertaken to test specific etiologic hypotheses, developed as a result of analysis of mortality statistics.

At our registry, mortality data has been obtained from the death records maintained by the Vital Statistics Division of the Mumbai Municipal Corporation. Copies are made by us of all death certificates which mention the words 'Cancer' or 'Tumor' as being the cause of death.


During the year 2011, a total of 7532 cancer deaths were recorded by the Mumbai Municipal Corporation. Out of these, 1252 were non residents of Greater Mumbai, 6280 were residents for over 1 year with 3253 males and 3027 females, Male/Female ratio of mortality cases being 1.1:1. The annual Crude incidence rate (CR) & age adjusted rate (AAR) were 48.4 and 58.2 among males 52.7 and 54.8 among females respectively per 100,000 persons. The Truncated rate among males and females were 72.3 and 85.2 per 100,000 respectively.


The leading sites of cancer deaths, ranked by age-adjusted rates in males and females, are given in Table S. Deaths from cancers of the lung, top the list in males, followed by deaths form cancers involving the prostate, liver, oesophagus, stomach and mouth. Among females, cancers of the breast being the leading site followed by the ovary, cervix and lung. (Fig 19)

The age-specific rates were found to follow the general patterns of increase with age. An increase for the first time was seen to occur in the fourth decade, in both sexes (Table R). The age-specific death rates for females were found to be generally lower than for males, except in the age-group i.e. 20-59 (Table R). This can be explained by the high mortality rates of female genital cancers that occur in the reproductive age groups (Fig 20.)

	: Annual Age Adjuste e leading sites, Greater			Per 100,000 Populati	ion at All Sites
	MALE			FEMALE	
RANK	SITE	AAR	RANK	SITE	AAR
1	Lung	8.0	1	Breast	11.7
2	Prostate	4.5	2	Ovary	4.5
3	Liver	4.4	3	Cervix	4.3
4	Oesophagus	3.0	4	Lung	3.1
5	Stomach	3.0	5	Oesophagus	2.6
6	Mouth	2.9	6	Gall Bladder	2.3
7	Leukemia	2.8	7	Liver	2.1
8	Lymphoma	2.7	8	Leukemia	2.0
9	Tongue	2.5	9	Colon	1.7
10	Larynx	2.4	10	Pancreas	1.7
	All Sites	58.2		All Sites	54.8

AGE ADJUSTED DEATH RATES PER 100,000 POPULATIONS AT TEN LEADING SITES, 2011





MALE

Fig.19

Age Group	Male	Female
00-04	2.3	1.3
05-09	2.9	2.1
10-14	3.2	2.6
15-19	4.2	2.7
20-24	3.8	1.9
25-29	5.7	4.4
30-34	8.8	13.5
35-39	15.3	21.0
40-44	26.9	38.6
45-49	41.8	72.4
50-54	76.1	95.7
55-59	132.6	144.0
60-64	206.2	198.4
65-69	333.9	283.1
70-74	457.8	372.0
75+	705.0	516.0
ALL AGES	58.2	54.8

AGE SPECIFIC MORTALITY RATE PER 100,000 POPULATION, FOR ALL CANCER SITES, 2011.




Fig. 20

It is important to determine whether the pattern of age and sex in cancer mortality rates, in fact reflects the incidence rates. The relative comparison of the age distribution in the mortality and morbidity analysis and the age distribution of the population by sex, are given Table S.

r	Fable U: Relati	ve Morbidity and M	ortality Rates of	Cancer by Sex, Gro	eater Mumbai, 2	011
SEX	AGE	POPULATION	CANCER CASES	INDICATOR OF RELATIVE FREQUENCY	CANCER DEATH	INDICATOR OF RELATIVE FREQUENCY
MALE	00-14	21.5	2.2	10.4	1.3	5.9
	15-34	40.4	6.4	15.8	4.6	11.5
	35-64	33.1	48.9	147.7	43.1	130.1
	65+	5.1	42.5	833.3	51.0	1000.6
FEMALE	00-14	22.6	1.2	5.3	0.9	3.8
	15-34	37.6	6.2	16.4	3.9	10.4
	35-64	33.7	59.1	175.3	49.5	146.8
	65+	6.2	33.5	541.1	45.8	738.5
TOTAL	00-14	22	1.7	7.7	1.2	5.4
	15-34	39	6.3	16.1	4.8	12.3
	35-64	31.7	54.2	170.9	51.6	162.6
	65+	5.6	37.9	676.0	54.2	967.7

Cancer incidence and mortality rates were found to be very low in the younger ages. The association of cancer incidence and mortality with the aging process, is clearly shown by the fact that the percentage of registered cancer cases and the percentage of the total number of deaths occurring in person 65 years of age and above, are 37.9 and 54.2 respectively, as this group comprises only about 5.0% of the general population. The relative cancer incidence and mortality rates increase with age, in both the sexes. Indicators of the relative incidence and mortality, shows that up to the age of 64 the incidence rates are higher but therefore the mortality rates reach higher levels in both the sexes.

Table 1: Estimated Resident Population by Age and Sex as on 1^{st} July 2011, Greater Mumbai, Total Population (All Religious Communities)

Age Group	Male		Femal	e	Total	
	#	%	#	%	#	%
0004	436587	6.5	399987	7.0	836574	6.7
0509	477210	7.1	430802	7.5	908012	7.3
1014	528130	7.9	468283	8.1	996413	8.0
1519	612347	9.1	487610	8.5	1099957	8.8
2024	762506	11.3	573755	10.0	1336261	10.7
2529	730545	10.9	584742	10.3	1325287	10.6
3034	611523	9.1	503795	8.8	1115318	8.9
3539	549500	8.2	471153	8.2	1020653	8.2
4044	469225	7.0	404468	7.0	873693	7.0
4549	403830	6.0	356219	6.2	760049	6.1
5054	334872	5.0	283208	4.9	618080	5.0
5559	260908	3.9	228416	4.0	489324	3.9
6064	204138	3.0	193576	3.4	397714	3.2
6569	133855	2.0	131413	2.3	265268	2.1
7074	92624	1.4	95150	1.7	187774	1.5
75+	111355	1.7	126555	2.2	237910	1.9
Total	6719155	100.0	5739132	100.0	12458287	100.0

Table 2: Estimated Resident Population by Religion and Sex as on 1st July 2011, Greater Mumbai

Religion	Male		Female		Total	
	#	%	#	%	#	%
Hindu	4574511	36.7	3821372	30.7	8395883	67.4
Muslims	1279261	10.3	1032838	8.3	2312099	18.6
Christians	225752	1.8	239238	1.9	464990	3.7
Sikhs	37625	0.3	34728	0.3	72353	0.6
Buddhist	325277	2.6	326701	2.6	651978	5.2
Jains	246385	2.0	252100	2.0	498485	4.0
Parsi	27916	0.2	30869	0.2	58785	0.5
Others	2427	0.0	1286	0.0	3714	0.0
Total	6719155	53.9	5739132	46.1	12458287	100.0

Table 3: Number of Incidence Cases of Cancer by Site (ICD10 & Age), with Percentages, Greater Mumbai, 2011, Male

ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	99	Total	%
C00	Lip	0	0	0	0	0	1	1	0	2	3	3	5	3	4	2	0	0	24	0.4
C01-02	Tongue	0	0	0	0	0	6	24	32	22	37	41	43	41	29	23	32	0	330	5.6
C03-06	Mouth	0	0	0	1	2	4	18	38	56	66	65	80	51	57	20	23	1	482	8.2
C07-08	Salivary Gland	0	2	0	0	0	0	2	3	1	3	6	6	2	1	2	3	0	31	0.5
C09-10	Oropharynx	0	0	0	0	0	0	0	0	3	4	16	15	12	10	8	7	0	75	1.3
C11	Nasopharynx	0	0	0	2	2	0	0	2	2	0	2	1	3	2	3	4	0	23	0.4
C12-13	Hypopharynx	0	0	0	0	0	1	0	0	2	6	3	15	21	19	23	28	1	119	2.0
C14	Other Oral	0	0	0	0	0	0	0	0	1	1	3	9	4	8	9	14	0	49	0.8
C15	Oesophagus	0	0	0	0	0	0	2	2	10	14	26	29	36	38	30	42	0	229	3.9
C16	Stomach	0	0	0	0	1	1	2	10	13	17	23	30	30	27	35	44	0	233	4.0
C17	Samll Intestine	0	0	0	0	0	2	2	0	3	3	2	6	3	1	1	0	0	23	0.4
C18	Colon	0	0	0	0	1	3	7	6	18	19	29	20	20	25	26	48	0	222	3.8
C19-21	Rectum	0	0	0	1	2	6	6	10	10	17	15	18	28	24	19	25	1	182	3.1
C22	Liver	2	0	0	2	0	2	2	6	8	12	21	34	44	43	38	62	0	276	4.7
C23-24	Gall Bladder	0	0	0	0	0	1	4	3	6	4	13	12	16	12	19	26	0	116	2.0
C25	Pancreas	1	0	0	0	1	2	3	2	4	10	18	15	25	23	20	29	0	153	2.6
C26	Oth Dig Org	0	0	0	0	0	1	0	0	0	0	1	2	2	1	0	3	0	10	0.2
C30-31	Nose, Sinuse	0	0	0	3	0	1	0	4	0	2	1	7	2	5	3	5	0	33	0.6
C32	Larynx	0	0	0	1	1	0	5	3	6	21	31	31	37	38	37	59	0	270	4.6
C33-34	Lung	1	1	0	0	1	5	1	3	13	19	50	71	87	108	78	116	0	554	9.4
C37-38	Mediastinum, Plura	0	0	0	0	0	0	0	0	0	2	0	1	1	3	0	3	0	10	0.2
C40-41	Bone	0	4	6	15	5	4	6	5	3	1	2	5	2	2	3	4	0	67	1.1
C43	Skin Melanoma	0	0	0	0	0	0	2	0	0	0	2	0	0	0	0	2	0	6	0.1
C44	Skin Others	1	1	0	1	1	0	2	3	2	8	11	6	7	13	7	17	0	80	1.4
C47	Nervous System	0	0	0	0	2	0	0	0	1	0	0	1	1	0	1	0	0	6	0.1
C48	Retroperitonium	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.0
C49	Conn & Soft Tissue	1	2	3	4	2	3	5	8	2	3	8	7	6	5	6	3	0	68	1.2
C50	Breast	0	0	0	0	0	2	1	0	3	4	7	5	5	5	3	4	0	39	0.7
C60	Penis	0	0	0	0	0	0	2	3	2	2	3	8	9	6	12	7	0	54	0.9
C61	Prostate	0	0	0	0	0	0	0	2	1	1	12	24	61	87	113	185	0	486	8.3
C62	Testis	0	0	0	3	4	4	10	8	6	3	2	0	0	1	1	0	0	42	0.7
C63	Oth Male Gen Org	0	0	0	0	0	0	0	2	0	0	0	0	1	0	0	1	0	4	0.1
C64-65	Kidney	2	1	0	0	2	1	3	3	5	12	16	21	25	19	15	15	1	141	2.4
C66-68	Urinary Bladder	0	0	1	0	0	4	2	2	5	9	7	23	45	22	28	69	0	217	3.7
C69	Eye	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	6	0.1
C70-72	Brain	6	7	6	8	12	8	14	13	18	24	19	19	21	11	11	18	0	215	3.7
C73	Thyroid	0	0	0	1	3	2	1	4	11	9	9	6	6	5	2	7	0	66	1.1
C74-75	Other Endocrine Gla	1	0	0	0	0	0	1	0	0	0	0	1	0	1	1	0	0	5	0.1
C76	Other Ill Def Sites	0	0	0	0	0	0	0	1	0	0	1	4	2	1	2	2	0	13	0.2
C77	Lymph Nodes	2	0	0	2	1	1	1	3	4	8	7	11	10	9	10	13	0	82	1.4
C78	Sec Resp & Dig	0	0	0	1	0	0	0	3	2	3	6	13	13	6	9	12	0	68	1.2
C79	Sec Others	0	0	0	1	0	0	1	0	2	0	4	2	3	2	2	4	0	21	0.4
C80	Unknown Primary	1	0	0	0	1	0	1	2	1	6	4	8	4	13	6	12	0	59	1.0
C81	Hodgkin Lymphoma	2	6	3	2	2	8	3	4	5	3	3	3	5	4	4	7	0	64	1.1
C82-85	N.H.Lymphoma	5	5	9	4	6	6	6	15	8	18	31	24	32	30	26	35	0	260	4.4
C90	Multiple Myloma	0	0	0	0	0	1	1	2	4	5	11	9	21	19	14	19	0	106	1.8
C91	Lymphoid Leukemia	8	11	12	7	5	2	1	5	4	4	4	9	3	8	2	11	0	96	1.6
C92	Myeloid Leukemia	1	2	1	8	2	7	5	10	8	8	11	13	6	8	8	23	0	121	2.1
C93-95	Other Leukemia	2	5	3	5	5	2	2	3	1	2	2	1	1	7	2	5	0	48	0.8
Total	All Sites	40	47	44	72	64	91	149	225	278	393	551	673	757	764	684	1049	4	5885	100.0

Table 4: Number of Incidence Cases of Cancer by Site (ICD10 & Age), with Percentages, Greater Mumbai, 2011, Female

ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	99	Total	%
C00	Lip	0	0	0	0	0	0	0	1	2	0	2	0	1	0	0	0	0	6	0.1
C01-02	Tongue	0	0	0	0	0	3	3	3	10	8	10	16	13	18	8	18	0	110	1.7
C03-06	Mouth	0	0	0	0	0	0	4	9	13	18	25	21	36	25	23	28	0	202	3.2
C07-08	Salivary Gland	0	0	0	0	0	0	2	1	0	3	2	2	0	0	2	2	0	14	0.2
C09-10	Oropharynx	0	0	0	0	0	0	1	2	0	1	4	3	3	4	6	5	0	29	0.5
C11	Nasopharynx	0	0	0	0	0	0	0	1	2	2	1	1	0	0	1	2	0	10	0.2
C12-13	Hypopharynx	0	0	0	0	0	1	0	0	0	8	6	5	8	7	2	4	0	41	0.6
C14	Other Oral	0	0	0	0	0	0	1	1	2	2	1	2	4	3	2	6	0	24	0.4
C15	Oesophagus	0	0	0	0	0	2	2	7	9	18	16	20	25	26	16	46	0	187	2.9
C16	Stomach	0	0	0	0	0	2	6	7	10	13	8	14	7	15	12	25	0	119	1.9
C17	Samll Intestine	0	0	0	0	0	0	0	0	5	1	4	1	3	1	4	3	0	22	0.3
C18	Colon	0	0	0	0	1	3	5	7	4	10	18	11	25	17	26	35	1	163	2.6
C19-21	Rectum	0	0	0	2	4	4	8	5	11	15	14	16	27	11	16	28	0	161	2.5
C22	Liver	0	0	0	0	0	0	5	5	8	9	11	18	18	17	13	39	1	144	2.3
C23-24	Gall Bladder	0	0	0	1	2	3	5	8	21	23	22	23	19	19	14	24	0	184	2.9
C25	Pancreas	0	0	0	1	0	1	1	1	3	6	8	10	14	15	13	27	0	100	1.6
C26	Oth Dig Org	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0	2	0	5	0.1
C30-31	Nose, Sinuse	0	0	0	0	0	0	1	1	1	2	1	1	2	3	4	3	0	19	0.3
C32	Larynx	0	0	0	0	2	0	1	2	1	2	2	6	4	4	2	10	0	36	0.6
C33-34	Lung	0	0	0	0	0	0	4	7	9	16	18	36	35	22	33	49	0	229	3.6
C37-38	Mediastinum, Plura	0	0	0	1	0	0	1	0	0	0	1	0	2	0	0	0	0	5	0.1
C40-41	Bone	0	3	5	4	3	1	1	5	7	1	2	4	2	3	0	3	0	44	0.7
C43	Skin Melanoma	1	0	0	0	0	0	0	0	0	2	1	1	0	1	2	1	0	9	0.1
C44	Skin Others	0	0	0	1	0	0	2	0	4	1	7	8	7	8	8	14	0	60	0.9
C47	Nervous System	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	3	0.0
C48	Retroperitonium	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.0
C49	Conn & Soft Tissue	0	0	2	2	1	3	4	8	8	9	7	9	8	5	1	4	0	71	1.1
C50	Breast	0	0	0	0	3	24	50	127	195	239	227	236	257	176	136	229	1	1900	29.9
C51-52	Oth Fem Gen Org	0	0	0	0	0	0	2	4	2	6	4	2	8	2	8	18	0	56	0.9
C53	Cervix	0	0	0	0	1	3	13	31	51	85	72	62	68	64	35	41	1	527	8.3
C54	Corpus Uteri	0	0	0	0	0	3	3	7	16	25	43	41	43	31	25	16	0	253	4.0
C55	Uterus	0	0	0	0	0	1	0	3	0	1	2	4	8	5	15	12	0	51	0.8
C56	Ovary	1	2	4	4	6	7	8	23	33	51	53	60	50	45	36	55	2	440	6.9
C57-58	Oth Unsp Fem Gen Or	0	0	0	0	1	0	0	1	0	0	3	0	0	0	2	0	0	7	0.1
C64-65	Kidney	1	1	0	0	1	1	0	2	3	5	3	8	14	8	8	13	0		1.1
C66-68	Urinary Bladder	0	0	0	0	0	0	0	0	1	6	3	8	4	6	6	16	0	50	0.8
C69	Eye	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0.1
C70-72	Brain	7	5	3	6	3	5	13	12	16	14	12	9	13	13	8	10	0	149	2.3
C73	Thyroid	0	0	1	7	5	16	17	12	12	12	9	8	13	7	6	10	0	135	2.1
C74-75	Other Endocrine Gla	0	0	0	1	0	0	0	1	0	3	1	0	2	1	0	0	1	10	0.2
C76	Other Ill Def Sites	1	0	2	1	0	0	0	2	0	0	0	3	2	4	2	0	0	17	0.3
C77	Lymph Nodes	0	0	0	0	1	0	2	4	4	6	6	4	5	8	5	7	0	52	0.8
C78	Sec Resp & Dig	0	0	0	0	1	0	5	3	5	8	10	13	9	14	10	13	0	91	1.4
C79	Sec Others	0	1	0	0	0	1	0	4	1	5	2	5	1	1	0	4	0	25	0.4
C80	Unknown Primary	0	0	0	0	2	4	1	3	4	4	4	3	11	8	8	12	0	64	1.0
C81	Hodgkin Lymphoma	0	1	2	4	6	4	2	1	3	3	5	0	4	4	4	8	0	51	0.8
C82-85	N.H.Lymphoma	1	1	0	3	5	1	5	10	10	18	13	14	21	26	18	27	0	173	2.7
C90	Multiple Myloma	0	0	0	0	0	0	0	3	1	7	4	3	10	6	3	11	0		0.8
C91	Lymphoid Leukemia	4	13	4	2	4	4	2	1	0	6	1	2	6	3	2	4	0	58	0.9
C92	Myeloid Leukemia	1	0	1	2	1	4	6	6	8	13	9	4	7	7	2	12	0	83	1.3
C93-95	Other Leukemia	0	3	1	1	3	1	4	0	1	2	2	4	1	3	2	8	0	36	0.6
Total	All Sites	21	30	25	43	56	102	191	343	496	690	679	721	820	668	549	904	8	6346	100.0

Table 5: Average Annual Age-Specific, World Age Adjusted, Truncated (35-64) Incidence Rates of Cancer Cases per 100,000 Persons, Greater Mumbai, 2011, Male

ICD-10 S	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	CR	AAR	TR
C00 I	Lip	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.4	0.7	0.9	1.9	1.5	3.0	2.2	0.0	0.4	0.4	0.8
	Tongue	0.0	0.0	0.0	0.0	0.0	0.8	3.9	5.8	4.7	9.2	12.2	16.5	20.1	21.7	24.8	28.7	4.9	5.3	10.5
	Mouth	0.0	0.0	0.0	0.2	0.3	0.5	2.9	6.9	11.9	16.3	19.4	30.7	25.0	42.6	21.6	20.7	7.2	7.7	17.1
C07-08	Salivary Gland	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.5	0.2	0.7	1.8	2.3	1.0	0.7	2.2	2.7	0.5	0.5	1.0
	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.0	4.8	5.7	5.9	7.5	8.6	6.3	1.1	1.3	2.6
	Nasopharynx	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.4	0.4	0.0	0.6	0.4	1.5	1.5	3.2	3.6	0.3	0.4	0.5
	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	1.5	0.9	5.7	10.3	14.2	24.8	25.1	1.8	2.2	2.6
C14 (Other Oral	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.9	3.4	2.0	6.0	9.7	12.6	0.7	0.9	0.9
	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	2.1	3.5	7.8	11.1	17.6	28.4	32.4	37.7	3.4	4.2	6.1
	Stomach	0.0	0.0	0.0	0.0	0.1	0.1	0.3	1.8	2.8	4.2	6.9	11.5	14.7	20.2	37.8	39.5	3.5	4.1	6.2
	Samll Intestine	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.6	0.7	0.6	2.3	1.5	0.7	1.1	0.0	0.3	0.3	0.9
	Colon	0.0	0.0	0.0	0.0	0.1	0.4	1.1	1.1	3.8	4.7	8.7	7.7	9.8	18.7	28.1	43.1	3.3	3.8	5.5
	Rectum	0.0	0.0	0.0	0.2	0.3	0.8	1.0	1.8	2.1	4.2	4.5	6.9	13.7	17.9	20.5	22.5	2.7	3.1	5.0
C22 I	Liver	0.5	0.0	0.0	0.3	0.0	0.3	0.3	1.1	1.7	3.0	6.3	13.0	21.6	32.1	41.0	55.7	4.1	5.1	6.6
	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.5	1.3	1.0	3.9	4.6	7.8	9.0	20.5	23.3	1.7	2.1	2.8
C25 I	Pancreas	0.2	0.0	0.0	0.0	0.1	0.3	0.5	0.4	0.9	2.5	5.4	5.7	12.2	17.2	21.6	26.0	2.3	2.8	3.9
	Oth Dig Org	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.8	1.0	0.7	0.0	2.7	0.1	0.2	0.3
	Nose, Sinuse	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.7	0.0	0.5	0.3	2.7	1.0	3.7	3.2	4.5	0.5	0.6	0.8
	Larynx	0.0	0.0	0.0	0.2	0.1	0.0	0.8	0.5	1.3	5.2	9.3	11.9	18.1	28.4	39.9	53.0	4.0	4.9	6.7
	Lung	0.2	0.2	0.0	0.0	0.1	0.7	0.2	0.5	2.8	4.7	14.9	27.2	42.6	80.7	84.2	104.2	8.2	10.3	13.0
	Mediastinum, Plura	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.4	0.5	2.2	0.0	2.7	0.1	0.2	0.2
	Bone	0.0	0.8	1.1	2.4	0.7	0.5	1.0	0.9	0.6	0.2	0.6	1.9	1.0	1.5	3.2	3.6		1.0	0.8
	Skin Melanoma	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.8	0.1	0.1	0.1
	Skin Others	0.2	0.2	0.0	0.2	0.1	0.0	0.3	0.5	0.4	2.0	3.3	2.3	3.4	9.7	7.6	15.3	1.2	1.4	1.8
	Nervous System	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.5	0.0	1.1	0.0		0.1	0.2
	Retroperitonium	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	
	Conn & Soft Tissue	0.2	0.4	0.6	0.7	0.3	0.4	0.8	1.5	0.4	0.7	2.4	2.7	2.9	3.7	6.5	2.7	1.0	1.1	1.6
	Breast	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.6	1.0	2.1	1.9	2.4	3.7	3.2	3.6	0.6	0.7	1.2
	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.4	0.5	0.9	3.1	4.4	4.5	13.0	6.3	0.8	1.0	
C61 1	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.2	3.6	9.2	29.9	65.0	122.0	166.1	7.2	9.5	5.8
C62	Testis	0.0	0.0	0.0	0.5	0.5	0.5	1.6	1.5	1.3	0.7	0.6	0.0	0.0	0.7	1.1	0.0	0.6	0.5	0.8
C63 (Oth Male Gen Org	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.9	0.1	0.1	0.1
	Kidney	0.5	0.2	0.0	0.0	0.3	0.1	0.5	0.5	1.1	3.0	4.8	8.0	12.2	14.2	16.2	13.5	2.1	2.5	4.3
C66-68 1	Urinary Bladder	0.0	0.0	0.2	0.0	0.0	0.5	0.3	0.4	1.1	2.2	2.1	8.8	22.0	16.4	30.2	62.0	3.2	4.0	5.0
C69 I	Eye	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.9	0.1	0.2	0.0
C70-72 1	Brain	1.4	1.5	1.1	1.3	1.6	1.1	2.3	2.4	3.8	5.9	5.7	7.3	10.3	8.2	11.9	16.2	3.2	3.4	5.5
C73	Thyroid	0.0	0.0	0.0	0.2	0.4	0.3	0.2	0.7	2.3	2.2	2.7	2.3	2.9	3.7	2.2	6.3	1.0	1.0	2.1
	Other Endocrine Gla	0.2	0.0	0.0		0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.7	1.1	0.0		0.1	0.0
C76	Other Ill Def Sites	0.0			0.0		0.0	0.0	0.2	0.0	0.0	0.3	1.5	1.0	0.7	2.2	1.8	0.2	0.2	0.4
	Lymph Nodes	0.5	0.0			0.1	0.1	0.2	0.5	0.9	2.0	2.1	4.2	4.9	6.7	10.8	11.7		1.4	2.2
	Sec Resp & Dig	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.4	0.7	1.8	5.0	6.4	4.5	9.7	10.8			2.1
	Sec Others	0.0	0.0		0.2	0.0	0.0	0.2	0.0	0.4	0.0	1.2	0.8	1.5	1.5	2.2	3.6		0.4	0.6
	Unknown Primary	0.2	0.0	_	0.0		0.0	0.2	0.4	0.2	1.5	1.2	3.1	2.0	9.7	6.5	10.8		1.1	1.2
	Hodgkin Lymphoma	0.5	1.3			0.3	1.1	0.5	0.7	1.1	0.7	0.9	1.1	2.4	3.0	4.3	6.3	1.0		
	N.H.Lymphoma	1.1		1.7	0.7	0.8	0.8	1.0	2.7	1.7	4.5	9.3	9.2	15.7	22.4	28.1	31.4	3.9	4.5	6.4
	Multiple Myloma		0.0	_		0.0	0.1	0.2	0.4	0.9	1.2	3.3	3.4	10.3	14.2	15.1	17.1	1.6		
	Lymphoid Leukemia	1.8	2.3		1.1	0.7	0.3	0.2	0.9	0.9	1.0	1.2	3.4	1.5	6.0	2.2	9.9		1.7	1.4
	Myeloid Leukemia	0.2	0.4			0.3	1.0	0.8	1.8	1.7	2.0	3.3	5.0	2.9	6.0	8.6	20.7	1.8	1.9	
	Other Leukemia	0.5		0.6	0.8		0.3	0.3	0.5	0.2	0.5	0.6	0.4	0.5	5.2	2.2	4.5		0.8	
	All Sites				11.8	_			40.9	_			257.9				942.0			

Table 6: Average Annual Age-Specific, World Age Adjusted, Truncated (35-64) Incidence Rates of Cancer Cases per 100,000 Persons, Greater Mumbai, 2011, Female

COL 10	ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	CR	AAR	TR
Colu-10 Tongue			-		_					_											
C19-10 Mouth		•																			
Control Con		_																			
Condition Cond																					
C11 Nacopharyax		-																			
C12-13 Mypopharymx																					
C14 Other Oral		1 1	0.0	0.0																	
C15		1 1 1 1																			
C16 Stormach***			0.0	0.0	0.0															3.4	
C17 SamIl Intestime		1 0	0.0	0.0	0.0																
C182 Rectum			0.0	0.0	0.0																
C19-21 Rectum		Colon	0.0	0.0	0.0	0.0	0.2	0.5		1.5			6.4							2.9	
C22 Liver		Rectum	0.0	0.0	0.0	0.4	0.7			1.1											
C25-24 Call Bladder			0.0		0.0																
C25		Gall Bladder	0.0	0.0	0.0	0.2	0.3	0.5	1.0	1.7											
C26		Pancreas	0.0	0.0	0.0	0.2	0.0		0.2							11.4					
C32		Oth Dig Org	0.0	0.0	0.0	0.0	0.0									1.5					
C32			0.0	0.0	0.0	0.0	0.0	0.0									4.2	2.4			
C33-34 Lung			0.0	0.0	0.0	0.0	0.3	0.0					0.7								1.0
C37-38 Mediastinum, Plura			0.0	0.0	0.0	0.0	0.0														7.0
C40-41 Bone 0.0 0.7 1.1 0.8 0.5 0.2 0.2 1.1 1.7 0.3 0.7 1.8 1.0 2.3 0.0 2.4 0.8 0.8 1.1 C43 Skin Melanoma 0.3 0.0	C37-38	Mediastinum, Plura	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	1.0	0.0	0.0	0.0	0.1	0.1	
C43 Skin Melanoma 0.3 0.0 <		Bone	0.0	0.7	1.1	0.8	0.5						0.7			2.3					
C44 Skin Others		Skin Melanoma	0.3	0.0	0.0	0.0	0.0			0.0			0.4							0.2	
C48 Retroperitonium 0.0	C44	Skin Others	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.0	1.0	0.3	2.5	3.5	3.6	6.1	8.4	11.1	1.0	1.1	1.6
C49 Conn & Soft Tissue 0.0 0.0 0.4 0.4 0.2 0.5 0.8 1.7 2.0 2.5 2.5 3.9 4.1 3.8 1.1 3.2 1.2 1.2 2.6 C50 Breast 0.0 0.0 0.0 0.0 0.5 4.1 9.9 27.0 48.2 67.1 80.2 103.3 132.8 133.9 142.9 180.9 33.1 33.4 70.9 C51-52 Oth Fem Gen Org 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C47	Nervous System	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
C50 Breast	C48	Retroperitonium	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C51-52 Oth Fem Gen Org	C49	Conn & Soft Tissue	0.0	0.0	0.4	0.4	0.2	0.5	0.8	1.7	2.0	2.5	2.5	3.9	4.1	3.8	1.1	3.2	1.2	1.2	2.6
C51-52 Oth Fem Gen Org	C50	Breast	0.0	0.0	0.0	0.0	0.5	4.1	9.9	27.0	48.2	67.1	80.2	103.3	132.8	133.9	142.9	180.9	33.1	33.4	70.9
C54 Corpus Uteri 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.6 1.5 4.0 7.0 15.2 17.9 22.2 23.6 26.3 12.6 4.4 4.7 10.0 C55 Uterus 0.0	C51-52	Oth Fem Gen Org	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	0.5	1.7	1.4	0.9	4.1		8.4	14.2	1.0	1.0	1.5
C55 Uterus	C53	Cervix	0.0	0.0	0.0	0.0	0.2	0.5	2.6	6.6	12.6	23.9	25.4	27.1	35.1	48.7	36.8	32.4	9.2	9.4	20.5
C56 Ovary 0.3 0.5 0.9 0.8 1.0 1.2 1.6 4.9 8.2 14.3 18.7 26.3 25.8 34.2 37.8 43.5 7.7 7.8 15.0 C57-58 Oth Unsp Fem Gen Or 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 C64-65 Kidney 0.3 0.2 0.0 0.0 0.2 0.2 0.0 0.4 0.7 1.4 1.1 3.5 7.2 6.1 8.4 10.3 1.2 1.3 2.1 1.3 2.1 2.6 C66-68 Urinary Bladder 0.0	C54	Corpus Uteri	0.0	0.0	0.0	0.0	0.0	0.5	0.6	1.5	4.0	7.0	15.2	17.9	22.2	23.6	26.3	12.6	4.4	4.7	10.0
C57-58 Oth Unsp Fem Gen Or 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0	C55	Uterus	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.3	0.7	1.8	4.1	3.8	15.8	9.5	0.9	1.0	1.1
C57-58 Oth Unsp Fem Gen Or 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0	C56	Ovary	0.3	0.5	0.9	0.8	1.0	1.2	1.6	4.9	8.2	14.3	18.7	26.3	25.8	34.2	37.8	43.5	7.7	7.8	15.0
C66-68 Urinary Bladder 0.0 0.1 0.1 0.0 C70-72 Brain 1.8 1.2 0.6 1.2 0.5 0.9 2.6 2.5 4.0 3.9 4.2 3.9 6.7 9.9 8.4 7.9 2.6 2.6 4.1 C73 Thyroid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	C57-58	Oth Unsp Fem Gen Or	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	1.1	0.0	0.0	0.0	2.1	0.0	0.1	0.1	0.2
C69 Eye 1.0 0.1 0.1 0.0 C70-72 Brain 1.8 1.2 0.6 1.2 0.5 0.9 2.6 2.5 4.0 3.9 4.2 3.9 6.7 9.9 8.4 7.9 2.6 2.6 4.1 C73 Thyroid 0.0 0.	C64-65	Kidney	0.3	0.2	0.0	0.0	0.2	0.2	0.0	0.4	0.7	1.4	1.1	3.5	7.2	6.1	8.4	10.3	1.2	1.3	2.1
C70-72 Brain 1.8 1.2 0.6 1.2 0.5 0.9 2.6 2.5 4.0 3.9 4.2 3.9 6.7 9.9 8.4 7.9 2.6 2.6 4.1 C73 Thyroid 0.0 0.0 0.2 1.4 0.9 2.7 3.4 2.5 3.0 3.4 3.2 3.5 6.7 5.3 6.3 7.9 2.4 2.2 3.6 C74-75 Other Endocrine Gla 0.0<	C66-68	Urinary Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.7	1.1	3.5	2.1	4.6	6.3	12.6	0.9	0.9	1.3
C73 Thyroid 0.0 0.0 0.2 1.4 0.9 2.7 3.4 2.5 3.0 3.4 3.2 3.5 6.7 5.3 6.3 7.9 2.4 2.2 3.6 C74-75 Other Endocrine Gla 0.0 <td>C69</td> <td>Eye</td> <td>1.0</td> <td>0.0</td> <td>0.1</td> <td>0.1</td> <td>0.0</td>	C69	Eye	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
C74-75 Other Endocrine Gla	C70-72	Brain	1.8	1.2	0.6	1.2	0.5	0.9	2.6	2.5	4.0	3.9	4.2	3.9	6.7	9.9	8.4	7.9	2.6	2.6	4.1
C76 Other III Def Sites 0.3 0.0 0.4 0.2 0.0	C73	Thyroid	0.0	0.0	0.2	1.4	0.9	2.7	3.4	2.5	3.0	3.4	3.2	3.5	6.7	5.3	6.3	7.9	2.4	2.2	3.6
C77 Lymph Nodes 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.8 1.0 1.7 2.1 1.8 2.6 6.1 5.3 5.5 0.9 0.9 1.6 C78 Sec Resp & Dig 0.0 0.0 0.0 0.0 0.2 0.0 1.0 0.6 1.2 2.2 3.5 5.7 4.6 10.7 10.5 10.3 1.6 1.6 2.7 C79 Sec Others 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.8 0.2 1.4 0.7 2.2 0.5 0.8 0.0 3.2 0.4 0.4 0.9 C80 Unknown Primary 0.0 0.0 0.0 0.0 0.3 0.7 0.2 0.6 1.0 1.1 1.4 1.3 5.7 6.1 8.4 9.5 1.1 1.2 1.7 C81 Hodgkin Lymphoma 0.0 0.2 0.4 0.8 1.0 0.7 0.4 0.2 0.7 0.8 1.8 0.0 2.1 3.0 4.2 6.3 0.9 0.9 0.9 C82-85 N.H.Lymphoma 0.3 0.2 0.0 0.6 0.9 0.2 1.0 2.1 2.5 5.1 4.6 6.1 10.8 19.8 18.9 21.3 3.0 3.1 4.8 C90 Multiple Myloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C74-75	Other Endocrine Gla	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.8	0.4	0.0	1.0	0.8	0.0	0.0	0.2	0.2	0.4
C78 Sec Resp & Dig	C76	Other Ill Def Sites	0.3	0.0	0.4	0.2	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.3	1.0	3.0	2.1	0.0	0.3	0.3	0.4
C79 Sec Others 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.8 0.2 1.4 0.7 2.2 0.5 0.8 0.0 3.2 0.4 0.4 0.9 C80 Unknown Primary 0.0 0.0 0.0 0.0 0.3 0.7 0.2 0.6 1.0 1.1 1.4 1.3 5.7 6.1 8.4 9.5 1.1 1.2 1.7 C81 Hodgkin Lymphoma 0.0 0.2 0.4 0.8 1.0 0.7 0.4 0.2 0.7 0.8 1.8 0.0 2.1 3.0 4.2 6.3 0.9 0.9 0.9 C82-85 N.H.Lymphoma 0.3 0.2 0.0 0.6 0.9 0.2 1.0 2.1 2.5 5.1 4.6 6.1 10.8 19.8 18.9 21.3 3.0 3.1 4.8 C90 Multiple Myloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C77	Lymph Nodes	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.8	1.0	1.7	2.1	1.8	2.6	6.1	5.3	5.5	0.9	0.9	1.6
C80 Unknown Primary	C78	Sec Resp & Dig	0.0	0.0	0.0	0.0	0.2	0.0	1.0	0.6	1.2	2.2	3.5	5.7	4.6	10.7	10.5	10.3	1.6	1.6	2.7
C81 Hodgkin Lymphoma 0.0 0.2 0.4 0.8 1.0 0.7 0.4 0.2 0.7 0.8 1.8 0.0 2.1 3.0 4.2 6.3 0.9 0.9 0.9 C82-85 N.H.Lymphoma 0.3 0.2 0.0 0.6 0.9 0.2 1.0 2.1 2.5 5.1 4.6 6.1 10.8 19.8 18.9 21.3 3.0 3.1 4.8 C90 Multiple Myloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 1.3 5.2 4.6 3.2 8.7 0.8 0.9 1.6 C91 Lymphoid Leukemia 1.0 3.0 0.9 0.4 0.7 0.7 0.4 0.2 0.0 1.7 0.4 0.9 3.1 2.3 2.1 3.2 1.0 1.1 0.9 C92 Myeloid Leukemia 0.3 0.0 0.2 0.7 1.2 1.3 2.0	C79	Sec Others	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.8	0.2	1.4	0.7	2.2	0.5	0.8	0.0	3.2	0.4	0.4	0.9
C82-85 N.H.Lymphoma 0.3 0.2 0.0 0.6 0.9 0.2 1.0 2.1 2.5 5.1 4.6 6.1 10.8 19.8 18.9 21.3 3.0 3.1 4.8 C90 Multiple Myloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 2.0 1.4 1.3 5.2 4.6 3.2 8.7 0.8 0.9 1.6 C91 Lymphoid Leukemia 1.0 3.0 0.9 0.4 0.7 0.7 0.4 0.2 0.0 1.7 0.4 0.9 3.1 2.3 2.1 3.2 1.0 1.1 0.9 C92 Myeloid Leukemia 0.3 0.0 0.2 0.7 1.2 1.3 2.0 3.6 3.2 1.8 3.6 5.3 2.1 9.5 1.4 1.4 2.5	C80	Unknown Primary	0.0	0.0	0.0	0.0	0.3	0.7	0.2	0.6	1.0	1.1	1.4	1.3	5.7	6.1	8.4	9.5	1.1	1.2	1.7
C90 Multiple Myloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 2.0 1.4 1.3 5.2 4.6 3.2 8.7 0.8 0.9 1.6 C91 Lymphoid Leukemia 1.0 3.0 0.9 0.4 0.7 0.7 0.4 0.2 0.0 1.7 0.4 0.9 3.1 2.3 2.1 3.2 1.0 1.1 0.9 C92 Myeloid Leukemia 0.3 0.0 0.2 0.4 0.2 0.7 1.2 1.3 2.0 3.6 3.2 1.8 3.6 5.3 2.1 9.5 1.4 1.4 2.5	C81	Hodgkin Lymphoma	0.0	0.2	0.4	0.8	1.0	0.7	0.4	0.2	0.7	0.8	1.8	0.0	2.1	3.0	4.2	6.3	0.9	0.9	0.9
C90 Multiple Myloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 2.0 1.4 1.3 5.2 4.6 3.2 8.7 0.8 0.9 1.6 C91 Lymphoid Leukemia 1.0 3.0 0.9 0.4 0.7 0.7 0.4 0.2 0.0 1.7 0.4 0.9 3.1 2.3 2.1 3.2 1.0 1.1 0.9 C92 Myeloid Leukemia 0.3 0.0 0.2 0.4 0.2 0.7 1.2 1.3 2.0 3.6 3.2 1.8 3.6 5.3 2.1 9.5 1.4 1.4 2.5		N.H.Lymphoma							1.0					6.1	10.8	19.8			3.0	3.1	4.8
C91 Lymphoid Leukemia 1.0 3.0 0.9 0.4 0.7 0.7 0.4 0.2 0.0 1.7 0.4 0.9 3.1 2.3 2.1 3.2 1.0 1.1 0.9 C92 Myeloid Leukemia 0.3 0.0 0.2 0.4 0.2 0.7 1.2 1.3 2.0 3.6 3.2 1.8 3.6 5.3 2.1 9.5 1.4 1.4 2.5	C90							0.0	0.0	0.6	0.2	2.0	1.4	1.3	5.2	4.6	3.2	8.7	0.8	0.9	1.6
C92 Myeloid Leukemia 0.3 0.0 0.2 0.4 0.2 0.7 1.2 1.3 2.0 3.6 3.2 1.8 3.6 5.3 2.1 9.5 1.4 1.4 2.5	C91							0.7	0.4	0.2	0.0	1.7	0.4	0.9	3.1	2.3	2.1	3.2	1.0	1.1	0.9
	C92	Myeloid Leukemia	0.3					0.7	1.2	1.3	2.0	3.6	3.2	1.8	3.6	5.3	2.1	9.5	1.4	1.4	2.5
	C93-95	Other Leukemia	0.0	0.7	0.2	0.2	0.5	0.2	0.8	0.0	0.2	0.6	0.7	1.8	0.5	2.3	2.1	6.3	0.6	0.6	0.6
Total All Sites 5.3 7.0 5.3 8.8 9.8 17.4 37.9 72.8 122.6 193.7 239.8 315.7 423.6 508.3 577.0 714.3 110.6 113.0 209.4	Total	All Sites	5.3	7.0	5.3	8.8	9.8	17.4	37.9	72.8	122.6	193.7	239.8	315.7	423.6	508.3	577.0	714.3	110.6	113.0	209.4

Table 7: Incidence Cases of Cancer by Most Valid Basis of Diagnosis and Site (ICD10) with Percentage, Greater Mumbai, 2011, Male

ICD 10	CUTE	Micros	copic	Clini	cal	Clin	Invs	DCC)	Tota	ıl
ICD-10	SITE	#	%	#	%	#	%	#	%	#	%
C00	Lip	24	100.0	0	0.0	0	0.0	0	0.0	24	100
C01-02	Tongue	296	89.7	13	3.9	0	0.0	21	6.4	330	100
C03-06	Mouth	439	91.1	28	5.8	1	0.2	14	2.9	482	100
C07-08	Salivary Gland	28	90.3	1	3.2	0	0.0	2	6.5	31	100
C09-10	Oropharynx	71	94.7	0	0.0	0	0.0	4	5.3	75	100
C11	Nasopharynx	14	60.9	6	26.1	0	0.0	3	13.0	23	100
C12-13	Hypopharynx	111	93.3	7	5.9	0	0.0	1	0.8	119	100
C14	Other Oral	25	51.0	2	4.1	0	0.0	22	44.9	49	100
C15	Oesophagus	173	75.5	17	7.4	1	0.4	38	16.6	229	100
	Stomach	195	83.7	17	7.3	0	0.0	21	9.0	233	100
C17	Samll Intestine	23	100.0	0	0.0	0	0.0	0	0.0	23	100
C18	Colon	191	86.0	14	6.3	1	0.5	16	7.2	222	100
C19-21	Rectum	161	88.5	11	6.0	0	0.0	10	5.5	182	100
	Liver	250	90.6	11	4.0	1	0.4	14	5.1	276	100
	Gall Bladder	88	75.9	15	12.9	1	0.9	12	10.3	116	100
	Pancreas	120	78.4	17	11.1	0	0.0	16	10.5	153	100
	Oth Dig Org	6	60.0	1	10.0	0	0.0	3	30.0	10	100
	Nose, Sinuse	29	87.9	3	9.1	1	3.0	0	0.0	33	100
	Larynx	230	85.2	19	7.0	1	0.4	20	7.4	270	100
	Lung	414	74.7	14	2.5	61	11.0	65	11.7	554	100
	Mediastinum, Plura	7	70.0	2	20.0	0	0.0	1	10.0	10	100
	Bone	63	94.0	2	3.0	0	0.0	2	3.0	67	100
	Skin Melanoma	6	100.0	0	0.0	0	0.0	0	0.0	6	100
	Skin Others	77	96.3	3	3.8	0	0.0	0	0.0	80	100
	Nervous System	6	100.0	0	0.0	0	0.0	0	0.0	6	100
	Retroperitonium	0	0.0	0	0.0	0	0.0	1	100.0	1	100
	Conn & Soft Tissue	67	98.5	1	1.5	0	0.0	0	0.0	68	100
	Breast	35	89.7	1	2.6	0	0.0	3	7.7	39	100
	Penis	45	83.3	8	14.8	0	0.0	1	1.9	54	100
	Prostate	396	81.5	21	4.3	1	0.0	68	14.0	486	100
	Testis	40	95.2	2	4.8	0	0.2	0	0.0	42	100
	Oth Male Gen Org	3	75.0	1	25.0	0	0.0	0	0.0	4	100
	Kidney	132	93.6	0	0.0	6	4.3	3	2.1	141	100
	Urinary Bladder	192	88.5	6	2.8	_	0.0	-	8.8		100
	Eye	6	100.0	0	0.0		0.0		0.0		100
	Brain	205	95.3	2	0.0		0.5	7	3.3		100
	Thyroid	60	90.9	3	4.5	0	0.0		4.5		100
	Other Endocrine Gla						0.0				100
		4	80.0	1	20.0				0.0		
	Other III Def Sites	9	69.2	0	0.0		0.0		30.8		100
	Lymph Nodes	78	95.1	4	4.9		0.0		0.0		100
	Sec Resp & Dig	64	94.1	3	4.4	1	1.5	0	0.0		100
	Sec Others	16	76.2	4	19.0		4.8	0	0.0		100
	Unknown Primary	47	79.7	5	8.5	0	0.0	7	11.9	59	100
	Hodgkin Lymphoma	64	100.0	0	0.0		0.0	0	0.0	64	100
	N.H.Lymphoma	260	100.0	0	0.0		0.0		0.0		100
	Multiple Myloma	106	100.0	0	0.0		0.0		0.0		100
	Lymphoid Leukemia	96	100.0	0	0.0		0.0		0.0		100
	Myeloid Leukemia	121	100.0	0	0.0		0.0		0.0		100
	Other Leukemia	48	100.0	0	0.0		0.0		0.0		100
Total	All sites	5141	87.4	265	4.5	78	1.3	401	6.8	5885	100

Table 8: Incidence Cases of Cancer by Most Valid Basis of Diagnosis and Site (ICD10) with Percentage, Greater Mumbai, 2011, Female

ICD-10	SITE	Microso	copic	Clinic	cal	Clin I	nvs	DC	0	Tot	tal
		#	%	#	%	#	%	#	%	#	%
	Lip	6	100.0	0	0.0	0	0.0	0	0.0	6	100
	Tongue	95	86.4	8	7.3	0	0.0	7	6.4	110	100
	Mouth	185	91.6	6	3.0	1	0.5	10	5.0	202	100
	Salivary Gland	12	85.7	2	14.3	0	0.0	0	0.0	14	100
	Oropharynx	23	79.3	3	10.3	0	0.0	3	10.3	29	100
C11	Nasopharynx	8	80.0	1	10.0	0	0.0	1	10.0	10	100
C12-13	Hypopharynx	37	90.2	4	9.8	0	0.0	0	0.0	41	100
C14	Other Oral	12	50.0	1	4.2	0	0.0	11	45.8	24	100
C15	Oesophagus	142	75.9	8	4.3	1	0.5	36	19.3	187	100
	Stomach	89	74.8	9	7.6	0	0.0	21	17.6	119	100
C17	Samll Intestine	18	81.8	1	4.5	0	0.0	3	13.6	22	100
C18	Colon	145	89.0	6	3.7	0	0.0	12	7.4	163	100
C19-21	Rectum	130	80.7	14	8.7	2	1.2	15	9.3	161	100
C22	Liver	118	81.9	2	1.4	0	0.0	24	16.7	144	100
C23-24	Gall Bladder	137	74.5	28	15.2	0	0.0	19	10.3	184	100
C25	Pancreas	64	64.0	13	13.0	1	1.0	22	22.0	100	100
C26	Oth Dig Org	1	20.0	0	0.0	0	0.0	4	80.0	5	100
C30-31	Nose, Sinuse	17	89.5	1	5.3	0	0.0	1	5.3	19	100
C32	Larynx	28	77.8	4	11.1	0	0.0	4	11.1	36	100
C33-34	Lung	166	72.5	9	3.9	31	13.5	23	10.0	229	100
C37-38	Mediastinum, Plura	5	100.0	0	0.0	0	0.0	0	0.0	5	100
C40-41	Bone	39	88.6	0	0.0	0	0.0	5	11.4	44	100
C43	Skin Melanoma	9	100.0	0	0.0	0	0.0	0	0.0	9	100
C44	Skin Others	57	95.0	2	3.3	0	0.0	1	1.7	60	100
C47	Nervous System	3	100.0	0	0.0	0	0.0	0	0.0	3	100
C48	Retroperitonium	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C49	Conn & Soft Tissue	70	98.6	0	0.0	0	0.0	1	1.4	71	100
C50	Breast	1752	92.2	68	3.6	2	0.1	78	4.1	1900	100
C51-52	Oth Fem Gen Org	46	82.1	6	10.7	0	0.0	4	7.1	56	100
C53	Cervix	444	84.3	19	3.6	28	5.3	36	6.8	527	100
C54	Corpus Uteri	242	95.7	3	1.2	5	2.0	3	1.2	253	100
C55	Uterus	31	60.8	4	7.8	3	5.9	13	25.5	51	100
C56	Ovary	343	78.0	30	6.8	40	9.1	27	6.1	440	100
C57-58	Oth Unsp Fem Gen Or	7	100.0	0	0.0	0	0.0	0	0.0	7	100
C64-65	Kidney	62	91.2	2	2.9	4	5.9	0	0.0	68	100
C66-68	Urinary Bladder	43	86.0	3	6.0	0	0.0	4	8.0	50	100
C69	Eye	4	100.0	0	0.0	0	0.0	0	0.0	4	100
C70-72	Brain	140	94.0	1	0.7	4	2.7	4	2.7	149	100
C73	Thyroid	120	88.9	10	7.4	0	0.0	5	3.7	135	100
C74-75	Other Endocrine Gla	8	80.0	2	20.0	0	0.0	0	0.0	10	100
C76	Other Ill Def Sites	3	17.6	0	0.0	0	0.0	14	82.4	17	100
C77	Lymph Nodes	50	96.2	2	3.8	0	0.0	0	0.0	52	100
C78	Sec Resp & Dig	87	95.6	4	4.4	0	0.0	0	0.0	91	100
C79	Sec Others	23	92.0	2	8.0	0	0.0	0	0.0	25	100
C80	Unknown Primary	52	81.3	6	9.4	0	0.0	6	9.4	64	100
C81	Hodgkin Lymphoma	51	100.0	0	0.0	0	0.0	0	0.0	51	100
C82-85	N.H.Lymphoma	173	100.0	0	0.0	0	0.0	0	0.0	173	100
	Multiple Myloma	48	100.0	0	0.0		0.0	0	0.0	48	100
	Lymphoid Leukemia	58	100.0	0	0.0		0.0	0	0.0	58	100
	Myeloid Leukemia	83	100.0	0	0.0		0.0	0	0.0	83	100
	Other Leukemia	36	100.0	0	0.0		0.0	0	0.0	36	100
Total	All Sites	5522	87.0	285	4.5	122	1.9	417	6.6	6346	100

Table 9: Incidence Cases of Cancer by Clinical Extent of Disease and Site (ICD10) with Percentage, Greater Mumbai, 2011, Male

ICD-10	SITE	Locali	sed	Dir E	Ext	Adv &	Mets	Not A	pp	Tota	al
1CD-10	SHE	#	%	#	%	#	%	#	%	#	%
C00	Lip	15	0.6	6	1.0	3	0.1	0	0.0	24	0.4
C01-02	Tongue	173	7.2	77	12.5	80	3.7	0	0.0	330	5.6
C03-06	Mouth	303	12.7	100	16.2	79	3.6	0	0.0	482	8.2
C07-08	Salivary Gland	15	0.6	4	0.6	12	0.5	0	0.0	31	0.5
C09-10	Oropharynx	33	1.4	21	3.4	21	1.0	0	0.0	75	1.3
C11	Nasopharynx	12	0.5	5	0.8	6	0.3	0	0.0	23	0.4
C12-13	Hypopharynx	58	2.4	31	5.0	30	1.4	0	0.0	119	2.0
C14	Other Oral	17	0.7	5	0.8	27	1.2	0	0.0	49	0.8
C15	Oesophagus	92	3.8	15	2.4	122	5.6	0	0.0	229	3.9
C16	Stomach	86	3.6	31	5.0	116	5.3	0	0.0	233	4.0
C17	Samll Intestine	16	0.7	3	0.5	4	0.2	0	0.0	23	0.4
C18	Colon	100	4.2	37	6.0	85	3.9	0	0.0	222	3.8
C19-21	Rectum	97	4.1	24	3.9	61	2.8	0	0.0	182	3.1
C22	Liver	61	2.6	7	1.1	208	9.5	0	0.0	276	4.7
C23-24	Gall Bladder	40	1.7	11	1.8	65	3.0	0	0.0	116	2.0
C25	Pancreas	41	1.7	2	0.3	110	5.0	0	0.0	153	2.6
C26	Oth Dig Org	2	0.1	1	0.2	7	0.3	0	0.0	10	0.2
C30-31	Nose, Sinuse	23	1.0	3	0.5	7	0.3	0	0.0	33	0.6
C32	Larynx	147	6.1	44	7.1	79	3.6	0	0.0	270	4.6
C33-34	Lung	132	5.5	43	7.0	379	17.4	0	0.0	554	9.4
C37-38	Mediastinum, Plura	9	0.4	0	0.0	1	0.0	0	0.0	10	0.2
C40-41	Bone	48	2.0	3	0.5	16	0.7	0	0.0	67	1.1
C43	Skin Melanoma	4	0.2	0	0.0	1	0.0	1	0.1	6	0.1
C44	Skin Others	58	2.4	6	1.0	16	0.7	0	0.0	80	1.4
C47	Nervous System	4	0.2	0	0.0	2	0.1	0	0.0	6	0.1
C48	Retroperitonium	0	0.0	0	0.0	1	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	49	2.0	5	0.8	14	0.6	0	0.0	68	1.2
C50	Breast	17	0.7	10	1.6	12	0.5	0	0.0	39	0.7
C60	Penis	36	1.5	6	1.0	12	0.5	0	0.0	54	0.9
C61	Prostate	263	11.0	19	3.1	204	9.3	0	0.0	486	8.3
C62	Testis	29	1.2	6	1.0	7	0.3	0	0.0	42	0.7
C63	Oth Male Gen Org	4	0.2	0	0.0	0	0.0	0	0.0	4	0.1
C64-65	Kidney	69	2.9	11	1.8	61	2.8	0	0.0		2.4
C66-68	Urinary Bladder	133	5.6	18	2.9	66	3.0	0	0.0	217	3.7
C69	Eye	5	0.2	1	0.2	0	0.0	0	0.0	6	0.1
C70-72	Brain	138	5.8	23	3.7	53	2.4	1	0.1	215	3.7
C73	Thyroid	40	1.7	7	1.1	19	0.9	0	0.0	66	1.1
C74-75	Other Endocrine Gla	2	0.1	0	0.0	3	0.1	0	0.0		0.1
C76	Other Ill Def Sites	5	0.2	0	0.0	8	0.4	0	0.0		0.2
C77	Lymph Nodes	0	0.0	31	5.0	51	2.3	0	0.0	82	1.4
C78	Sec Resp & Dig	0	0.0	0	0.0	68	3.1	0	0.0	68	1.2
C79	Sec Others	0	0.0	0	0.0	21	1.0	0	0.0	21	0.4
C80	Unknown Primary	13	0.5	0	0.0	46	2.1	0	0.0	59	1.0
C81	Hodgkin Lymphoma	1	0.0	0	0.0	0	0.0	63	9.1	64	1.0
C82-85	N.H.Lymphoma	2	0.0	1	0.0	1	0.0	256	37.0	260	4.4
C82-83 C90	Multiple Myloma	0	0.0	0	0.2	0	0.0	106	15.3	106	1.8
C90 C91	Lymphoid Leukemia	0	0.0	0	0.0	0	0.0	96	13.5	96	1.6
C91 C92	Myeloid Leukemia		0.0	0	0.0	0	0.0	96 121	17.5	96 121	2.1
C92 C93-95	Other Leukemia	0	0.0	0	0.0					121 48	
		2202				2184	0.0	48	6.9		0.8
Total	All Sites	2392	100.0	617	100.0	2184	100.0	692	100.0	5885	100.0

Table 10: Incidence Cases of Cancer by Clinical Extent of Disease and Site (ICD10) with Percentage, Greater Mumbai, 2011, Female

ICD-10	SITE	Local		Dir l		Adv &		Not A			tal
		#	%	#	%	#	%	#	%	#	%
C00	Lip	3	0.1	2	0.2	1	0.0	0	0.0		0.1
	Tongue	57	2.0	20	2.2	33	1.5	0	0.0		1.7
	Mouth	121	4.3	46	5.1	35	1.6	0	0.0		3.2
	Salivary Gland	8	0.3	3	0.3	3	0.1	0	0.0		0.2
	Oropharynx	12	0.4	7	0.8	10	0.5	0	0.0	29	0.5
C11	Nasopharynx	4	0.1	3	0.3	3	0.1	0	0.0	10	0.2
C12-13	Hypopharynx	26	0.9	8	0.9	7	0.3	0	0.0	41	0.6
C14	Other Oral	5	0.2	3	0.3	16	0.7	0	0.0	24	0.4
C15	Oesophagus	64	2.3	23	2.5	100	4.6	0	0.0	187	2.9
C16	Stomach	42	1.5	18	2.0	59	2.7	0	0.0	119	1.9
C17	Samll Intestine	7	0.2	2	0.2	13	0.6	0	0.0	22	0.3
C18	Colon	63	2.2	34	3.7	66	3.0	0	0.0	163	2.6
C19-21	Rectum	68	2.4	34	3.7	59	2.7	0	0.0	161	2.5
C22	Liver	28	1.0	7	0.8	109	5.0	0	0.0	144	2.3
C23-24	Gall Bladder	56	2.0	13	1.4	115	5.3	0	0.0	184	2.9
C25	Pancreas	18	0.6	6	0.7	76	3.5	0	0.0	100	1.6
C26	Oth Dig Org	0	0.0	0	0.0	5	0.2	0	0.0	5	0.1
C30-31	Nose, Sinuse	7	0.2	4	0.4	8	0.4	0	0.0	19	0.3
C32	Larynx	16	0.6	6	0.7	14	0.6	0	0.0	36	0.6
C33-34	Lung	61	2.2	14	1.5	154	7.1	0	0.0	229	3.6
	Mediastinum, Plura	2	0.1	2	0.2	1	0.0	0	0.0	5	0.1
	Bone	26	0.9	1	0.1	17	0.8	0	0.0	44	0.7
C43	Skin Melanoma	3	0.1	0	0.0	3	0.1	3	0.7	9	0.1
C44	Skin Others	41	1.5	10	1.1	9	0.4	0	0.0	60	0.9
C47	Nervous System	1	0.0	1	0.1	1	0.0	0	0.0	3	0.0
C48	Retroperitonium	1	0.0	0	0.0	0	0.0	0	0.0		0.0
C49	Conn & Soft Tissue	54	1.9	3	0.3	14	0.6	0	0.0		1.1
C50	Breast	1002	35.6	425	46.9	472	21.7	1	0.2		29.9
C51-52	Oth Fem Gen Org	36	1.3	11	1.2	9	0.4	0	0.0		0.9
C53	Cervix	340	12.1	63	6.9	124	5.7	0	0.0		8.3
C54	Corpus Uteri	178	6.3	42	4.6		1.5	0	0.0		4.0
C55	Uterus	9	0.3	4	0.4	38	1.7	0	0.0		0.8
C56	Ovary	159	5.7	33	3.6		11.4	0	0.0		6.9
	Oth Unsp Fem Gen Or	5	0.2	1	0.1	1	0.0	0	0.0	7	0.1
C64-65		34	1.2	5	0.6	29	1.3	0	0.0	68	1.1
	Urinary Bladder	37	1.3	1	0.1	12	0.6	0	0.0		0.8
	Eye	3	0.1	0	0.0	1	0.0	0	0.0		0.1
	Brain	101	3.6	8	0.9	40	1.8	0	0.0		2.3
C73	Thyroid	89	3.2	19	2.1	27	1.2	0	0.0		2.1
	Other Endocrine Gla	5	0.2	0	0.0	5	0.2	0	0.0		0.2
C76	Other Ill Def Sites	0	0.0	0	0.0	17	0.8	0	0.0		0.3
C77	Lymph Nodes	0	0.0	24	2.6	28	1.3	0	0.0		0.8
C78	Sec Resp & Dig	0	0.0	1	0.1	90	4.1	0	0.0		1.4
C79	Sec Others	0	0.0	0	0.0	25	1.1	0	0.0		0.4
C80	Unknown Primary	18	0.6	0	0.0	46	2.1	0	0.0		1.0
C81	Hodgkin Lymphoma	10	0.0	0	0.0	0	0.0	50	11.1	51	0.8
	N.H.Lymphoma	3	0.0	0	0.0	0	0.0	170	37.9		2.7
C90	Multiple Myloma	0	0.0	0	0.0	0	0.0	48	10.7	48	0.8
C90	Lymphoid Leukemia	0	0.0	0	0.0	0	0.0	58	10.7		0.8
C91	Myeloid Leukemia	0	0.0	0	0.0	0	0.0	83	18.5		1.3
	Other Leukemia	_	0.0				0.0	83 36	8.0		
		2814		007	0.0						0.6
Total	All sites	2814	100.0	907	100.0	2176	100.0	449	100.0	6346	100.0

Table 11: Incidence Cases of Cancer by Religion and Site (ICD10) with Crude Incidence Rate (CR), Greater Mumbai, 2011, Male

		Hin	ıdu	Mus	slim	Christ	tian	Pa	rsi	Jai	ins	NeoBu	dhist	Sil	kh	To	tal
ICD-10	SITE	#	CR	#	CR	#	CR	#	CR	#	CR	#	CR	#	CR	#	CR
C00	Lip	21	0.5	2	0.2	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	24	0.4
C01-02	Tongue	221	4.8	74	5.8	16	7.1	2	7.2	13	5.3	3	0.9	1	2.7	330	4.9
C03-06	Mouth	354	7.7	96	7.5	12	5.3	2	7.2	4	1.6	10	3.1	4	10.6	482	7.2
C07-08	Salivary Gland	26	0.6	5	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	31	0.5
C09-10	Oropharynx	51	1.1	16	1.3	4	1.8	0	0.0	2	0.8	1	0.3	1	2.7	75	1.1
C11	Nasopharynx	17	0.4	4	0.3	2	0.9	0	0.0	0	0.0	0	0.0	0	0.0	23	0.3
C12-13	Hypopharynx	77	1.7	30	2.3	10	4.4	1	3.6	0	0.0	1	0.3	0	0.0	119	1.8
C14	Other Oral	34	0.7	11	0.9	4	1.8	0	0.0	0	0.0	0	0.0	0	0.0	49	0.7
C15	Oesophagus	168	3.7	44	3.4	14	6.2	0	0.0	1	0.4	2	0.6	0	0.0	229	3.4
C16	Stomach	175	3.8	36	2.8	16	7.1	1	3.6	1	0.4	3	0.9	1	2.7	233	3.5
C17	Samll Intestine	17	0.4	3	0.2	1	0.4	0	0.0	0	0.0	2	0.6	0	0.0	23	0.3
C18	Colon	158	3.5	39	3.0	15	6.6	0	0.0	6	2.4	1	0.3	3	8.0	222	3.3
C19-21	Rectum	137	3.0	24	1.9	8	3.5	1	3.6	5	2.0	7	2.2	0	0.0	182	2.7
C22	Liver	199	4.4	46	3.6	15	6.6	3	10.7	4	1.6	8	2.5	1	2.7	276	4.1
C23-24	Gall Bladder	84	1.8	20	1.6	8	3.5	2	7.2	0	0.0	0	0.0	2	5.3	116	1.7
C25	Pancreas	117	2.6	25	2.0	6	2.7	1	3.6	2	0.8	2	0.6	0	0.0	153	2.3
C26	Oth Dig Org	10	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	10	0.1
C30-31	Nose, Sinuse	25	0.5	6	0.5	2	0.9	0	0.0	0	0.0	0	0.0	0	0.0	33	0.5
C32	Larynx	193	4.2	56	4.4	11	4.9	3	10.7	6	2.4	1	0.3	0	0.0	270	4.0
C33-34	Lung	358	7.8	143	11.2	38	16.8	1	3.6	8	3.2	5	1.5	1	2.7	554	8.2
C37-38	Mediastinum, Plura	8	0.2	2	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	10	0.1
C40-41	Bone	48	1.0	14	1.1	1	0.4	0	0.0	1	0.4	2	0.6	1	2.7	67	1.0
C43	Skin Melanoma	3	0.1	2	0.2	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	6	0.1
C44	Skin Others	55	1.2	13	1.0	7	3.1	0	0.0	2	0.8	0	0.0	3	8.0	80	1.2
C47	Nervous System	3	0.1	2	0.2	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	6	0.1
C48	Retroperitonium	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	45	1.0	15	1.2	5	2.2	2	7.2	1	0.4	0	0.0	0	0.0	68	1.0
C50	Breast	30	0.7	5	0.4	3	1.3	0	0.0	1	0.4	0	0.0	0	0.0	39	0.6
C60	Penis	51	1.1	0	0.0	2	0.9	0	0.0	0	0.0	1	0.3	0	0.0	54	0.8
C61	Prostate	387	8.5	44	3.4	37	16.4	2	7.2	13	5.3	1	0.3	2	5.3	486	7.2
C62	Testis	26	0.6	11	0.9	2	0.9	1	3.6	0	0.0	2	0.6	0	0.0	42	0.6
C63	Oth Male Gen Org	3	0.1	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	0.1
	Kidney	111	2.4	17	1.3	6	2.7	1	3.6	4	1.6		0.6	0	0.0	141	2.1
	Urinary Bladder	154	3.4	49	3.8	7	3.1	2	7.2	5	2.0		0.0	0	0.0	217	3.2
	Eye	5	0.1	1	0.1	0	0.0	0	0.0	0	0.0		0.0	0	0.0	6	0.1
	Brain	151	3.3	49	3.8	10	4.4	0	0.0		0.8		0.3	2	5.3	215	3.2
C73	Thyroid	50	1.1	12	0.9	1	0.4	1	3.6		0.0		0.6	0	0.0	66	1.0
C74-75	Other Endocrine Gla	5	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	5	0.1
C76	Other Ill Def Sites	9	0.2	1	0.1	2	0.9	0	0.0	1	0.4	0	0.0	0	0.0	13	0.2
	Lymph Nodes	56	1.2	19	1.5	4	1.8	0	0.0	1	0.4	2	0.6	0	0.0	82	1.2
	Sec Resp & Dig	50	1.1	10	0.8	4	1.8	1	3.6	1	0.4		0.6	0	0.0	68	1.0
	Sec Others	14	0.3	4	0.3	2	0.9	1	3.6	0	0.0		0.0	0	0.0	21	0.3
	Unknown Primary	40	0.9	15	1.2	3	1.3	0	0.0	1	0.4	0	0.0	0	0.0	59	0.9
	Hodgkin Lymphoma	44	1.0	13	1.0	3	1.3	3	10.7	1	0.4	0	0.0	0	0.0	64	1.0
C82-85	N.H.Lymphoma	205	4.5	35	2.7	14	6.2	2	7.2	3	1.2		0.0	1	2.7	260	3.9
C90	Multiple Myloma	93	2.0	11	0.9	1	0.4	1	3.6	0	0.0	0	0.0	0	0.0	106	1.6
C91	Lymphoid Leukemia	62	1.4	22	1.7	9	4.0	0	0.0	1	0.4	2	0.6	0	0.0	96	1.4
C92	Myeloid Leukemia	86	1.9	22	1.7	8	3.5	0	0.0	1	0.4	3	0.9	1	2.7	121	1.8
C93-95	Other Leukemia	35	0.8	10	0.8	2	0.9	0	0.0	0	0.0		0.3	0	0.0	48	0.7
Total	All Sites	4271	93.4	1080	84.4	318	####	34	121.8	91	36.9	67	20.6	24	63.8	5885	87.6

Table 12: Incidence Cases of Cancer by Religion and Site (ICD10) with Crude Incidence Rate (CR), Greater Mumbai, 2011, Female

		Hi	ndu	Mus	lim	Chris	stian	Ps	arsi	Jai	ins	NeoBi	ıdhist	Si	kh	То	tal
ICD-10	SITE	#	CR	#	CR	#	CR	#	CR	#	CR	#	CR	#	CR	#	CR
C00	Lip	5	0.1	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	6	0.1
C01-02	*	79	2.1	20	1.9	3	1.3	4	13.0	2	0.8	1	0.3	1	2.9	110	1.9
C03-06		153	4.0	40	3.9	2	0.8	3	9.7	1	0.4	3	0.9	0	0.0	202	3.5
C07-08	Salivary Gland	10	0.3	4	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	14	0.2
	Oropharynx	23	0.6	3	0.3	3	1.3	0	0.0	0	0.0	0	0.0	0	0.0	29	0.5
	Nasopharynx	8	0.2	0	0.0	2	0.8	0	0.0	0	0.0	0	0.0	0	0.0	10	0.2
C12-13	Hypopharynx	31	0.8	6	0.6	2	0.8	0	0.0	0	0.0	2	0.6	0	0.0	41	0.7
C14	Other Oral	16	0.4	7	0.7	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	24	0.4
C15	Oesophagus	153	4.0	25	2.4	3	1.3	0	0.0	1	0.4	5	1.5	0	0.0	187	3.3
C16	Stomach	88	2.3	16	1.5	9	3.8	1	3.2	2	0.8	2	0.6	1	2.9	119	2.1
C17	Samll Intestine	16	0.4	5	0.5	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	22	0.4
C18	Colon	116	3.0	30	2.9	11	4.6	3	9.7	2	0.8	1	0.3	0	0.0	163	2.8
C19-21	Rectum	117	3.1	32	3.1	9	3.8	0	0.0	0	0.0	2	0.6	1	2.9	161	2.8
C22	Liver	106	2.8	24	2.3	9	3.8	3	9.7	1	0.4	0	0.0	1	2.9	144	2.5
C23-24	Gall Bladder	136	3.6	44	4.3	2	0.8	0	0.0	0	0.0	1	0.3	1	2.9	184	3.2
C25	Pancreas	79	2.1	11	1.1	5	2.1	3	9.7	1	0.4	0	0.0	1	2.9	100	1.7
C26	Oth Dig Org	3	0.1	1	0.1	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	5	0.1
C30-31	Nose, Sinuse	14	0.4	2	0.2	2	0.8	0	0.0	0	0.0	1	0.3	0	0.0	19	0.3
C32	Larynx	27	0.7	6	0.6	0	0.0	0	0.0	0	0.0	3	0.9	0	0.0	36	0.6
C33-34	Lung	180	4.7	26	2.5	13	5.4	0	0.0	3	1.2	7	2.1	0	0.0	229	4.0
C37-38	Mediastinum, Plura	3	0.1	0	0.0	1	0.4	0	0.0	1	0.4	0	0.0	0	0.0	5	0.1
C40-41	Bone	30	0.8	12	1.2	1	0.4	0	0.0	1	0.4	0	0.0	0	0.0	44	0.8
C43	Skin Melanoma	7	0.2	1	0.1	0	0.0	0	0.0	0	0.0	1	0.3	0	0.0	9	0.2
C44	Skin Others	42	1.1	13	1.3	2	0.8	0	0.0	1	0.4	2	0.6	0	0.0	60	1.0
C47	Nervous System	1	0.0	1	0.1	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	3	0.1
	Retroperitonium	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	54	1.4	7	0.7	8	3.3	0	0.0	2	0.8	0	0.0	0	0.0	71	1.2
	Breast	1354	35.4	302	29.2	122	51.0	23	74.5	50	19.8	31	9.5	18	51.8	1900	33.1
	Oth Fem Gen Org	40	1.0	5	0.5	2	0.8	2	6.5	3	1.2	3	0.9	1	2.9	56	1.0
C53	Cervix	411	10.8	75	7.3	21	8.8	0	0.0	4	1.6	14	4.3	2	5.8	527	9.2
C54	Corpus Uteri	190	5.0	30	2.9	16	6.7	2	6.5	7	2.8	4	1.2	4	11.5	253	4.4
C55	Uterus	41	1.1	7	0.7	2	0.8	0	0.0	0	0.0	1	0.3	0	0.0	51	0.9
C56	Ovary	326	8.5	63	6.1	31	13.0	4	13.0	7	2.8	8	2.4	1	2.9	440	7.7
	Oth Unsp Fem Gen Or	5	0.1	1	0.1	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0	7	0.1
C64-65	-	49	1.3	12	1.2	2	0.8	0	0.0		1.2	2	0.6	0	0.0		1.2
	Urinary Bladder	43	1.1	4	0.4	0	0.0	2	6.5	1	0.4	0	0.0	0	0.0		0.9
	Eye	2	0.1	1	0.1	0	0.0	0	0.0	0	0.0	1	0.3	0	0.0		0.1
C70-72 C73	Brain Thyroid	110	2.9	26	2.5 2.7	8	3.3	1	3.2	2	0.8	1	0.3	1	2.9	149	2.6
	_	7	2.5	28		6	2.5	1	3.2	3	1.2 0.0	3	0.9	0	0.0		2.4
	Other Endocrine Gla Other Ill Def Sites	8	0.2	1 9	0.1 0.9	1	0.4 0.0	0	0.0	0	0.0	1	0.3	0	0.0		0.2
	Lymph Nodes	36	0.2	11	1.1	1		0	0.0	3	1.2	0	0.0	1	2.9		0.3
	Sec Resp & Dig	66	1.7	19	1.1	3	0.4 1.3	0	0.0	1	0.4			0	0.0		
	Sec Resp & Dig Sec Others	16	0.4	6	0.6	2	0.8	0	0.0	0	0.4		0.6	0	0.0		1.6 0.4
	Unknown Primary	47	1.2	14	1.4	1	0.8	0	0.0	0	0.0		0.5	0	0.0		1.1
	Hodgkin Lymphoma	39	1.0	9	0.9	0	0.4	0	0.0		0.0		0.6	1	2.9		0.9
	N.H.Lymphoma	123	3.2	26	2.5	11	4.6	3	9.7	4	1.6		1.2	2	5.8		3.0
	Multiple Myloma	37	1.0	6	0.6	1	0.4	2	6.5	1	0.4		0.0	1	2.9		0.8
	Lymphoid Leukemia	36	0.9	15	1.5	3	1.3	0	0.0		0.0		0.6	2	5.8		1.0
	Myeloid Leukemia	71	1.9	9	0.9	1	0.4	1	3.2	1	0.4		0.0	0	0.0		1.4
	Other Leukemia	23	0.6	10	1.0	2	0.4	1	3.2	0	0.0	0	0.0	0	0.0		0.6
Total	All sites	4671	122.2		99.3	328	137.1	59	191.1	109	43.2	113	34.6		115.2		

Table 13: Incidence Cases of Cancer by Language and Site (ICD10) with Percentage, Greater Mumbai, 2011, Male

ICD 10	CUDE	Mar	athi	Guj	rati	Hin	di	Uı	rdu	South-	India	Eng	lish	Otl	ners	To	tal
ICD-10	SITE	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	14	0.7	4	0.5	3	0.2	2	0.2	1	0.4	0	0.0	0	0.0	24	0.4
C01-02	Tongue	103	5.4	41	5.0	95	6.3	56	6.1	10	3.8	13	5.1	12	5.1	330	5.6
C03-06	Mouth	164	8.7	59	7.2	146	9.7	73	8.0	18	6.9	12	4.7	10	4.3	482	8.2
C07-08	Salivary Gland	12	0.6	6	0.7	8	0.5	5	0.5	0	0.0	0	0.0	0	0.0	31	0.5
C09-10	Oropharynx	22	1.2	13	1.6	20	1.3	10	1.1	5	1.9	2	0.8	3	1.3	75	1.3
C11	Nasopharynx	5	0.3	2	0.2	8	0.5	4	0.4	2	0.8	1	0.4	1	0.4	23	0.4
C12-13	Hypopharynx	39	2.1	14	1.7	28	1.9	22	2.4	5	1.9	8	3.1	3	1.3	119	2.0
C14	Other Oral	22	1.2	7	0.9	3	0.2	10	1.1	2	0.8	4	1.6	1	0.4	49	0.8
C15	Oesophagus	80	4.2	33	4.0	49	3.2	39	4.3	12	4.6	9	3.5	7	3.0	229	3.9
C16	Stomach	85	4.5	30	3.7	54	3.6	29	3.2	14	5.4	16	6.3	5	2.1	233	4.0
C17	Samll Intestine	10	0.5	3	0.4	8	0.5	1	0.1	0	0.0	1	0.4	0	0.0	23	0.4
C18	Colon	65	3.4	25	3.1	62	4.1	36	3.9	6	2.3	12	4.7	16	6.8	222	3.8
C19-21	Rectum	78	4.1	21	2.6	41	2.7	23	2.5	7	2.7	5	2.0	7	3.0	182	3.1
C22	Liver	104	5.5	39	4.8	58	3.8	42	4.6	11	4.2	15	5.9	7	3.0	276	4.7
C23-24	Gall Bladder	35	1.8	12	1.5	36	2.4	18	2.0	3	1.2	6	2.4	6	2.6	116	2.0
C25	Pancreas	48	2.5	27	3.3	43	2.8	20	2.2	4	1.5	6	2.4	5	2.1	153	2.6
C26	Oth Dig Org	5	0.3	0	0.0	3	0.2	0	0.0	1	0.4	0	0.0	1	0.4	10	0.2
C30-31	Nose, Sinuse	12	0.6	2	0.2	11	0.7	5	0.5	0	0.0	1	0.4	2	0.9	33	0.6
C32	Larynx	82	4.3	36	4.4	68	4.5	47	5.1	14	5.4	8	3.1	15	6.4	270	4.6
C33-34	Lung	149	7.9	69	8.4	133	8.8	126	13.8	28	10.8	28	11.0	21	9.0	554	9.4
C37-38	Mediastinum, Plura	3	0.2	1	0.1	2	0.1	2	0.2	1	0.4	0	0.0	1	0.4	10	0.2
C40-41	Bone	20	1.1	7	0.9	20	1.3	10	1.1	5	1.9	1	0.4	4	1.7	67	1.1
C43	Skin Melanoma	1	0.1	0	0.0	2	0.1	2	0.2	0	0.0	1	0.4	0	0.0	6	0.1
C44	Skin Others	21	1.1	11	1.3	20	1.3	12	1.3	3	1.2	6	2.4	7	3.0	80	1.4
C47	Nervous System	1	0.1	0	0.0	1	0.1	2	0.2	1	0.4	1	0.4	0	0.0	6	0.1
C48	Retroperitonium	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	13	0.7	11	1.3	24	1.6	10	1.1	2	0.8	4	1.6	4	1.7	68	1.2
C50	Breast	11	0.6	10	1.2	8	0.5	5	0.5	0	0.0	3	1.2	2	0.9	39	0.7
C60	Penis	26	1.4	5	0.6	16	1.1	0	0.0	4	1.5	1	0.4	2	0.9	54	0.9
C61	Prostate	125	6.6	116	14.2	128	8.5	43	4.7	17	6.5	30	11.8	27	11.5	486	8.3
C62	Testis	13	0.7	4	0.5	11	0.7	11	1.2	0	0.0	1	0.4	2	0.9	42	0.7
C63	Oth Male Gen Org	1	0.1	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0	1	0.4	4	0.1
C64-65	Kidney	54	2.9	25	3.1	28	1.9	16	1.8	5	1.9	5	2.0	8	3.4	141	2.4
C66-68	Urinary Bladder	68	3.6	34	4.2	49	3.2	44	4.8	11	4.2	6	2.4	5	2.1	217	3.7
C69	Eye	4	0.2	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0	0	0.0	6	0.1
C70-72	Brain	70	3.7	19	2.3	54	3.6	39	4.3	12	4.6	9	3.5	12	5.1	215	3.7
C73	Thyroid	33	1.7	5	0.6	10	0.7	11	1.2	3	1.2	0	0.0	4	1.7	66	1.1
C74-75	Other Endocrine Gla	3	0.2	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	1	0.4	5	0.1
C76	Other Ill Def Sites	3	0.2	3	0.4	2	0.1	1	0.1	2	0.8	2	0.8	0	0.0	13	0.2
	Lymph Nodes	24	1.3	6	0.7	30	2.0	12	1.3	5	1.9	2	0.8	3	1.3	82	1.4
	Sec Resp & Dig	30	1.6	7	0.9	9	0.6	8	0.9	8	3.1	2	0.8	4	1.7	68	1.2
	Sec Others	3	0.2	4	0.5	7	0.5	3	0.3	1	0.4	1	0.4	2	0.9	21	0.4
	Unknown Primary	21	1.1	8	1.0	11	0.7	14	1.5	0	0.0	2	0.8	3	1.3	59	1.0
	Hodgkin Lymphoma	13	0.7	14	1.7	20	1.3	12	1.3	1	0.4	2	0.8	2	0.9	64	1.1
	N.H.Lymphoma	84	4.4	34	4.2	71	4.7	29	3.2	20	7.7	11	4.3	11	4.7	260	4.4
	Multiple Myloma	37	2.0	21	2.6	34	2.2	10	1.1	2	0.8	1	0.4	1	0.4	106	1.8
	Lymphoid Leukemia	24	1.3	10	1.2	25	1.7	19	2.1	7	2.7	8	3.1	3	1.3	96	1.6
C92	Myeloid Leukemia	35	1.8	19	2.3	35	2.3	20	2.2	4	1.5	6	2.4	2	0.9	121	2.1
C93-95	Other Leukemia	18	1.0	2	0.2	15	1.0	7	0.8	3	1.2	2	0.8	1	0.4	48	0.8
Total	All Sites	1893	100.0	819	100.0			913	100.0	260	100.0	254	100.0		100.0		100.0

Table 14: Incidence Cases of Cancer by Language and Site (ICD10) with Percentage, Greater Mumbai, 2011, Female

ICD-10	SITE	Mar	athi	Gujr	ati	Hi	ndi	Ur	du	South-	India	Eng	glish	Oth	ers	To	tal
1CD-10	SITE	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	0.1	1	0.1	1	0.1	0	0.0	1	0.4	0	0.0	0	0.0	6	0.1
C01-02	Tongue	40	1.6	15	1.6	19	1.4	14	1.6	9	3.3	3	1.3	10	3.6	110	1.7
C03-06	Mouth	95	3.9	24	2.6	41	3.1	31	3.6	5	1.9	2	0.9	4	1.4	202	3.2
C07-08	Salivary Gland	4	0.2	3	0.3	2	0.1	4	0.5	1	0.4	0	0.0	0	0.0	14	0.2
C09-10	Oropharynx	13	0.5	3	0.3	4	0.3	3	0.3	4	1.5	1	0.4	1	0.4	29	0.5
C11	Nasopharynx	2	0.1	3	0.3	2	0.1	0	0.0	1	0.4	2	0.9	0	0.0	10	0.2
C12-13	Hypopharynx	20	0.8	3	0.3	8	0.6	6	0.7	2	0.7	1	0.4	1	0.4	41	0.6
C14	Other Oral	13	0.5	1	0.1	1	0.1	6	0.7	2	0.7	1	0.4	0	0.0	24	0.4
C15	Oesophagus	95	3.9	27	2.9	31	2.3	23	2.6	6	2.2	2	0.9	3	1.1	187	2.9
C16	Stomach	45	1.9	16	1.7	29	2.2	16	1.8	3	1.1	7	3.0	3	1.1	119	1.9
C17	Samll Intestine	8	0.3	3	0.3	6	0.4	4	0.5	0	0.0	1	0.4	0	0.0	22	0.3
C18	Colon	65	2.7	23	2.5	26	1.9	29	3.3	6	2.2	8	3.4	6	2.2	163	2.6
C19-21	Rectum	65	2.7	20	2.2	35	2.6	26	3.0	3	1.1	6	2.6	6	2.2	161	2.5
C22	Liver	50	2.1	21	2.3	31	2.3	22	2.5	8	3.0	8	3.4	4	1.4	144	2.3
C23-24	Gall Bladder	39	1.6	19	2.1	78	5.8	41	4.7	2	0.7	2	0.9	3	1.1	184	2.9
C25	Pancreas	37	1.5	16	1.7	27	2.0	11	1.3	3	1.1	3	1.3	3	1.1	100	1.6
C26	Oth Dig Org	2	0.1	0	0.0	1	0.1	1	0.1	0	0.0	1	0.4	0	0.0	5	0.1
C30-31	Nose, Sinuse	8	0.3	2	0.2	4	0.3	2	0.2	1	0.4	2	0.9	0	0.0	19	0.3
C32	Larynx	21	0.9	4	0.4	4	0.3	5	0.6	1	0.4	0	0.0	1	0.4	36	0.6
C33-34	Lung	102	4.2	31	3.3	47	3.5	23	2.6	10	3.7	12	5.1	4	1.4	229	3.6
C37-38	Mediastinum, Plura	1	0.0	1	0.1	1	0.1	0	0.0	1	0.4	0	0.0	1	0.4	5	0.1
C40-41	Bone	13	0.5	7	0.8	14	1.0	7	0.8	3	1.1	0	0.0	0	0.0	44	0.7
C43	Skin Melanoma	3	0.1	1	0.1	3	0.2	0	0.0	2	0.7	0	0.0	0	0.0	9	0.1
C44	Skin Others	16	0.7	12	1.3	8	0.6	12	1.4	4	1.5	1	0.4	7	2.5	60	0.9
C47	Nervous System	1	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	3	0.0
C48	Retroperitonium	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	31	1.3	9	1.0	14	1.0	5	0.6	3	1.1	6	2.6	3	1.1	71	1.1
C50	Breast	672	27.7	330	35.6	354	26.5	259	29.7	80	29.6	88	37.4	117	42.1	1900	29.9
C51-52	Oth Fem Gen Org	21	0.9	12	1.3	13	1.0	2	0.2	3	1.1	2	0.9	3	1.1	56	0.9
C53	Cervix	229	9.4	47	5.1	139	10.4	56	6.4	23	8.5	12	5.1	21	7.6	527	8.3
C54	Corpus Uteri	90	3.7	49	5.3	48	3.6	27	3.1	10	3.7	9	3.8	20	7.2	253	4.0
C55	Uterus	22	0.9	10	1.1	8	0.6	7	0.8	1	0.4	2	0.9	1	0.4	51	0.8
C56	Ovary	176	7.2	49	5.3	93	7.0	58	6.7	24	8.9	23	9.8	17	6.1	440	6.9
C57-58	Oth Unsp Fem Gen Or	3	0.1	1	0.1	2	0.1	0	0.0	1	0.4	0	0.0	0	0.0	7	0.1
	Kidney	24	1.0	15	1.6	16	1.2	8	0.9	0	0.0	3	1.3	2	0.7	68	1.1
	Urinary Bladder	17	0.7	12	1.3	17	1.3	2	0.2	1	0.4	0	0.0	1	0.4	50	0.8
C69	Eye	2	0.1	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0	0	0.0		0.0
C70-72	Brain	46	1.9	26	2.8	36	2.7	23	2.6	4	1.5	8	3.4	6	2.2	149	2.3
C73	Thyroid	55	2.3	18	1.9	20	1.5	27	3.1	8	3.0	4	1.7	3	1.1	135	2.1
C74-75	Other Endocrine Gla	7	0.3	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0	1	0.4	10	0.2
C74-73	Other Ill Def Sites	7	0.3	0	0.0	1	0.1	9	1.0	0	0.0	0	0.0	0	0.0		0.2
	Lymph Nodes	20	0.8	7	0.8	14	1.0	8	0.9	1	0.0	0	0.0	2	0.7	52	0.8
	Sec Resp & Dig	37	1.5	7	0.8	27	2.0	14	1.6		1.1	1	0.0	2	0.7	91	1.4
	Sec Resp & Dig Sec Others		0.4	4	0.8		0.4	3		3	0.7	2		0	0.7		
	Unknown Primary	9				5			0.3	2			0.9				0.4
C80	•	26	1.1	7	0.8	13	1.0	14	1.6	2	0.7	1	0.4	1	0.4	64	1.0
C81	Hodgkin Lymphoma	20	0.8	4	0.4	13	1.0	8	0.9	4	1.5	0	0.0	2	0.7	51	0.8
	N.H.Lymphoma	73	3.0	26	2.8	29	2.2	22	2.5	6	2.2	9	3.8	8	2.9		2.7
	Multiple Myloma	14	0.6	14	1.5	10	0.7	4	0.5	2	0.7	1	0.4	3	1.1	48	0.8
C91	Lymphoid Leukemia	21	0.9	8	0.9	8	0.6	13	1.5	3	1.1	1	0.4	4	1.4	58	0.9
C92	Myeloid Leukemia	31	1.3	12	1.3	23	1.7	6	0.7	7	2.6	0	0.0	4	1.4		1.3
C93-95	Other Leukemia	14	0.6	3	0.3	8	0.6	7	0.8	4	1.5	0	0.0	0	0.0		0.6
Total	All Sites	2428	100.0	926	100.0	1338	100.0	871	100.0	270	100.0	235	100.0	278	100.0	6346	100.0

Table 15: Incidence Cases of Cancer by Marital Status and Site (ICD10) with Percentage, Greater Mumbai, 2011, Male

		Unmar	ried	Marr	ied	Widov	ved	Oth	ers	Tota	al
ICD-10	SITE	#	%	#	%	#	%	#	%	#	%
C00	Lip	0	0.0	24	0.5	0	0.0	0	0.0	24	0.4
C01-02	Tongue	7	1.8	318	6.0	3	1.6	2	6.1	330	5.6
C03-06	Mouth	15	3.9	446	8.4	14	7.5	7	21.2	482	8.2
C07-08	Salivary Gland	2	0.5	29	0.5	0	0.0	0	0.0	31	0.5
C09-10	Oropharynx	5	1.3	67	1.3	2	1.1	1	3.0	75	1.3
C11	Nasopharynx	4	1.0	18	0.3	1	0.5	0	0.0	23	0.4
C12-13	Hypopharynx	7	1.8	102	1.9	9	4.8	1	3.0	119	2.0
C14	Other Oral	0	0.0	49	0.9	0	0.0	0	0.0	49	0.8
C15	Oesophagus	7	1.8	215	4.1	6	3.2	1	3.0	229	3.9
C16	Stomach	4	1.0	220	4.2	8	4.3	1	3.0	233	4.0
C17	Samll Intestine	0	0.0	23	0.4	0	0.0	0	0.0	23	0.4
C18	Colon	1	0.3	211	4.0	10	5.3	0	0.0	222	3.8
C19-21	Rectum	5	1.3	172	3.3	5	2.7	0	0.0	182	3.1
C22	Liver	5	1.3	257	4.9	14	7.5	0	0.0	276	4.7
C23-24	Gall Bladder	2	0.5	111	2.1	3	1.6	0	0.0	116	2.0
C25	Pancreas	5	1.3	139	2.6	8	4.3	1	3.0	153	2.6
C26	Oth Dig Org	1	0.3	9	0.2	0	0.0	0	0.0	10	0.2
C30-31	Nose, Sinuse	4	1.0	28	0.5	1	0.5	0	0.0	33	0.6
C32	Larynx	8	2.1	245	4.6	13	7.0	4	12.1	270	4.6
C33-34	-	16	4.2	521	9.9	15	8.0	2	6.1	554	9.4
	Mediastinum, Plura	0	0.0	10	0.2	0	0.0	0	0.0	10	0.2
	Bone	34	8.9	33	0.6	0	0.0	0	0.0	67	1.1
C43	Skin Melanoma	0	0.0	6	0.1	0	0.0	0	0.0	6	0.1
C44	Skin Others	8	2.1	65	1.2	7	3.7	0	0.0	80	1.4
C47	Nervous System	3	0.8	3	0.1	0	0.0	0	0.0	6	0.1
C48	Retroperitonium	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	13	3.4	54	1.0	0	0.0	1	3.0	68	1.2
C50	Breast	3	0.8	35	0.7	1	0.5	0	0.0	39	0.7
C60	Penis	1	0.3	51	1.0	1	0.5	1	3.0	54	0.9
C61	Prostate	5	1.3	457	8.7	22	11.8	2	6.1	486	8.3
C62	Testis	8	2.1	33	0.6	0	0.0	1	3.0	42	0.7
C63	Oth Male Gen Org	0	0.0	4	0.1	0	0.0	0	0.0	4	0.1
C64-65	Kidney	7	1.8	129	2.4	4	2.1	1	3.0	141	2.4
C66-68	Urinary Bladder	4	1.0	204	3.9	9	4.8	0	0.0	217	3.7
C69	Eye	5	1.3	1	0.0	0	0.0	0	0.0	6	0.1
C70-72	Brain	42	11.0	166	3.1	4	2.1	3	9.1	215	3.7
C73	Thyroid	4	1.0	60	1.1	2	1.1	0	0.0	66	1.1
C74-75	Other Endocrine Gla	1	0.3	4	0.1	0	0.0	0	0.0	5	0.1
C76	Other Ill Def Sites	0	0.0	13	0.2	0	0.0	0	0.0	13	0.2
C77	Lymph Nodes	5	1.3	71	1.3	6	3.2	0	0.0	82	1.4
C78	Sec Resp & Dig	4	1.0	61	1.2	3	1.6	0	0.0	68	1.2
C79	Sec Others	1	0.3	18	0.3	2	1.1	0	0.0	21	0.4
C80	Unknown Primary	1	0.3	58	1.1	0	0.0	0	0.0	59	1.0
C81	Hodgkin Lymphoma	23	6.0	41	0.8	0	0.0	0	0.0	64	1.1
	N.H.Lymphoma	33	8.6	221	4.2	4	2.1	2	6.1	260	4.4
C90	Multiple Myloma	2	0.5	99	1.9	5	2.7	0	0.0	106	1.8
C91	Lymphoid Leukemia	43	11.2	51	1.0	1	0.5	1	3.0	96	1.6
C92	Myeloid Leukemia	16	4.2	101	1.9	3	1.6	1	3.0	121	2.1
C93-95	Other Leukemia	19	5.0	28	0.5	1	0.5	0	0.0	48	0.8
Total	All Sites	383	100.0	5282	100.0	187	100.0	33	100.0	5885	100.0

Table 16: Incidence Cases of Cancer by Marital Status and Site (ICD10) with Percentage, Greater Mumbai, 2011, Female

ICD-10	SITE	Unma	rried	Mar	ried	Wido	wed	Oth	ers	Tot	al
1CD-10	SHE	#	%	#	%	#	%	#	%	#	%
C00	Lip	0	0.0	6	0.1	0	0.0	0	0.0	6	0.1
C01-02	Tongue	4	1.4	91	1.7	8	1.4	7	3.5	110	1.7
C03-06	Mouth	6	2.1	158	3.0	24	4.2	14	7.0	202	3.2
C07-08	Salivary Gland	0	0.0	14	0.3	0	0.0	O	0.0	14	0.2
C09-10	Oropharynx	1	0.3	22	0.4	3	0.5	3	1.5	29	0.5
C11	Nasopharynx	1	0.3	8	0.2	1	0.2	0	0.0	10	0.2
C12-13	Hypopharynx	0	0.0	36	0.7	4	0.7	1	0.5	41	0.6
C14	Other Oral	0	0.0	22	0.4	2	0.3	O	0.0	24	0.4
C15	Oesophagus	6	2.1	149	2.8	23	4.0	9	4.5	187	2.9
C16	Stomach	0	0.0	107	2.0	9	1.6	3	1.5	119	1.9
C17	Samll Intestine	0	0.0	21	0.4	0	0.0	1	0.5	22	0.3
C18	Colon	4	1.4	136	2.6	17	2.9	6	3.0	163	2.6
C19-21	Rectum	8	2.7	129	2.4	19	3.3	5	2.5	161	2.5
C22	Liver	3	1.0	125	2.4	15	2.6	1	0.5	144	2.3
C23-24	Gall Bladder	4	1.4	162	3.1	11	1.9	7	3.5	184	2.9
C25	Pancreas	2	0.7	86	1.6	12	2.1	0	0.0	100	1.6
C26	Oth Dig Org	0	0.0	4	0.1	1	0.2	0	0.0	5	0.1
C30-31	Nose, Sinuse	0	0.0	17	0.3	1	0.2	1	0.5	19	0.3
C32	Larynx	1	0.3	32	0.6	3	0.5	0	0.0	36	0.6
C33-34	Lung	3	1.0	200	3.8	18	3.1	8	4.0	229	3.6
C37-38	Mediastinum, Plura	1	0.3	4	0.1	0	0.0	0	0.0	5	0.1
C40-41	Bone	14	4.8	28	0.5	2	0.3	0	0.0	44	0.7
C43	Skin Melanoma	1	0.3	4	0.1	2	0.3	2	1.0	9	0.1
C44	Skin Others	1	0.3	47	0.9	10	1.7	2	1.0	60	0.9
C47	Nervous System	0	0.0	3	0.1	0	0.0	0	0.0	3	0.0
C48	Retroperitonium	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	9	3.1	57	1.1	3	0.5	2	1.0	71	1.1
C50	Breast	49	16.8	1641	31.1	164	28.4	46	22.9	1900	29.9
C51-52	Oth Fem Gen Org	1	0.3	46	0.9	6	1.0	3	1.5	56	0.9
C53	Cervix	3	1.0	429	8.1	57	9.9	38	18.9	527	8.3
C54	Corpus Uteri	11	3.8	212	4.0	23	4.0	7	3.5	253	4.0
C55	Uterus	4	1.4	43	0.8	4	0.7	0	0.0	51	0.8
C56	Ovary	26	8.9	366	6.9	39	6.7	9	4.5	440	6.9
C57-58	Oth Unsp Fem Gen Or	0	0.0	6	0.1	1	0.2	0	0.0	7	0.1
C64-65	Kidney	4	1.4	54	1.0	9	1.6	1	0.5	68	1.1
C66-68	Urinary Bladder	0	0.0	42	0.8	7	1.2	1	0.5	50	0.8
C69	Eye	4	1.4	0	0.0	0	0.0	0	0.0	4	0.1
C70-72	Brain	28	9.6	113	2.1	6	1.0	2	1.0	149	2.3
C73	Thyroid	13	4.5	112	2.1	8	1.4	2	1.0	135	2.1
C74-75	Other Endocrine Gla	1	0.3	8	0.2	0	0.0	1	0.5	10	0.2
C76	Other Ill Def Sites	4	1.4	12	0.2	1	0.2	0	0.0	17	0.3
C77	Lymph Nodes	1	0.3	44	0.8	6	1.0	1	0.5	52	0.8
C78	Sec Resp & Dig	2	0.7	72	1.4	10	1.7	7	3.5	91	1.4
C79	Sec Others	1	0.3	22	0.4	2	0.3	0	0.0	25	0.4
C80	Unknown Primary	3	1.0	54	1.0	6	1.0	1	0.5	64	1.0
C81	Hodgkin Lymphoma	13	4.5	32	0.6	6	1.0	O	0.0	51	0.8
C82-85	N.H.Lymphoma	12	4.1	137	2.6	18	3.1	6	3.0	173	2.7
C90	Multiple Myloma	1	0.3	41	0.8	4	0.7	2	1.0	48	0.8
C91	Lymphoid Leukemia	29	9.9	25	0.5	4	0.7	O	0.0	58	0.9
C92	Myeloid Leukemia	7	2.4	69	1.3	5	0.9	2	1.0	83	1.3
C93-95	Other Leukemia	6	2.1	26	0.5	4	0.7	0	0.0	36	0.6
Total	All Sites	292	100.0	5275	100.0	578	100.0	201	100.0	6346	100.0

Table 17: Incidence Cases of Cancer by Education and Site (ICD10) with Percentage, Greater Mumbai, 2011, Male

ICD-10	SITE	Illit	erate	Lite	rate	Prim	& Mid	Sec e	& Tech	Col	lege	Ot	thers	To	tal
ICD-10	SIIE	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	0.2	3	0.3	9	0.4	11	0.6	0	0.0	0	0.0	24	0.4
C01-02	Tongue	27	5.0	37	3.5	141	6.7	99	5.8	25	5.4	1	9.1	330	5.6
C03-06	Mouth	42	7.8	62	5.8	199	9.5	151	8.8	27	5.8	1	9.1	482	8.2
C07-08	Salivary Gland	1	0.2	3	0.3	16	0.8	9	0.5	2	0.4	0	0.0	31	0.5
C09-10	Oropharynx	10	1.9	7	0.7	36	1.7	19	1.1	3	0.6	0	0.0	75	1.3
C11	Nasopharynx	О	0.0	6	0.6	10	0.5	5	0.3	2	0.4	0	0.0	23	0.4
C12-13	Hypopharynx	23	4.3	7	0.7	44	2.1	40	2.3	5	1.1	0	0.0	119	2.0
C14	Other Oral	6	1.1	15	1.4	18	0.9	7	0.4	3	0.6	0	0.0	49	0.8
C15	Oesophagus	17	3.2	46	4.3	82	3.9	67	3.9	17	3.7	0	0.0	229	3.9
C16	Stomach	16	3.0	43	4.0	83	4.0	69	4.0	22	4.7	0	0.0	233	4.0
C17	Samll Intestine	1	0.2	2	0.2	6	0.3	11	0.6	3	0.6	0	0.0	23	0.4
C18	Colon	14	2.6	54	5.1	73	3.5	51	3.0	30	6.5	0	0.0	222	3.8
C19-21	Rectum	10	1.9	27	2.5	59	2.8	68	4.0	18	3.9	0	0.0	182	3.1
C22	Liver	21	3.9	69	6.5	96	4.6	71	4.1	19	4.1	0	0.0	276	4.7
C23-24	Gall Bladder	11	2.0	24	2.2	37	1.8	39	2.3	4	0.9	1	9.1	116	2.0
C25	Pancreas	14	2.6	36	3.4	54	2.6	37	2.2	12	2.6	0	0.0	153	2.6
C26	Oth Dig Org	0	0.0	4	0.4	2	0.1	3	0.2	1	0.2	0	0.0	10	0.2
C30-31	Nose, Sinuse	2	0.4	5	0.5	15	0.7	7	0.4	4	0.9	0	0.0	33	0.6
C32	Larynx	27	5.0	47	4.4	111	5.3	68	4.0	15	3.2	2	18.2	270	4.6
C33-34	Lung	46	8.6	124	11.6	219	10.5	131	7.6	32	6.9	2	18.2	554	9.4
C37-38	Mediastinum, Plura	2	0.4	5	0.5	1	0.0	1	0.1	1	0.2	0	0.0	10	0.2
C40-41	Bone	4	0.7	3	0.3	26	1.2	24	1.4	10	2.2	0	0.0	67	1.1
C43	Skin Melanoma	1	0.2	0	0.0	2	0.1	2	0.1	1	0.2	0	0.0	6	0.1
C44	Skin Others	9	1.7	8	0.7	34	1.6	21	1.2	8	1.7	0	0.0	80	1.4
C47	Nervous System	2	0.4	1	0.1	2	0.1	1	0.1	0	0.0	0	0.0	6	0.1
C48	Retroperitonium	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	6	1.1	5	0.5	27	1.3	19	1.1	11	2.4	0	0.0	68	1.2
C50	Breast	6	1.1	6	0.6	10	0.5	15	0.9	2	0.4	0	0.0	39	0.7
C60	Penis	3	0.6	10	0.9	16	0.8	21	1.2	3	0.6	1	9.1	54	0.9
C61	Prostate	58	10.8	144	13.5	130	6.2	126	7.3	27	5.8	1	9.1	486	8.3
C62	Testis	1	0.2	2	0.2	11	0.5	16	0.9	12	2.6	0	0.0	42	0.7
C63	Oth Male Gen Org	0	0.0	0	0.0	2	0.1	1	0.1	1	0.2	0	0.0	4	0.1
C64-65	Kidney	9	1.7	21	2.0		2.0	56	3.3	14	3.0	0	0.0	141	2.4
C66-68	Urinary Bladder	23	4.3	61	5.7	55	2.6	62	3.6	16	3.4	0	0.0	217	3.7
C69	Eye	4	0.7	0	0.0	1	0.0	1	0.1	0	0.0	0	0.0	6	0.1
C70-72	Brain	19	3.5	27	2.5	58	2.8	81	4.7	30	6.5	0	0.0	215	3.7
C73	Thyroid	8	1.5	8	0.7	22	1.1	21	1.2	7	1.5	0	0.0	66	1.1
C74-75	Other Endocrine Gla	1	0.2	1	0.1	О	0.0	2	0.1	1	0.2	0	0.0	5	0.1
C76	Other Ill Def Sites	2	0.4	2	0.2	2	0.1	5	0.3	2	0.4	0	0.0	13	0.2
C77	Lymph Nodes	13	2.4	12	1.1	31	1.5	23	1.3	3	0.6	0	0.0	82	1.4
C78	Sec Resp & Dig	7	1.3	16	1.5	16	0.8	23	1.3	6	1.3	0	0.0	68	1.2
C79	Sec Others	3	0.6	5	0.5	4	0.2	8	0.5	1	0.2	0	0.0	21	0.4
C80	Unknown Primary	5	0.9	16	1.5	20	1.0	16	0.9	2	0.4	0	0.0	59	1.0
C81	Hodgkin Lymphoma	6	1.1	8	0.7	18	0.9	24	1.4	8	1.7	0	0.0	64	1.1
	N.H.Lymphoma	22	4.1	35	3.3	101	4.8	78	4.5	23	5.0	1	9.1	260	4.4
C90	Multiple Myloma	7	1.3	15	1.4	45	2.2	30	1.7	9	1.9	0	0.0	106	1.8
C91	Lymphoid Leukemia	12	2.2	12	1.1	47	2.2	22	1.7	3	0.6	0	0.0	96	1.6
C92	Myeloid Leukemia	9	1.7	17	1.6	42	2.0	36	2.1	16	3.4	1	9.1	121	2.1
C92 C93-95	Other Leukemia	5	0.9	7	0.7	15	0.7	18	1.0	3	0.6	0	0.0	48	0.8
					100.0							_			
Total	All Sites	537	100.0	1008	100.0	2089	100.0	1716	100.0	404	100.0	11	100.0	2882	100.0

Table 18: Incidence Cases of Cancer by Education and Site (ICD10) with Percentage, Greater Mumbai, 2011, Female

ICD 10	CHER	Illite	erate	Lite	rate	Prim &	& Mid	Sec &	Tech	Coll	lege	Ot	hers	Tot	tal
ICD-10	SITE	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	0.3	0	0.0	2	0.1	1	0.1	0	0.0	0	0.0	6	0.1
C01-02	Tongue	24	2.3	21	2.3	35	1.6	23	1.3	7	1.5	0	0.0	110	1.7
C03-06	Mouth	55	5.3	29	3.2	75	3.4	36	2.1	5	1.1	2	14.3	202	3.2
C07-08	Salivary Gland	0	0.0	2	0.2	5	0.2	7	0.4	0	0.0	0	0.0	14	0.2
C09-10	Oropharynx	6	0.6	8	0.9	6	0.3	7	0.4	2	0.4	0	0.0	29	0.5
C11	Nasopharynx	4	0.4	0	0.0	3	0.1	2	0.1	1	0.2	0	0.0	10	0.2
C12-13	Hypopharynx	11	1.1	5	0.6	13	0.6	11	0.6	1	0.2	0	0.0	41	0.6
C14	Other Oral	6	0.6	5	0.6	8	0.4	5	0.3	0	0.0	0	0.0	24	0.4
C15	Oesophagus	42	4.0	36	4.0	65	2.9	31	1.8	12	2.6	1	7.1	187	2.9
C16	Stomach	19	1.8	17	1.9	40	1.8	38	2.2	5	1.1	0	0.0	119	1.9
C17	Samll Intestine	3	0.3	3	0.3	9	0.4	6	0.3	1	0.2	0	0.0	22	0.3
C18	Colon	28	2.7	28	3.1	55	2.5	38	2.2	13	2.9	1	7.1	163	2.6
C19-21	Rectum	27	2.6	24	2.7	52	2.4	48	2.8	10	2.2	0	0.0	161	2.5
C22	Liver	33	3.2	23	2.6	48	2.2	36	2.1	4	0.9	0	0.0	144	2.3
C23-24	Gall Bladder	33	3.2	31	3.5	61	2.8	54	3.1	5	1.1	0	0.0	184	2.9
C25	Pancreas	17	1.6	22	2.4	30	1.4	25	1.4	6	1.3	0	0.0	100	1.6
C26	Oth Dig Org	1	0.1	3	0.3	1	0.0	0	0.0	0	0.0	0	0.0	5	0.1
C30-31	Nose, Sinuse	5	0.5	2	0.2	9	0.4	2	0.1	1	0.2	0	0.0	19	0.3
C32	Larynx	4	0.4	9	1.0	9	0.4	12	0.7	2	0.4	0	0.0	36	0.6
C33-34	Lung	30	2.9	44	4.9	93	4.2	52	3.0	10	2.2	0	0.0	229	3.6
C37-38	Mediastinum, Plura	1	0.1	1	0.1	1	0.0	2	0.1	0	0.0	0	0.0	5	0.1
C40-41	Bone	4	0.4	6	0.7	20	0.9	12	0.7	2	0.4	0	0.0	44	0.7
C43	Skin Melanoma	6	0.6	0	0.0	1	0.0	2	0.1	0	0.0	0	0.0	9	0.1
C44	Skin Others	15	1.4	7	0.8	16	0.7	19	1.1	3	0.7	0	0.0	60	0.9
C47	Nervous System	0	0.0	0	0.0	2	0.1	1	0.1	0	0.0	0	0.0	3	0.0
C48	Retroperitonium	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	7	0.7	10	1.1	26	1.2	21	1.2	7	1.5	0	0.0	71	1.1
C50	Breast	210	20.2	253	28.2	691	31.2	541	31.3	203	44.8	2	14.3	1900	29.9
C51-52	Oth Fem Gen Org	11	1.1	6	0.7	20	0.9	18	1.0	1	0.2	0	0.0	56	0.9
C53	Cervix	148	14.3	72	8.0	182	8.2	110	6.4	14	3.1	1	7.1	527	8.3
C54	Corpus Uteri	28	2.7	33	3.7	86	3.9	84	4.9	22	4.9	0	0.0	253	4.0
C55	Uterus	10	1.0	10	1.1	17	0.8	11	0.6	3	0.7	0	0.0	51	0.8
C56	Ovary	67	6.5	59	6.6	137	6.2	137	7.9	36	7.9	4	28.6	440	6.9
C57-58	Oth Unsp Fem Gen Or	3	0.3	0	0.0	1	0.0	1	0.1	2	0.4	0	0.0	7	0.1
	Kidney	15	1.4	9	1.0	16	0.7	22	1.3	6	1.3	0	0.0	68	1.1
C66-68	Urinary Bladder	9	0.9	12	1.3	16	0.7	11	0.6	1	0.2	1	7.1	50	0.8
C69	Eye	4	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	0.1
C70-72	Brain	24	2.3	17	1.9	43	1.9	49	2.8	15	3.3	1	7.1	149	2.3
C73	Thyroid	9	0.9	11	1.2	58	2.6	45	2.6	12	2.6	0	0.0	135	2.1
C74-75	Other Endocrine Gla	1	0.1	1	0.1	2	0.1	6	0.3	0	0.0	0	0.0	10	0.2
C76	Other Ill Def Sites	2	0.2	7	0.8	5	0.2	2	0.1	1	0.2	0	0.0	17	0.3
C77	Lymph Nodes	15	1.4	5	0.6	18	0.8	12	0.7	1	0.2	1	7.1	52	0.8
C78	Sec Resp & Dig	18	1.7	10	1.1	34	1.5	25	1.4	4	0.9	0	0.0	91	1.4
C79	Sec Others	3	0.3	0	0.0	11	0.5	10	0.6	1	0.2	0	0.0	25	0.4
C80	Unknown Primary	6	0.6	8	0.9	27	1.2	20	1.2	3	0.7	0	0.0	64	1.0
C81	Hodgkin Lymphoma	9	0.9	1	0.1	17	0.8	18	1.0	6	1.3	0	0.0	51	0.8
C82-85	N.H.Lymphoma	31	3.0	25	2.8	57	2.6	44	2.5	16	3.5	0	0.0	173	2.7
C90	Multiple Myloma	6	0.6	8	0.9	16	0.7	17	1.0	10	0.2	0	0.0	48	0.8
C91	Lymphoid Leukemia	12	1.2	5	0.5	27	1.2	13	0.8	1	0.2	0	0.0	58	0.8
C92	Myeloid Leukemia	8	0.8	5	0.6	31	1.4	33	1.9	6	1.3	0	0.0	83	1.3
C93-95	Other Leukemia	5	0.5	5	0.6	14	0.6	11	0.6	1	0.2	0	0.0	36	0.6
Total	All Sites		100.0		100.0	2212	100.0	1731	100.0		100.0		100.0		100.0
rotal	VII SIIES	1038	100.0	078	100.0	2212	100.0	1/31	100.0	433	100.0	14	100.0	0540	100.0

Table 19: Incidence Cases of Cancer by Ward and Site (ICD10) with Percentage, Greater Mumbai, 2011, Male

ICD-10	SITE	Cit	ty	Sub	ırb	Ext. Su	ıburb	Unkn	own	Tot	al
		#	%	#	%	#	%	#	%	#	%
C00	Lip	11	0.6	8	0.3	5	0.3	0	0.0	24	0.4
C01-02	Tongue	103	5.8	123	4.9	104	6.6	0	0.0	330	5.6
C03-06	Mouth	152	8.5	198	7.9	132	8.3	0	0.0	482	8.2
C07-08	Salivary Gland	7	0.4	12	0.5	12	0.8	0	0.0	31	0.5
C09-10	Oropharynx	24	1.3	28	1.1	23	1.5	0	0.0	75	1.3
C11	Nasopharynx	4	0.2	10	0.4	9	0.6	0	0.0	23	0.4
C12-13	Hypopharynx	38	2.1	47	1.9	34	2.2	0	0.0	119	2.0
C14	Other Oral	14	0.8	23	0.9	11	0.7	1	20.0	49	0.8
C15	Oesophagus	59	3.3	96	3.8	74	4.7	0	0.0	229	3.9
C16	Stomach	84	4.7	80	3.2	69	4.4	0	0.0	233	4.0
C17	Samll Intestine	6	0.3	14	0.6	3	0.2	0	0.0	23	0.4
C18	Colon	64	3.6	92	3.7	64	4.0	2	40.0	222	3.8
C19-21	Rectum	67	3.7	72	2.9	43	2.7	0	0.0	182	3.1
C22	Liver	66	3.7	126	5.0	84	5.3	0	0.0	276	4.7
C23-24	Gall Bladder	39	2.2	49	2.0	28	1.8	0	0.0	116	2.0
C25	Pancreas	52	2.9	68	2.7	33	2.1	0	0.0	153	2.6
C26	Oth Dig Org	4	0.2	2	0.1	4	0.3	0	0.0	10	0.2
C30-31	Nose, Sinuse	9	0.5	16	0.6	8	0.5	0	0.0	33	0.6
C32	Larynx	85	4.8	118	4.7	67	4.2	0	0.0	270	4.6
C33-34	Lung	157	8.8	250	10.0	146	9.2	1	20.0	554	9.4
C37-38	Mediastinum, Plura	3	0.2	3	0.1	4	0.3	0	0.0	10	0.2
C40-41	Bone	25	1.4	23	0.9	19	1.2	0	0.0	67	1.1
C43	Skin Melanoma	2	0.1	3	0.1	1	0.1	0	0.0	6	0.1
C44	Skin Others	26	1.5	37	1.5	17	1.1	0	0.0	80	1.4
C47	Nervous System	3	0.2	2	0.1	1	0.1	0	0.0	6	0.1
C48	Retroperitonium	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0
C49	Conn & Soft Tissue	24	1.3	27	1.1	17	1.1	0	0.0	68	1.2
C50	Breast	13	0.7	16	0.6	10	0.6	0	0.0	39	0.7
C60	Penis	17	1.0	21	0.8	16	1.0	0	0.0	54	0.9
C61	Prostate	149	8.3	214	8.5	123	7.8	0	0.0	486	8.3
C62	Testis	15	0.8	18	0.7	9	0.6	0	0.0	42	0.7
C63	Oth Male Gen Org	2	0.1	2	0.1	0	0.0	0	0.0	4	0.1
C64-65	Kidney	43	2.4	66	2.6	32	2.0	0	0.0	141	2.4
C66-68	Urinary Bladder	65	3.6	92	3.7	59	3.7	1	20.0	217	3.7
C69	Eye	3	0.2	3	0.1	0	0.0	0	0.0	6	0.1
C70-72	Brain	53	3.0	108	4.3	54	3.4	0	0.0	215	3.7
C73	Thyroid	22	1.2	33	1.3	11	0.7	0	0.0	66	1.1
C74-75	Other Endocrine Gla	0	0.0	4	0.2	1	0.1	0	0.0	5	0.1
C76	Other Ill Def Sites	4	0.0	4	0.2	5	0.3	0	0.0	13	0.1
C77	Lymph Nodes	24	1.3	37	1.5	21	1.3	0	0.0	82	1.4
C78	Sec Resp & Dig	22	1.2	29	1.2	17	1.1	0	0.0	68	1.2
C79	Sec Others	4	0.2	14	0.6	3	0.2	0	0.0	21	0.4
C80	Unknown Primary	14	0.2	27	1.1	18	1.1	0	0.0	59	1.0
C81	Hodgkin Lymphoma	19	1.1	30	1.1	15	0.9	0	0.0	64	1.0
C82-85	N.H.Lymphoma	84	4.7	105	4.2	71		0	0.0	260	4.4
							4.5				
C90	Multiple Myloma	33	1.8	38	1.5	35	2.2	0	0.0	106	1.8
C91	Lymphoid Leukemia	28	1.6	44 52	1.8	24	1.5		0.0	96	1.6
C92	Myeloid Leukemia	36	2.0	52	2.1	33	2.1	0	0.0	121	2.1
C93-95	Other Leukemia	1799	0.6	26	1.0	12	0.8	0	0.0	48	0.8
Total	All Sites	1788	100.0	2511	100.0	1581	100.0	5	100.0	5885	100.0

Table 20: Incidence Cases of Cancer by Ward and Site (ICD10) with Percentage, Greater Mumbai, 2011, Female

		C	ity	Sub	urb	Ext. S	uburb	Unkı	nown	Total		
ICD-10	SITE	#	%	#	%	#	%	#	%	#	%	
C00	Lip	3	0.1	2	0.1	1	0.1	О	0.0	6	0.1	
C01-02	Tongue	30	1.5	54	2.0	26	1.7	0	0.0	110	1.7	
C03-06	Mouth	59	2.9	90	3.3	52	3.3	1	16.7	202	3.2	
C07-08	Salivary Gland	5	0.2	8	0.3	1	0.1	0	0.0	14	0.2	
C09-10	Oropharynx	10	0.5	17	0.6	2	0.1	О	0.0	29	0.5	
C11	Nasopharynx	1	0.0	3	0.1	6	0.4	0	0.0	10	0.2	
C12-13	Hypopharynx	14	0.7	18	0.7	9	0.6	0	0.0	41	0.6	
C14	Other Oral	5	0.2	14	0.5	5	0.3	0	0.0	24	0.4	
C15	Oesophagus	58	2.8	70	2.5	59	3.8	0	0.0	187	2.9	
C16	Stomach	37	1.8	48	1.7	34	2.2	0	0.0	119	1.9	
C17	Samll Intestine	7	0.3	10	0.4	5	0.3	0	0.0	22	0.3	
C18	Colon	61	3.0	69	2.5	33	2.1	0	0.0	163	2.6	
C19-21	Rectum	52	2.5	72	2.6	37	2.4	0	0.0	161	2.5	
C22	Liver	42	2.1	62	2.3	40	2.6	0	0.0	144	2.3	
C23-24	Gall Bladder	39	1.9	94	3.4	51	3.3	0	0.0	184	2.9	
C25	Pancreas	36	1.8	35	1.3	29	1.9	0	0.0	100	1.6	
C26	Oth Dig Org	0	0.0	2	0.1	3	0.2	0	0.0	5	0.1	
C30-31	Nose, Sinuse	10	0.5	3	0.1	6	0.4	0	0.0	19	0.3	
C32	Larynx	13	0.6	14	0.5	9	0.6	0	0.0	36	0.6	
C33-34	Lung	77	3.8	108	3.9	44	2.8	0	0.0	229	3.6	
C37-38	Mediastinum, Plura	1	0.0	2	0.1	2	0.1	0	0.0	5	0.1	
C40-41	Bone	15	0.7	22	0.1	7	0.5	0	0.0	44	0.7	
C43	Skin Melanoma	2	0.1	4	0.1	3	0.2	0	0.0	9	0.1	
C44	Skin Others	25	1.2	29	1.1	6	0.4	0	0.0	60	0.1	
C47	Nervous System	23	0.1	1	0.0	0	0.0	0	0.0	3	0.0	
C48	Retroperitonium	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0	
C49	Conn & Soft Tissue	23	1.1	32	1.2	16	1.0	0	0.0	71	1.1	
C50	Breast	604	29.6	825	30.0	469	30.2	2	33.3	1900	29.9	
C51-52	Oth Fem Gen Org	27	1.3	16	0.6	13	0.8	0	0.0	56	0.9	
C53	Cervix	156	7.6	244	8.9	127	8.2	0	0.0	527	8.3	
C54	Corpus Uteri	87	4.3	103	3.7	62	4.0	1	16.7	253	4.0	
C55	Uterus	15	0.7	21	0.8	15	1.0	0	0.0	51	0.8	
C56	Ovary	150	7.4	182	6.6	108	7.0	0	0.0	440	6.9	
C57-58	Oth Unsp Fem Gen Or	2	0.1	5	0.0	0	0.0	0	0.0	7	0.9	
C64-65	Kidney	28	1.4	28	1.0	12	0.8	0	0.0	68	1.1	
C66-68	Urinary Bladder	22	1.1	17	0.6	10	0.6	1	16.7	50	0.8	
C69	Eye	0	0.0	3	0.0	10	0.0	0	0.0	4	0.8	
C70-72	Brain	43	2.1	55	2.0	50	3.2	1	16.7	149	2.3	
C73		57		51	1.9	27	1.7	0	0.0		2.3	
C74-75	Thyroid Other Endocrine Gla		2.8 0.1	4	0.1	4	0.3	0	0.0	135 10		
C74-73	Other Ill Def Sites	3		10	0.1	4	0.3	0	0.0	17	0.2	
C77		21	0.1	17	0.4	14	0.3	0	0.0	52	0.3	
	Lymph Nodes		1.0									
C78	Sec Resp & Dig	29	1.4	38	1.4	24	1.5	0	0.0	91	1.4	
C79	Sec Others	10	0.2	15	0.5	6	0.4	0	0.0	25	0.4	
C80	Unknown Primary	18	0.9	34	1.2	12	0.8	0	0.0	64	1.0	
C81	Hodgkin Lymphoma	13	0.6	27	1.0	11	0.7	0	0.0	51	0.8	
C82-85	N.H.Lymphoma	41	2.0	81	2.9	51	3.3	0	0.0	173	2.7	
C90	Multiple Myloma	21	1.0	15	0.5	12	0.8	0	0.0	48	0.8	
C91	Lymphoid Leukemia	22	1.1	26	0.9	10	0.6	0	0.0	58	0.9	
C92	Myeloid Leukemia	35	1.7	31	1.1	17	1.1	0	0.0	83	1.3	
C93-95	Other Leukemia	13	0.6	15	0.5	8	0.5	0	0.0	36	0.6	
Total	All Sites	2040	100.0	2747	100.0	1553	100.0	6	100.0	6346	100.0	

Table 21: Number of Incidence Cases of Cancer by Histology (ICDO3) and Sex, Greater Mumbai, 2011

ICD-O-3	HISTOLOGY	Ma	le	Fem	ale	Total			
1CD-O-3	HISTOLOGY	#	%	#	%	#	%		
800	Malignant Neoplasms, Nos	747	12.7	827	13.0	1574	12.9		
8001-8005	Malignant Tumors	68	1.2	100	1.6	168	1.4		
801-804	Malignant Epithelial Neoplasms	626	10.6	500	7.9	1126	9.2		
805-808	Squamus Cell Neoplasms	1501	25.5	1064	16.8	2565	21.0		
809-811	Basal Cell Neoplasms	17	0.3	18	0.3	35	0.3		
812-813	Transitional Cell Carcinomas	166	2.8	38	0.6	204	1.7		
814-838	Adenocarcinomas	1480	25.1	1176	18.5	2656	21.7		
839-842	Adnexal and Skin Appendage Neoplasms	2	0.0	3	0.0	5	0.0		
843	Mucoepidermoid Neoplasms	10	0.2	7	0.1	17	0.1		
844-849	Cystic, Mucious & Serous Neoplasms	91	1.5	204	3.2	295	2.4		
850-854	Ductal and Lobular Neoplasms	33	0.6	1589	25.0	1622	13.3		
855	Acinar Cell Neoplasms	22	0.4	2	0.0	24	0.2		
856-857	Complex Epithelial Neoplasms	4	0.1	13	0.2	17	0.1		
858	Thymic Epithelial Neoplasms	1	0.0	2	0.0	3	0.0		
859-867	Specialised Gonadal Neoplasm	0	0.0	2	0.0	2	0.0		
872-879	Nevi and Melanomas	13	0.2	12	0.2	25	0.2		
880	Soft Tissue Tumors and Sarcomas	39	0.7	33	0.5	72	0.6		
881-883	Fibromatous Neoplasms	5	0.1	3	0.0	8	0.1		
884-888	Lipomatous Neoplasms	11	0.2	9	0.1	20	0.2		
889-892	Myomatous Neoplasms	10	0.2	26	0.4	36	0.3		
893-899	Complex mixed and stromal Neoplasms	21	0.4	36	0.6	57	0.5		
900-903	Fibroepithelial Neoplasms	0	0.0	12	0.2	12	0.1		
904	Synovial Neoplasms	13	0.2	9	0.1	22	0.2		
905	Mesothelial Neoplasms	4	0.1	3	0.0	7	0.1		
906-909	Germ Cell Neoplasms	37	0.6	18	0.3	55	0.4		
910	Triphoblastic Neoplasms	0	0.0	5	0.1	5	0.0		
912-916	Blood Vessel Tumors	6	0.1	1	0.0	7	0.1		
918-924	Osseous and Chrondromatous Neoplasms	31	0.5	20	0.3	51	0.4		
925	Giant Cell Tumors	8	0.1	3	0.0	11	0.1		
926	Miscellaneous Bone Tumors	7	0.1	7	0.1	14	0.1		
927-934	Odontogenic Tumors	3	0.1	0	0.0	3	0.0		
935-937	Miscellaneous Bone Tumors	10	0.2	5	0.1	15	0.1		
938-948	Gliomas	190	3.2	131	2.1	321	2.6		
949-952	Neuroepitheliomatous Neoplasms	8	0.1	9	0.1	17	0.1		
953	Meningiomas	2	0.0	1	0.0	3	0.0		
954-957	Nerve Sheath Tumors	2	0.0	4	0.1	6	0.0		
959	Malignant Lymphomas, Nos, or Diffuse	155	2.6	100	1.6	255	2.1		
965-966	Hodgkins Lymphoma	65	1.1	52	0.8	117	1.0		
967-972	Non Hodgkins Lymphoma	103	1.8	72	1.1	175	1.4		
973	Plasma Cell Tumors	108	1.8	51	0.8	159	1.3		
975	Neoplasms of Hisiocytes and Accessory	1	0.0	1	0.0	2	0.0		
	Leukemias	260	4.4	175	2.8	435	3.6		
995-996	Chronic Myeloproliferative Disorder	5	0.1	3	0.0	8	0.1		
Total	All Histologies	5885	100.0	6346	100.0	12231	100.0		

Table 22: Number of Cancer Deaths by Age and Site (ICD10) with Percentages, Greater Mumbai, 2011, Male

ICD10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	99	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	1	2	0	1	1	3	0	0	8	0.2
C01-02	Tongue	0	0	0	0	0	2	6	12	10	14	17	20	21	15	9	23	0	149	4.6
C03-06	Mouth	0	0	0	0	2	3	5	16	19	25	17	35	19	20	7	11	1	180	5.5
C07-08	Salivary Gland	0	0	0	0	0	0	1	1	2	0	1	2	1	1	1	2	0	12	0.4
C09-10	Oropharynx	0	0	0	0	0	0	1	0	2	3	6	6	7	6	5	6	0	42	1.3
C11	Nasopharynx	0	0	0	0	0	0	0	2	0	1	0	0	3	0	2	3	0	11	0.3
C12-13	Hypopharynx	0	0	0	0	0	1	1	0	0	4	5	11	9	13	11	22	1	78	2.4
C14	Other Oral	0	0	0	0	0	0	0	0	2	2	4	3	4	6	5	14	0	40	1.2
C15	Oesophagus	0	0	0	0	0	1	1	3	5	6	23	17	21	32	19	36	0	164	5.0
C16	Stomach	0	0	0	0	0	0	1	3	11	9	14	23	24	22	23	39	0	169	5.2
C17	Small Intestine	0	0	0	0	0	0	0	0	3	1	0	1	1	0	0	0	0	6	0.2
C18	Colon	0	0	0	0	1	0	5	2	6	4	9	11	11	11	17	37	0	114	3.5
C19-21	Retum	0	0	0	0	1	0	1	2	1	8	11	15	18	9	6	20	1	93	2.9
C22	Liver	0	0	0	1	0	2	1	1	7	9	20	27	35	35	40	58	0	236	7.3
C23-24	Gall Bladder	0	0	0	0	0	2	2	О	3	2	6	6	10	8	16	21	0	76	2.3
C25	Pancreas	0	0	0	0	1	1	2	3	3	6	10	12	21	22	18	28	0	127	3.9
C26	Oth Dig Org	0	0	0	0	0	1	0	1	0	0	1	1	2	0	0	2	0	8	0.2
C30-31	Nose, Sinuse	0	0	0	0	0	0	0	1	0	1	0	2	1	4	1	4	0	14	0.4
C32	Larynx	0	0	0	0	0	0	0	0	4	7	8	18	17	15	23	39	0	131	4.0
C33-34	Lung	0	1	0	0	0	3	1	4	7	15	32	37	59	89	74	97	0	419	12.9
C37-38	Mediastinum, Plura	0	0	0	0	0	0	0	О	0	0	1	1	0	2	0	1	0	5	0.2
C40-41	Bone	0	1	2	4	4	2	3	0	1	1	3	2	0	0	2	2	0	27	0.8
C43	Skin Melanoma	0	0	0	0	1	0	0	O	0	0	1	0	1	0	0	2	0	5	0.2
C44	Skin Others	0	1	0	0	0	0	0	О	1	4	1	1	3	6	1	6	0	24	0.7
C47	Nervous System	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2	0.1
C48	Retroperitonium	0	0	0	0	0	0	0	O	0	0	0	0	0	1	0	0	0	1	0.0
C49	Conn & Soft Tissu	0	2	1	0	0	1	1	1	1	1	1	1	3	4	2	1	0	20	0.6
C50	Breast	0	0	0	0	0	0	0	1	0	2	1	1	1	0	2	2	0	10	0.3
C60	Penis	0	0	0	0	0	0	1	1	1	0	1	0	1	3	1	3	0	12	0.4
C61	Prostate	0	0	O	0	0	0	0	O	0	1	2	5	25	30	40	132	1	236	7.3
C62	Testis	0	0	0	0	1	2	0	2	2	0	1	0	1	0	0	0	0	9	0.3
C64-65	Kidney	0	1	O	0	0	0	0	2	1	6	4	7	12	11	5	11	0	60	1.8
C66-68	Urinary Bladder	0	0	0	0	0	1	0	2	3	2	2	8	13	8	19	41	0	99	3.0
C70-72	Brain	2	0	4	4	5	6	5	6	9	10	7	7	13	2	8	11	0	99	3.0
C73	Thyroid	0	0	0	0	0	0	0	O	1	1	3	5	3	2	0	5	0	20	0.6
C74-75	Other Endocrine Gla	О	0	O	0	0	0	0	O	0	0	0	2	0	1	1	0	0	4	0.1
C76	Other Ill Def Sit	0	0	O	0	0	0	0	O	0	1	1	2	1	3	1	2	0	11	0.3
C77	Lymph Nodes	0	0	0	0	0	0	1	0	1	2	3	5	5	5	5	9	0	36	1.1
C78	Sec Resp & Dig	0	0	0	0	0	0	0	1	4	2	3	7	9	3	7	10	0	46	1.4
C79	Sec Others	0	0	0	0	0	0	0	0	1	0	2	1	2	1	1	2	0	10	0.3
C80	Unknown Primary	1	0	0	0	1	0	1	1	1	4	3	6	4	9	7	11	0	49	1.5
C81	Hodgkin Lymphoma	1	0	2	0	2	1	2	0	2	0	1	2	1	1	3	5	0	23	0.7
C82-85	N.H.Lymphoma	1	2	2	3	4	4	5	5	4	6	13	10	19	20	18	17	0	133	4.1
C90	Multiple Mye	0	0	0	0	0	1	1	1	2	1	5	7	10	8	11	20	0	67	2.1
C91	Lymphoid Leuk	2	4	4	3	2	2	1	4	1	2	1	4	2	3	1	9	0	45	1.4
C92	Myeloid Leuke	1	0	1	8	2	5	3	4	4	3	9	13	4	9	8	18	0	92	2.8
C93-95	Other Leukemia	2	2	1	3	2	1	2	2	1	2	0	1	2	6	1	3	0	31	1.0
Total	All Sites	10	14	17	26	29	42	54	84	126	169	255	346	421	447	424	785	4	3253	100.0

Table 23: Number of Cancer Deaths by Age and Site (ICD10) with Percentages, Greater Mumbai, 2011, Female

ICD10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	99	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.0
C01-02	Tongue	0	0	0	0	0	0	3	1	3	4	4	4	6	5	5	10	0	45	1.5
C03-06		0	0	0	0	0	1	4	2	4	8	10	13	7	11	13	18	1	92	3.0
C07-08	Salivary Gland	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	3	0.1
	Oropharynx	0	0	0	1	0	0	0	0	0	1	2	1	1	3	2	2	0	13	0.4
C11	Nasopharynx	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	2	0	4	0.1
C12-13	Hypopharynx	0	0	0	0	0	0	0	1	0	5	3	3	3	1	2	3	0	21	0.7
C14	Other Oral	0	0	0	0	0	0	0	0	2	3	1	1	4	2	1	5	0	19	0.6
C15	Oesophagus	0	0	0	0	0	2	0	2	4	12	11	19	15	21	18	38	0	142	4.7
C16	Stomach	0	0	0	0	1	2	3	5	4	8	10	8	6	10	13	21	0		3.0
C17	Small Intestine	0	0	0	0	0	0	0	0	2	1	2	0	1	1	5	3	0		
C18	Colon	0	0	0	0	0	1	1	5	2	4	14	6	10	8	18	22	1	92	
C19-21	Retum	0	0	0	0	1	1	0	3	4	4	10	9	14	9	6	23	0		
C22	Liver	0	0	0	0	0	0	3	3	8	4	10	13	16	15	11	35	1	119	
C23-24	Gall Bladder	0	0	0	0	1	1	2	4	8	13	18	13	14	19	10	22	0		
C25 24	Pancreas	0	0	0	0	0	0	1	0	2	4	7	8	15	15	11	25	0		
C26	Oth Dig Org	0	0	0	0	0	0	0	1	1	0	0	0	0	2	0	2	0		
	Nose, Sinuse	0	0	0	0	0	0	0	0	1	1	1	0	1	2	1	5	0		
C32	Larynx	0	0	0	0	1	0	1	0	1	1	0	4	4	4	3	7	0		
C33-34	Lung	0	0	0	0	0	0	2	4	6	8	11	25	25	15	35	38	0		5.6
C37-38	Mediastinum, Plura	0	0	0	0	0	0	0	0	0	0	0	0	1	13	0	0	0		
C40-41	Bone	0	0	0	5	2	0	1	0	2	1	0	3	4	1	0	3	0		0.1
C40-41	Skin Melanoma	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0		
				-					-	-	0			4			2	0		
C44	Skin Others	0	0	0	0	1	0	1	0	0	-	0	0		1	5				
C47	Nervous System	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	
C48	Retroperitonium	0	0	1	0	0	0	0	0	1	0	0	0	0	0	2	1	0		
C49	Conn & Soft Tissu	0	0	1	0	0	0	0	24	0	2	2	3	3	2	2	2	0		
C50	Breast	0	0	0	0	0	6	15	34	41	79	66	91	73 4	64	66	122	1	658	
C51-52	Oth Fem Gen Org	0	0	0	0	0	0	-	0	1	1	0	20	_	3	3 18	8 34	0		0.7
C53	Cervix	0	0	0	0	0	1	7	5	14	30	27	30	36	35		_	0		
C54	Corpus Uteri	0	0	0	0	0	0	1	0	1	3	3	7	11	5	8	8	0		
C55	Uterus	0	0	0	0	0	0	0	2	1	1	1	2	5	3	16	14	0		
C56	Ovary	0	1	1	0	0	2	3	6	20	18	21	24	31	39	31	50	2		
C57-58	Oth Unsp Fem Gen Or	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0		
C64-65	Kidney	0	0	0	0	0	0	0	0	0	0	1	1	6	2	4	11	0		0.9
	Urinary Bladder	0	1	0	0	0	0	0	0	0	1	1	0	2		2	10	0		
C69	Eye	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0		
C70-72	Brain	3	1	2	2	1	1	2	3	5	6	5	7	9	7	4	8	0		
C73	Thyroid	0	0	0	0	0	0	0	0	0	2	1	2	3	5	5	5	0		
	Other Endocrine Gla	0	0	0	0	0	0	0	1	0	2	1	0	1	1	0	0	0		
C76	Other Ill Def Sit	1	0	2	1	0	0	0	2	1	0	1	3	2	5	2	1	0		0.7
C77	Lymph Nodes	0	0	0	0	0	0	1	1	1	1	1	3	4	2	2	5	0		
C78	Sec Resp & Dig	0	0	0	0	0	0	1	1	4	2	4	4	1	6	2	7	0		
C79	Sec Others	0	0	0	0	0	0	0	3	1	2	3	3	0	3	0	4	0		
C80	Unknown Primary	0	0	0	0	0	3	1	1	2	2	3	1	5	7	7	14	0		
C81	Hodgkin Lymphoma	0	0	0	0	0	0	1	0	1	1	1	2	1	3	2	5	0		
	N.H.Lymphoma	0	0	0	1	0	0	3	4	3	7	6	1	12	12	9	23	0		
C90	Multiple Mye	0	0	0	0	0	0	0	1	0	3	1	3	9	4	4	11	0		
C91	Lymphoid Leuk	0	4	3	2	3	2	1	0	0	4	0	3	5	2	1	5	0	35	
C92	Myeloid Leuke	0	0	2	1	0	2	6	2	5	7	6	4	6	8	2	8	0	59	
C93-95	Other Leukemia	0	2	0	0	0	0	4	0	0	1	1	1	1	3	2	7	0		
Total	All Sites	5	9	12	13	11	26	68	99	156	258	271	329	384	372	354	653	7	3027	100.0

Table 24: Average Annual Age-Specific World Age Adjusted, Truncated (35-64) Cancer Death Rates per 100,000 Persons, Greater Mumbai, 2011, Male

Crool Lip	ICD10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	CR	AAR	TR
COS-10 Mosthy Mosthy COS-10 Mosthy M	C00	Lip	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.2	0.6	0.0	0.5	0.7	3.2		0.1	0.2	0.2
038-04 Month	C01-02	Tongue	0.0	0.0	0.0	0.0	0.0	0.3	1.0	2.2	2.1	3.5	5.1	7.7	10.3	11.2	9.7	20.7	2.2	2.5	4.6
COP-10 COPAIRPYNK 0.0	C03-06	Mouth	0.0	0.0	0.0	0.0	0.3	0.4	0.8	2.9	4.0	6.2	5.1	13.4	9.3	14.9	7.6	9.9	2.7	2.9	6.3
COS-14 C	C07-08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.4	0.0	0.3	0.8	0.5	0.7	1.1	1.8	0.2	0.2	0.3
C11 Nosspharynx		•	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.7	1.8	2.3	3.4	4.5	5.4	5.4	0.6		1.3
C12-13 Hypopharymx			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.0	1.5	0.0	2.2	2.7	0.2	0.2	0.3
C144 Order Oral Order Oral Order Oral Order Oral Order		Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	1.0	1.5	4.2	4.4	9.7	11.9	19.8	1.2	1.4	1.5
C154 Osephagus	C14		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	1.2	1.1	2.0	4.5	5.4	12.6	0.6	0.7	
C161 Stomach		Oesophagus	0.0		0.0		0.0	0.1	0.2		1.1								2.4		
C171 Small Intestine	C16		0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.5	2.3	2.2	4.2	8.8	11.8	16.4	24.8		2.5	3.0	4.3
C18 Clone	C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.4	0.5	0.0	0.0	0.0		0.1	
C191-21 Return C22 Liver C32-24 Gall Bladder C32-24 Gall Bladder C33-34 Gall Bladder C33-34 Gall Bladder C34-34 Gall Bladder C35-34 Gall Bladder C35-34 Gall Bladder C36-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4		Colon	0.0	0.0	0.0	0.0	0.1	0.0	0.8	0.4	1.3	1.0	2.7	4.2		8.2	18.4	33.2	1.7	2.0	
C22 Liver C32 C33 C34 C34		Retum	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	0.2	2.0			8.8				1.4	1.6	
C23-24 Gall Bladder 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3	C22	Liver	0.0	0.0	0.0	0.2	0.0	0.3	0.2	0.2	1.5	2.2		10.3		26.1	43.2	52.1	3.5	4.4	
C25 Pancreas 0.0 0		Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.6	0.5		2.3	4.9	6.0		18.9	1.1	1.4	
C26																					
C30-31 Nose, Sinuse			0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.3	0.4	1.0	0.0	0.0	1.8	0.1		
C32 Larynx 0.0			0.0				0.0		0.0				0.0			3.0					
C33-34 Lung C33-34 Lung C33-34 Mediastinum, Plura C40-41 Bone C40-43 Skin Melanoma C40-41 O. C40-44 Skin Melanoma C40-40 O. C40-40 Skin Melanoma C51-40 O. C40-40 Skin Melanoma C61-40 Skin Melanoma C61-40 Skin Melanoma C62-40 Skin Melanoma C62-40 O. C40-40 Skin Melanoma C61-40 Skin Melanoma C61-4		_	0.0		0.0		0.0		0.0		0.9		2.4						1.9		
C37-38 Mediastinum, Plura		Ť	0.0	0.2	0.0	0.0	0.0	0.4	0.2	0.7	1.5	3.7	9.6	14.2		66.5	79.9	87.1	6.2	8.0	
C40-41 Bone		\mathcal{E}					0.0	0.0											0.1		
C43 Skin Melanoma 0.0 0.0 0.0 0.1 0.0 <		·							0.5										0.4		0.3
C44 Skin Others 0.0 0.2 0.0 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>																					
C47 Nervous System 0.0			0.0																		
C48 Retroperitonium 0.0																					
Conn & Soft Tissu		•																			
C50 Breast 0.0<		•																			
C60 Penis 0.0 </td <td></td>																					
C61 Prostate			0.0				0.0		0.2		0.2					2.2					
C62 Testis																					
C64-65 Kidney																					
C66-68 Urinary Bladder 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.6 0.5 0.6 3.1 6.4 6.0 20.5 36.8 1.5 1.8 1.6 C70-72 Brain 0.5 0.0 0.8 0.7 0.7 0.8 0.8 1.1 1.9 2.5 2.1 2.7 6.4 1.5 8.6 9.9 1.5 1.6 2.6 C73 Thyroid 0.0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																					
C70-72 Brain		•																			
C73 Thyroid																					
C74-75 Other Endocrine Gla 0.0																					
C76 Other III Def Sit 0.0																					
C77 Lymph Nodes 0.0 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>																					
C78 Sec Resp & Dig																					
C79 Sec Others		• •																			
C80 Unknown Primary		, ,																			
C81 Hodgkin Lymphoma																					
C82-85 N.H.Lymphoma 0.2 0.4 0.4 0.5 0.5 0.5 0.8 0.9 0.9 1.5 3.9 3.8 9.3 14.9 19.4 15.3 2.0 2.3 3.0 C90 Multiple Mye 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.4 0.2 1.5 2.7 4.9 6.0 11.9 18.0 1.0 1.2 1.4 C91 Lymphoid Leuk 0.5 0.8 0.8 0.5 0.3 0.3 0.2 0.7 0.2 0.5 0.3 1.5 1.0 2.2 1.1 8.1 0.7 0.8 0.7 C92 Myeloid Leuke 0.2 0.0 0.2 1.3 0.3 0.7 0.5 0.7 0.9 0.7 2.7 5.0 2.0 6.7 8.6 16.2 1.4 1.5 1.8 C93-95 Other Leukemia 0.5 0.4 0.2 0.5 0.3 0.1 0.3 0.4 0.2 0.5 0.0 0.4 1.0 4.5 <																					
C90 Multiple Mye 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.4 0.2 1.5 2.7 4.9 6.0 11.9 18.0 1.0 1.2 1.4 C91 Lymphoid Leuk 0.5 0.8 0.8 0.5 0.3 0.3 0.2 0.7 0.2 0.5 0.3 1.5 1.0 2.2 1.1 8.1 0.7 0.8 0.7 C92 Myeloid Leuke 0.2 0.0 0.2 1.3 0.3 0.7 0.5 0.7 0.9 0.7 2.7 5.0 2.0 6.7 8.6 16.2 1.4 1.5 1.8 C93-95 Other Leukemia 0.5 0.4 0.2 0.5 0.3 0.1 0.3 0.4 0.2 0.5 0.0 0.4 1.0 4.5 1.1 2.7 0.5 0.4																					
C91 Lymphoid Leuk 0.5 0.8 0.8 0.5 0.3 0.3 0.2 0.7 0.2 0.5 0.3 1.5 1.0 2.2 1.1 8.1 0.7 0.8 0.7 C92 Myeloid Leuke 0.2 0.0 0.2 1.3 0.3 0.7 0.5 0.7 0.9 0.7 2.7 5.0 2.0 6.7 8.6 16.2 1.4 1.5 1.8 C93-95 Other Leukemia 0.5 0.4 0.2 0.5 0.3 0.1 0.3 0.4 0.2 0.5 0.0 0.4 1.0 4.5 1.1 2.7 0.5 0.5		. –																			
C92 Myeloid Leuke 0.2 0.0 0.2 1.3 0.3 0.7 0.5 0.7 0.9 0.7 2.7 5.0 2.0 6.7 8.6 16.2 1.4 1.5 1.8 C93-95 Other Leukemia 0.5 0.4 0.2 0.5 0.3 0.1 0.3 0.4 0.2 0.5 0.0 0.4 1.0 4.5 1.1 2.7 0.5 0.5 0.4																					
C93-95 Other Leukemia 0.5 0.4 0.2 0.5 0.3 0.1 0.3 0.4 0.2 0.5 0.0 0.4 1.0 4.5 1.1 2.7 0.5 0.5 0.4		· -																			
		*																			
																			_		

Table 25: Average Annual Age-Specific World Age Adjusted, Truncated (35-64) Cancer Death Rates per 100,000 Persons, Greater Mumbai, 2011, Female

ICD10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C01-02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.7	1.1	1.4	1.8	3.1	3.8	5.3	7.9	0.8	0.8	1.3
C03-06	Mouth	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.4	1.0	2.2	3.5	5.7	3.6	8.4	13.7	14.2	1.6	1.6	2.5
C07-08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.0	0.0	0.8	0.1	0.1	0.1
	Oropharynx	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.4	0.5	2.3	2.1	1.6	0.2	0.3	0.3
	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.6	0.1	0.1	0.1
	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.4	1.1	1.3	1.5	0.8	2.1	2.4	0.4	0.4	0.9
	Other Oral	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.8	0.4	0.4	2.1	1.5	1.1	4.0	0.3	0.3	0.6
	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	1.0	3.4	3.9	8.3	7.7	16.0	18.9	30.0	2.5	2.6	
	Stomach	0.0	0.0	0.0	0.0	0.2	0.3	0.6	1.1	1.0	2.2	3.5	3.5	3.1	7.6	13.7	16.6	1.6	1.6	
	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.7	0.0	0.5	0.8	5.3	2.4	0.3	0.3	
	Colon	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.1	0.5	1.1	4.9	2.6	5.2	6.1	18.9	17.4	1.6	1.7	2.3
C19-21		0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.6	1.0	1.1	3.5	3.9	7.2	6.8	6.3	18.2	1.5	1.5	2.5
	Liver	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.6	2.0	1.1	3.5	5.7	8.3	11.4	11.6	27.7	2.1	2.1	3.1
	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	2.0	3.6	6.4	5.7	7.2	14.5	10.5	17.4	2.1	2.1	3.9
	Pancreas	0.0	0.0	0.0	0.0	0.2	0.2	0.4	0.0	0.5	1.1	2.5	3.5	7.7	11.4	11.6	19.8	1.5	1.7	2.2
			0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	1.5	0.0		0.1	0.1	0.1
	Oth Dig Org	0.0															1.6			
	Nose, Sinuse	0.0	0.0	0.0	$0.0 \\ 0.0$	0.0	0.0	0.0	0.0	0.2	0.3	0.4	0.0	0.5 2.1	1.5 3.0	1.1 3.2	4.0	0.2	0.2	0.2
	Larynx	0.0	0.0	0.0			0.0		0.0		0.3	0.0					5.5		0.5	
C33-34	~	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	1.5	2.2	3.9	10.9	12.9	11.4	36.8	30.0	2.9	3.1	4.6
	Mediastinum, Plura	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.8	0.0	0.0	0.0	0.0	
C40-41		0.0	0.0	0.0	1.0	0.3	0.0	0.2	0.0	0.5	0.3	0.0	1.3	2.1	0.8	0.0	2.4	0.4	0.4	0.6
	Skin Melanoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.8	1.1	0.8	0.1	0.1	0.1
	Skin Others	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.1	0.8	5.3	1.6	0.2	0.3	0.3
	Nervous System	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1
	Retroperitonium	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.1	0.8	0.1	0.1	0.0
	Conn & Soft Tissu	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.6	0.7	1.3	1.5	1.5	2.1	1.6	0.3	0.3	0.7
	Breast	0.0	0.0	0.0	0.0	0.0	1.0	3.0	7.2	10.1	22.2	23.3	39.8	37.7	48.7	69.4	96.4	11.5	11.7	21.4
	Oth Fem Gen Org	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.9	2.1	2.3	3.2	6.3	0.4	0.4	0.5
	Cervix	0.0	0.0	0.0	0.0	0.0	0.2	1.4	1.1	3.5	8.4	9.5	13.1	18.6	26.6	18.9	26.9	4.1	4.3	8.1
	Corpus Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.8	1.1	3.1	5.7	3.8	8.4	6.3	0.8	0.9	
C55	Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.3	0.4	0.9	2.6	2.3	16.8	11.1	0.8	0.8	
	Ovary	0.0	0.2	0.2	0.0	0.0	0.3	0.6	1.3	4.9	5.1	7.4	10.5	16.0	29.7	32.6	39.5	4.3	4.5	6.8
	Oth Unsp Fem Gen Or	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	
C64-65	•	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	3.1	3.0	4.2	8.7	0.5	0.5	
	Urinary Bladder	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	1.0	1.5	2.1	7.9			
	Eye	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8			
C70-72		0.8	0.2	0.4	0.4	0.2	0.2	0.4	0.6	1.2	1.7	1.8	3.1	4.6	5.3	4.2	6.3		1.2	
	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.4	0.9	1.5	3.8	5.3	4.0		0.4	
	Other Endocrine Gla	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.4	0.0	0.5	0.8	0.0	0.0		0.1	
	Other Ill Def Sit	0.3	0.0	0.4	0.2	0.0	0.0	0.0	0.4	0.2	0.0	0.4	1.3	1.0	3.8	2.1	0.8		0.4	
	Lymph Nodes	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.3	0.4	1.3	2.1	1.5	2.1	4.0	0.4	0.4	
	Sec Resp & Dig	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.0	0.6	1.4	1.8	0.5	4.6	2.1	5.5	0.6		
C79	Sec Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.6	1.1	1.3	0.0	2.3	0.0	3.2	0.3	0.3	
C80	Unknown Primary	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.2	0.5	0.6	1.1	0.4	2.6	5.3	7.4	11.1	0.8	0.8	0.8
	Hodgkin Lymphoma	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.3	0.4	0.9	0.5	2.3	2.1	4.0	0.3	0.3	0.3
C82-85	N.H.Lymphoma	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.8	0.7	2.0	2.1	0.4	6.2	9.1	9.5	18.2	1.4	1.5	
C90	Multiple Mye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.8	0.4	1.3	4.6	3.0	4.2	8.7	0.6	0.7	1.0
C91	Lymphoid Leuk	0.0	0.9	0.6	0.4	0.5	0.3	0.2	0.0	0.0	1.1	0.0	1.3	2.6	1.5	1.1	4.0	0.6	0.6	0.7
C92	Myeloid Leuke	0.0	0.0	0.4	0.2	0.0	0.3	1.2	0.4	1.2	2.0	2.1	1.8	3.1	6.1	2.1	6.3	1.0	1.0	1.7
	Other Leukemia	0.0	0.5	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.3	0.4	0.4	0.5	2.3	2.1	5.5	0.4	0.4	
Total	All Sites	1.3	2.1	2.6	2.7	1.9	4.4	13.5	21.0	38.6	72.4	95.7	144.0	198.4	283.1	372.0	516.0	52.7	54.8	_

APPENDIX

Calculation of rates

Age Specific Rates are calculated by dividing the number of cases in each 5 year age and sex stratum by corresponding population estimates for that stratum and multiplying the product by 100,000 to give the rates per 100,000.

Crude Rates are calculated by same way using the total cancer cases and total cases and total population by sex.

Age-Adjusted Rates are calculated by summing the products of the age specific rates and the world standard population strata. They provide a rate which is independent of the age structure of the population of interest and are therefore useful in making comparisons between different populations, time periods.etc.

Cumulative Rates are calculated by multiplying the five year age specific rates per person by 5 and summing over age groups from 0-4 to 70-74. This rate is then expressed as a percentage. This rate is good indicator of life time risk.